Courses & outcomes
Course descriptions and learning outcomes.
Interim Stream Review · Prototype
Stream Overview
What does learning in this stream look like across the program and within each year?
This workspace moves from a high-level orientation to an interactive curriculum portrait and then to searchable source records, helping reviewers understand the stream across the program, examine year-specific evidence, and verify the records behind the summary.
Evidence at a Glance
What curriculum evidence am I reviewing?
Teaching & topics
Sessions, topics, types, duration, and instructional characteristics.
Assessment
Assessment structure and available descriptions.
High-Level Overview of Learning
What does learning look like in this stream?
Overall focus
The Pharmaceutical Sciences stream presents foundational medicinal chemistry, pharmaceutics, pharmacology, anatomy/physiology and toxicology across Years 1–3. Outcomes emphasize cognitive knowledge and applied skills (e.g., pKa/pH problems, compounding, PK calculations, toxicology identification and management) with attitudes documented inconsistently across courses.
Development across years
Documented progression moves from broad foundational science in Year 1 toward application‑focused pharmaceutics and pharmacokinetics in Year 2, culminating in a Year‑3 toxicology course focused on clinically oriented toxicology knowledge, case work and attitudinal outcomes; instructional minutes and assessment item counts decline across years in the packet.
How to read this curriculum portrait
Top-line metrics summarize the selected academic cycle. Within each curriculum portrait figure, Years 1, 2 and 3 are shown separately so reviewers can compare the same program year across available academic cycles. No Overall distribution is shown.
What students learn
The Pharmaceutical Sciences stream concentrates on foundational biomedical and pharmaceutical science knowledge and applied laboratory/compounding skills. Documented outcomes cover medicinal chemistry, pharmaceutics and dosage‑form design, pharmacology, pharmacokinetics and biopharmaceutics, toxicology, anatomy and physiology, and pharmaceutical biotechnology. Skills emphasize quantitative problem solving (pKa/pH, PK calculations), compounding and aseptic technique, dosage‑form design and use of laboratory data, with attitudes such as lifelong learning and professional responsibility noted in some courses.
120Documented learning outcomes
270Documented topics
3AFPC roles represented
27CCAPP categories represented
Learning-outcome and curriculum-framework profiles
Learning outcomes
KSAs are heavily weighted toward knowledge, with substantial skills for quantitative calculation and compounding; attitudes are recorded but less consistently across courses, often focusing on lifelong learning and professional responsibility.
- Knowledge
- Skills
- Attitudes
Year 1
2025-2026n = 73
2024-2025n = 66
2023-2024n = 63
Year 2
2025-2026n = 36
2024-2025n = 36
2023-2024n = 41
Year 3
2025-2026n = 3
2024-2025n = 16
2023-2024n = 16
AFPC professional roles
AFPC mappings are overwhelmingly Scholar, with minor Care Provider and Professional entries, documenting curriculum emphasis on scholarly and disciplinary knowledge rather than clinical care roles in this stream.
- Scholar
- Care Provider
- Professional
Year 1
2025-2026n = 238
2024-2025n = 249
2023-2024n = 251
Year 2
2025-2026n = 84
2024-2025n = 117
2023-2024n = 119
Year 3
2025-2026n = 49
2024-2025n = 51
2023-2024n = 51
CCAPP curriculum topics
CCAPP mappings concentrate in pharmaceutical sciences domains — pharmaceutics, pharmacology, pharmacokinetics, biopharmaceutics and toxicology — documenting curriculum focus on drug‑centred science, formulation and safety topics.
- pharmaceutics
- toxicology
- pharmacology
- pharmacokinetics
- biopharmaceutics
- Other
Year 1
2025-2026n = 238
2024-2025n = 249
2023-2024n = 251
Year 2
2025-2026n = 84
2024-2025n = 117
2023-2024n = 119
Year 3
2025-2026n = 49
2024-2025n = 51
2023-2024n = 51
View all mapped CCAPP topic categories
Percentages are the governed CCAPP topic-category mapping proportions for the selected program-year perspective in each academic cycle. The denominator used for each cycle is shown in its column header.
| Topic category | 2025-2026 n = 146 | 2024-2025 n = 183 | 2023-2024 n = 186 |
|---|---|---|---|
| pharmaceutics | 70% | 87% | 86% |
| pharmacology | 68% | 63% | 62% |
| toxicology | 56% | 51% | 53% |
| pharmacokinetics | 58% | 43% | 44% |
| biopharmaceutics | 15% | 32% | 32% |
| pharmaceutical biotechnology | 13% | 15% | 15% |
| medicinal chemistry | 17% | 15% | 15% |
| immunology | 13% | 12% | 12% |
| anatomy | 10% | 11% | 11% |
| physiology | 11% | 11% | 10% |
| substance use disorders, dependency, and addiction | 12% | 9% | 9% |
| practical compounding | 10% | 8% | 8% |
| molecular and cell biology | 9% | 6% | 7% |
| cardiology | 9% | 8% | 6% |
| drugs in pregnancy and lactation | — | 4% | 5% |
| oncology | 5% | 4% | 4% |
| pharmacy law and regulatory issues | 5% | 4% | 4% |
| pathophysiology | 3% | 3% | 3% |
| prescriptive decision making (i.e. prescribing, deprescribing, adapting a prescription) | 2% | 2% | 2% |
| pharmacoepidemiology | — | 2% | 2% |
| monitoring & follow-up | — | 2% | 2% |
| conditions affecting head, eyes, ears, nose, throat (EENT) | 3% | 2% | 2% |
| neurology | 2% | 2% | 2% |
| psychiatric and mental health | 2% | 2% | 2% |
| diagnostic and point-of-care testing | 1% | 1% | 1% |
| pain | 1% | 1% | 1% |
| respirology | 1% | 1% | 1% |
| ethical and professional standards of practice | 2% | — | — |
| patient assessment/pharmacotherapy work-up | 2% | — | — |
Relationships with other streams
These summaries identify documented areas of shared or adjacent curriculum with the other program streams.
BASE
Professional, regulatory and health-system context
The streams share documented learning around pharmacy law/regulatory issues, evidence appraisal, and medication‑use and safety topics across the three‑year span. Pharmaceutical Sciences frames this territory with foundational knowledge in medicinal chemistry, pharmaceutics, pharmacokinetics and toxicology that informs understanding of drug properties, dosing and adverse effects. BASE documents adjacent applied and professional content—communication, medication‑use processes, monitoring/adherence and system‑level patient safety—that intersects with the Pharmaceutical Sciences topics (including recorded overlaps in regulatory and pharmacoepidemiology areas).
Practice Skills
Patient care, communication and applied practice
Pharmaceutical Sciences shares documented learning with Practice Skills across Years 1–3 in applied pharmacology/pharmaceutics topics (medicinal chemistry, pharmaceutics, pharmacokinetics) that align with practice-focused skills such as compounding, diagnostic/point‑of‑care testing, monitoring and prescriptive decision‑making. This relationship is reflected in course‑level outcomes, session topic lists and framework mappings that show overlapping coverage in clinical condition topics (e.g., cardiology, neurology), compounding and monitoring/follow‑up across the three years.
Therapeutics
Therapeutic decision-making and clinical application
Pharmaceutical Sciences and Therapeutics share documented curricular territory across Years 1–3, with Pharmaceutical Sciences providing foundational content in pharmacology, pharmacokinetics, pharmaceutics/biopharmaceutics and toxicology that connects to Therapeutics’ clinical topics (e.g., cardiology, infectious disease, neurology, drugs in pregnancy/lactation, substance use). This relationship is supported by course‑level learning outcomes, session inventories, assessment summaries and CCAPP/AFPC mapping counts reported for both streams in the 2023–24 packet.
These relationships reflect documented curriculum portraits and governed cross-stream evidence. They identify shared or adjacent curriculum territory but do not by themselves demonstrate intentional coordination, integration, sequencing quality or curriculum quality.
How learning is delivered
Teaching is structured around frequent short lectures to introduce principles, with extensive laboratory immersion and periodic seminars to connect theory to practice. Students learn core chemistry and pharmacology concepts in lecture blocks and then spend extended lab sessions performing compounding, emulsion and semisolid preparations, simulation exercises and lab practicums. Distinctive learning activities include hands‑on compounding labs (capsules, semisolids, suspensions), lab practical exams, seminar case work linking functional groups to clinical relevance, and simulation‑style biopharmaceutics labs.
Documented delivery mix
305Lecture
15Seminar
39Lab
17Other
- Lecture
- Seminar
- Lab
- Other
Year 1
2025-2026n = 219
2024-2025n = 224
2023-2024n = 228
Year 2
2025-2026n = 90
2024-2025n = 109
2023-2024n = 109
Year 3
2025-2026n = 39
2024-2025n = 39
2023-2024n = 39
How learning is assessed
Students are expected to demonstrate domain knowledge, quantitative problem solving, laboratory technique and scientific communication. Assessment predominantly uses multiple‑choice midterms and finals to probe conceptual mastery, supplemented by laboratory reports and lab practicals to evaluate experimental skill, data interpretation and technical write‑ups. Regular online unit quizzes and in‑class checks monitor incremental learning, while occasional ‘hot topic’ assignments capture concise literature synthesis. The overall pattern balances objective testing for breadth with lab‑based written products for applied competency.
Assessment pattern
11Quiz
10Assignment/written work
9Final exam
8Midterm exam
5Other exam/test
- Quiz
- Assignment/written work
- Final exam
- Midterm exam
- Other exam/test
- Other
Year 1
2025-2026n = 17
2024-2025n = 24
2023-2024n = 27
Year 2
2025-2026n = 11
2024-2025n = 12
2023-2024n = 12
Year 3
2025-2026n = 6
2024-2025n = 6
2023-2024n = 5
Overall focus
The Pharmaceutical Sciences stream covers medicinal chemistry, pharmaceutics/compounding, pharmacology/pharmacogenomics, anatomy/physiology, pharmacokinetics and toxicology across Years 1–3. Documented skills include problem solving, compounding techniques, PK calculations, assay interpretation and toxicology problem solving; attitudes such as lifelong learning and professional responsibility appear in selected courses.
Development across years
Documented content shifts from foundational molecular and formulation sciences in Year 1 to applied formulation, biopharmaceutics and pharmacokinetics in Year 2 and a focused toxicology application unit in Year 3. Delivery is lecture‑dominant with labs concentrated in Years 1–2 and fewer applied seminar sessions in Year 3, per the packet metrics.
How to read this curriculum portrait
Top-line metrics summarize the selected academic cycle. Within each curriculum portrait figure, Years 1, 2 and 3 are shown separately so reviewers can compare the same program year across available academic cycles. No Overall distribution is shown.
What students learn
The Pharmaceutical Sciences curriculum documents medicinal chemistry, pharmaceutics and dosage‑form theory, pharmacology and pharmacogenomics, pharmacokinetics and biopharmaceutics, sterile and advanced compounding, immunology and pharmaceutical biotechnology, and toxicology. Outcomes emphasize chemical and physicochemical determinants of drug behavior, formulation rationale and quality control, PK calculations and individualized dosing, compounding technique, and clinical relevance of molecular and biotechnological therapeutics.
118Documented learning outcomes
269Documented topics
3AFPC roles represented
27CCAPP categories represented
Learning-outcome and curriculum-framework profiles
Learning outcomes
Across the stream, KSAs are knowledge‑heavy with a substantial skills component (quantitative problems, compounding, PK dosing); attitudes such as commitment to currency and lifelong learning are present but less prominent.
- Knowledge
- Skills
- Attitudes
Year 1
2025-2026n = 73
2024-2025n = 66
2023-2024n = 63
Year 2
2025-2026n = 36
2024-2025n = 36
2023-2024n = 41
Year 3
2025-2026n = 3
2024-2025n = 16
2023-2024n = 16
AFPC professional roles
AFPC mappings overwhelmingly identify Scholar as the dominant role, documenting curriculum emphasis on scientific and scholarly preparation rather than clinical care roles within this stream.
- Scholar
- Care Provider
- Professional
Year 1
2025-2026n = 238
2024-2025n = 249
2023-2024n = 251
Year 2
2025-2026n = 84
2024-2025n = 117
2023-2024n = 119
Year 3
2025-2026n = 49
2024-2025n = 51
2023-2024n = 51
CCAPP curriculum topics
CCAPP mappings are concentrated in pharmaceutics, pharmacology, pharmacokinetics and toxicology, documenting the curriculum’s sustained focus on drug design, formulation, dose‑concentration relationships and safety.
- pharmaceutics
- toxicology
- pharmacology
- pharmacokinetics
- biopharmaceutics
- Other
Year 1
2025-2026n = 238
2024-2025n = 249
2023-2024n = 251
Year 2
2025-2026n = 84
2024-2025n = 117
2023-2024n = 119
Year 3
2025-2026n = 49
2024-2025n = 51
2023-2024n = 51
View all mapped CCAPP topic categories
Percentages are the governed CCAPP topic-category mapping proportions for the selected program-year perspective in each academic cycle. The denominator used for each cycle is shown in its column header.
| Topic category | 2025-2026 n = 146 | 2024-2025 n = 183 | 2023-2024 n = 186 |
|---|---|---|---|
| pharmaceutics | 70% | 87% | 86% |
| pharmacology | 68% | 63% | 62% |
| toxicology | 56% | 51% | 53% |
| pharmacokinetics | 58% | 43% | 44% |
| biopharmaceutics | 15% | 32% | 32% |
| pharmaceutical biotechnology | 13% | 15% | 15% |
| medicinal chemistry | 17% | 15% | 15% |
| immunology | 13% | 12% | 12% |
| physiology | 11% | 11% | 10% |
| anatomy | 10% | 11% | 11% |
| substance use disorders, dependency, and addiction | 12% | 9% | 9% |
| cardiology | 9% | 8% | 6% |
| practical compounding | 10% | 8% | 8% |
| molecular and cell biology | 9% | 6% | 7% |
| oncology | 5% | 4% | 4% |
| pharmacy law and regulatory issues | 5% | 4% | 4% |
| drugs in pregnancy and lactation | — | 4% | 5% |
| pathophysiology | 3% | 3% | 3% |
| prescriptive decision making (i.e. prescribing, deprescribing, adapting a prescription) | 2% | 2% | 2% |
| pharmacoepidemiology | — | 2% | 2% |
| monitoring & follow-up | — | 2% | 2% |
| conditions affecting head, eyes, ears, nose, throat (EENT) | 3% | 2% | 2% |
| neurology | 2% | 2% | 2% |
| psychiatric and mental health | 2% | 2% | 2% |
| diagnostic and point-of-care testing | 1% | 1% | 1% |
| pain | 1% | 1% | 1% |
| respirology | 1% | 1% | 1% |
| ethical and professional standards of practice | 2% | — | — |
| patient assessment/pharmacotherapy work-up | 2% | — | — |
Relationships with other streams
These summaries identify documented areas of shared or adjacent curriculum with the other program streams.
BASE
Professional, regulatory and health-system context
Across 2024–2025 the streams share documented learning around regulatory/legal topics, research methods and medication‑safety/evidence appraisal. Pharmaceutical Sciences frames its contribution as foundational scientific content (medicinal chemistry, pharmaceutics, pharmacokinetics and toxicology) and methodological mappings that inform interpretation of drug effects and study results. BASE frames adjacent applied territory in patient‑centred communication, medication‑use workflow, quality improvement, and service planning/advocacy that intersect with the Pharmaceutical Sciences content in documented mappings.
Practice Skills
Patient care, communication and applied practice
Pharmaceutical Sciences shares documented learning with Practice Skills across Years 1–3 in pharmaceutics/compounding, pharmacokinetics/biopharmaceutics, pharmacology and Year‑3 toxicology, with adjacent practice coverage in monitoring, diagnostic testing and prescriptive decision‑making. Course‑level outcomes, session topics and CCAPP/AFPC mappings provided for the academic cycle document these overlapping topical areas across the three year levels.
Therapeutics
Therapeutic decision-making and clinical application
Across the 2024–25 cycle Pharmaceutical Sciences documents foundational and applied content (medicinal chemistry, pharmaceutics/compounding, pharmacology, pharmacokinetics and toxicology) that shares curricular territory with Therapeutics’ clinical coverage (respirology, cardiology, infectious disease, neurology, oncology and practice skills). The connection is evidenced by course‑level outcomes, session inventories, assessment summaries and aggregated CCAPP/AFPC mappings provided for both streams in 2024–25.
These relationships reflect documented curriculum portraits and governed cross-stream evidence. They identify shared or adjacent curriculum territory but do not by themselves demonstrate intentional coordination, integration, sequencing quality or curriculum quality.
How learning is delivered
Instruction blends frequent short lectures with scheduled, extended laboratory experiences and seminars. Students receive core content in lecture format and then apply concepts during multi‑hour lab sessions and problem‑based seminars. Distinctive learning tasks include repeated hands‑on compounding labs, pre‑lab seminars that prepare students for sterile compounding/dissolution testing, lab practicals and seminar cases that connect molecular concepts to formulation and therapeutic function.
Documented delivery mix
300Lecture
17Seminar
39Lab
16Other
- Lecture
- Seminar
- Lab
- Other
Year 1
2025-2026n = 219
2024-2025n = 224
2023-2024n = 228
Year 2
2025-2026n = 90
2024-2025n = 109
2023-2024n = 109
Year 3
2025-2026n = 39
2024-2025n = 39
2023-2024n = 39
How learning is assessed
Students are expected to show rigorous content knowledge, laboratory proficiency, and clear scientific communication. Assessment combines multiple‑choice and written midterms/finals for broad conceptual evaluation with lab reports and lab exams that require method description, quantitative analysis and interpretation. Online assignments and case quizzes provide regular practice and formative feedback. Course weights for major exams are prominent, while lab‑based written products surface applied competencies and adherence to lab rubrics where documented.
Assessment pattern
10Assignment/written work
10Midterm exam
9Final exam
7Quiz
5Other exam/test
- Assignment/written work
- Midterm exam
- Final exam
- Quiz
- Other exam/test
- Other
Year 1
2025-2026n = 17
2024-2025n = 24
2023-2024n = 27
Year 2
2025-2026n = 11
2024-2025n = 12
2023-2024n = 12
Year 3
2025-2026n = 6
2024-2025n = 6
2023-2024n = 5
Overall focus
The Pharmaceutical Sciences stream documents core knowledge in medicinal chemistry, pharmaceutics, pharmacology, immunology/biotechnology and toxicology across Years 1–3. Skills include physicochemical problem solving, compounding and laboratory techniques, PK calculations, immunoassay interpretation and toxicology assessment; attitudes emphasize lifelong learning and professional responsibility in select courses.
Development across years
Documented development moves from extensive foundational disciplinary content in Year 1 to applied pharmaceutics, pharmacokinetics and laboratory work in Year 2, and to a concentrated, clinically oriented toxicology focus in Year 3. Instructional delivery is lecture‑dominant throughout with practical/lab sessions concentrated in Years 1–2 and applied case formats in Year 3.
How to read this curriculum portrait
Top-line metrics summarize the selected academic cycle. Within each curriculum portrait figure, Years 1, 2 and 3 are shown separately so reviewers can compare the same program year across available academic cycles. No Overall distribution is shown.
What students learn
The Pharmaceutical Sciences stream documents comprehensive foundational and applied pharmaceutical science learning: medicinal chemistry and structure–activity relationships, formulation and dosage‑form design, pharmaceutics/biopharmaceutics, pharmacokinetics and individualized dosing, sterile and advanced compounding, immunology and biotechnology, and toxicology with clinical application. Outcomes cover both quantitative problem solving and laboratory/compounding practice alongside principles for evaluating biologics and novel therapies.
112Documented learning outcomes
298Documented topics
3AFPC roles represented
26CCAPP categories represented
Learning-outcome and curriculum-framework profiles
Learning outcomes
Documented KSAs show strong knowledge emphasis with nearly equal practical skills (compounding, PK calculations, lab techniques); attitudes are present and oriented to lifelong learning and professional responsibility.
- Knowledge
- Skills
- Attitudes
Year 1
2025-2026n = 73
2024-2025n = 66
2023-2024n = 63
Year 2
2025-2026n = 36
2024-2025n = 36
2023-2024n = 41
Year 3
2025-2026n = 3
2024-2025n = 16
2023-2024n = 16
AFPC professional roles
AFPC mappings for the stream are heavily Scholar‑oriented with limited Care Provider and Professional mappings, documenting focus on disciplinary scholarship and scientific foundations.
- Scholar
- Care Provider
- Professional
Year 1
2025-2026n = 238
2024-2025n = 249
2023-2024n = 251
Year 2
2025-2026n = 84
2024-2025n = 117
2023-2024n = 119
Year 3
2025-2026n = 49
2024-2025n = 51
2023-2024n = 51
CCAPP curriculum topics
CCAPP topic mappings emphasize pharmacology, pharmaceutics and pharmacokinetics with representation for toxicology and medicinal chemistry — documenting curriculum attention to drug action, formulation and dose–concentration relationships.
- toxicology
- pharmaceutics
- pharmacokinetics
- pharmacology
- immunology
- Other
Year 1
2025-2026n = 238
2024-2025n = 249
2023-2024n = 251
Year 2
2025-2026n = 84
2024-2025n = 117
2023-2024n = 119
Year 3
2025-2026n = 49
2024-2025n = 51
2023-2024n = 51
View all mapped CCAPP topic categories
Percentages are the governed CCAPP topic-category mapping proportions for the selected program-year perspective in each academic cycle. The denominator used for each cycle is shown in its column header.
| Topic category | 2025-2026 n = 146 | 2024-2025 n = 183 | 2023-2024 n = 186 |
|---|---|---|---|
| pharmaceutics | 70% | 87% | 86% |
| pharmacology | 68% | 63% | 62% |
| pharmacokinetics | 58% | 43% | 44% |
| toxicology | 56% | 51% | 53% |
| medicinal chemistry | 17% | 15% | 15% |
| biopharmaceutics | 15% | 32% | 32% |
| immunology | 13% | 12% | 12% |
| pharmaceutical biotechnology | 13% | 15% | 15% |
| substance use disorders, dependency, and addiction | 12% | 9% | 9% |
| physiology | 11% | 11% | 10% |
| practical compounding | 10% | 8% | 8% |
| anatomy | 10% | 11% | 11% |
| molecular and cell biology | 9% | 6% | 7% |
| cardiology | 9% | 8% | 6% |
| pharmacy law and regulatory issues | 5% | 4% | 4% |
| oncology | 5% | 4% | 4% |
| pathophysiology | 3% | 3% | 3% |
| conditions affecting head, eyes, ears, nose, throat (EENT) | 3% | 2% | 2% |
| ethical and professional standards of practice | 2% | — | — |
| patient assessment/pharmacotherapy work-up | 2% | — | — |
| prescriptive decision making (i.e. prescribing, deprescribing, adapting a prescription) | 2% | 2% | 2% |
| neurology | 2% | 2% | 2% |
| psychiatric and mental health | 2% | 2% | 2% |
| diagnostic and point-of-care testing | 1% | 1% | 1% |
| pain | 1% | 1% | 1% |
| respirology | 1% | 1% | 1% |
| drugs in pregnancy and lactation | — | 4% | 5% |
| pharmacoepidemiology | — | 2% | 2% |
| monitoring & follow-up | — | 2% | 2% |
Relationships with other streams
These summaries identify documented areas of shared or adjacent curriculum with the other program streams.
BASE
Professional, regulatory and health-system context
Across 2025–2026 the streams share documented learning around regulatory and ethical standards, patient assessment and later‑year substance‑use/toxicology topics. Pharmaceutical Sciences frames the stream with foundational disciplinary content in pharmacology, pharmaceutics, pharmacokinetics and toxicology that informs understanding of drug effects, dosing and toxicity. BASE frames adjacent applied and professional competencies—patient assessment/pharmacotherapy work‑up, medication‑use processes, communication, advocacy and quality improvement—that are documented alongside the Pharmaceutical Sciences material, with recorded overlaps in law/ethics and substance‑use mappings.
Practice Skills
Patient care, communication and applied practice
Pharmaceutical Sciences shares documented learning with Practice Skills across Years 1–3 in core pharmacology, pharmaceutics/compounding, pharmacokinetics and Year‑3 toxicology, with adjacent practice coverage in patient assessment, compounding, diagnostic testing, monitoring and prescriptive decision‑making. Course outcomes, session topic lists and framework mappings in the supplied materials consistently record overlapping topical territory across the three years.
Therapeutics
Therapeutic decision-making and clinical application
For 2025–26 Pharmaceutical Sciences documents foundational and applied topics (medicinal chemistry, pharmaceutics/compounding, pharmacology, pharmacokinetics and toxicology) that share curricular territory with Therapeutics’ broad clinical coverage (self‑care/respirology, infectious disease, cardiology, nephrology, oncology, neurology, pain and practice skills). This relationship is supported by course‑level outcomes, session inventories, assessment descriptions and CCAPP/AFPC mapping counts provided for both streams in the 2025–26 materials.
These relationships reflect documented curriculum portraits and governed cross-stream evidence. They identify shared or adjacent curriculum territory but do not by themselves demonstrate intentional coordination, integration, sequencing quality or curriculum quality.
How learning is delivered
Delivery is dominated by in‑person lectures supported by scheduled laboratory sessions, seminars and occasional recorded lectures. Students learn theory in lectures (sometimes recorded), then practice techniques in hands‑on labs that include capsule preparation, semisolids and suspensions, plus online quizzes and lab exams. Distinctive activities across the stream are repeated, supervised lab exercises, pre‑lab briefings, computer‑based quizzes, and structured lab evaluations to verify practical competencies.
Documented delivery mix
297Lecture
14Seminar
9Lab
28Other
- Lecture
- Seminar
- Lab
- Other
Year 1
2025-2026n = 219
2024-2025n = 224
2023-2024n = 228
Year 2
2025-2026n = 90
2024-2025n = 109
2023-2024n = 109
Year 3
2025-2026n = 39
2024-2025n = 39
2023-2024n = 39
How learning is assessed
Students are expected to combine conceptual mastery with demonstrable lab competence and technical precision. The characteristic assessment mix includes multiple‑choice and short‑answer midterms/finals to assess breadth, practical compounding or lab practical exams to assess hands‑on skills, and multiple lab reports submitted with an explicit rubric to evaluate experimental design, results and interpretation. Timed online quizzes and web‑based assignments offer frequent formative checks.
Assessment pattern
12Midterm exam
9Final exam
6Assignment/written work
5Quiz
1Other exam/test
- Midterm exam
- Final exam
- Assignment/written work
- Quiz
- Other exam/test
- Other
Year 1
2025-2026n = 17
2024-2025n = 24
2023-2024n = 27
Year 2
2025-2026n = 11
2024-2025n = 12
2023-2024n = 12
Year 3
2025-2026n = 6
2024-2025n = 6
2023-2024n = 5
Explore the Curriculum
What curriculum records sit behind this overview?
Use these searchable records to verify the course, session and assessment evidence behind the curriculum portrait. The browser supports inspection and verification rather than additional curriculum analysis.
Course Information
| PHARM 201 — PHARM 201 - Medicinal Chemistry | Y1 | Fall | 38 | 4 | 0 | Final exam (1); Quiz (8) | — |
| PHARM 202 — PHARM 202 - Pharmaceutics 1 | Y1 | Winter | 38 | 9 | 18 | Assignment/written work (6); Final exam (1); Midterm exam (1); Other exam/test (1) | — |
| PHARM 203 — PHARM 203 - Pharmacology 1 | Y1 | Fall | 37 | 0 | 0 | Final exam (1); Midterm exam (1) | — |
| PHARM 204 — PHARM 204 - Anatomy/Physiology for Pharmacy | Y1 | Fall | 38 | 0 | 0 | Assignment/written work (1); Final exam (1); Midterm exam (1); Quiz (1) | — |
| PHARM 233 — PHARM 233 - Pharmacology 2 | Y1 | Winter | 37 | 0 | 0 | Final exam (1); Midterm exam (2) | — |
| PHARM 302 — PHARM 302 - Pharmaceutics 2 | Y2 | Fall | 37 | 2 | 21 | Assignment/written work (2); Final exam (1); Other exam/test (2) | — |
| PHARM 303 — PHARM 303 - Pharmacokinetics | Y2 | Fall | 37 | 0 | 0 | Assignment/written work (1); Final exam (1); Midterm exam (2); Participation/professionalism (1) | — |
| PHARM 310 — PHARM 310 - Immunology and Biotechnology | Y2 | Fall | 8 | 0 | 0 | Final exam (1); Midterm exam (1) | — |
| PHARM 401 — PHARM 401 - Toxicology | Y3 | Winter | 35 | 0 | 0 | Final exam (1); Other exam/test (2); Quiz (2) | — |
Session Information
| PHARM 201 | Y1 | Fall | 2023-09-06 | Lecture | Course overview | Course overview | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2023-09-08 | Lecture | Functional groups - characteristics and roles | Definition of a functional group; relevant functional groups in drug molecules. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2023-09-11 | Lecture | Functional groups - characteristics and roles | Physical chemical properties associated to functional groups in drug molecules. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2023-09-13 | Lecture | Functional groups - characteristics and roles | Electronic and inductive effects. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2023-09-15 | Lecture | Functional groups - characteristics and roles | Steric effects; solubility effects; binding interactions. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2023-09-18 | Lecture | Acidic and basic functional groups | Most common types of acidic and basic functional groups in drug molecules. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2023-09-19 | Seminar/case session | Seminar 1 | Clinical relevance of organic functional groups in drug therapy | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2023-09-20 | Lecture | Acidic and basic functional groups | Physiologically relevant acidic and basic functional groups. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2023-09-22 | Lecture | Acidic and basic functional groups | Therapeutic significance of acidic and basic groups. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2023-09-25 | Lecture | Acidic and basic functional groups | Correlating the presence (or absence) of acidic / basic groups to therapeutic effects. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2023-09-27 | Lecture | Problems involving pH and pKa | pH and pKa: principles and applications in clinical practice; using the Henderson-Hasselbach equation. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2023-09-29 | Lecture | Problems involving pH and pKa | Importance of pH and pKa in drug therapy; influence of pH and pKa on the solubility of a drug molecule. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2023-10-02 | Lecture | Problems involving pH and pKa | Relationship between pH and pKa on the duration of action of drug molecules; influence of pH and pKa on drug binding interactions (drug potency). | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2023-10-04 | Lecture | Problems involving pH and pKa | Predicting chemical antagonism between drug molecules using their pKa values. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2023-10-06 | Lecture | Problems involving pH and pKa | Drug interactions based on pH and their pKa values. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2023-10-11 | Lecture | Salts and solubility | Salts and solubility of drug molecules; definition of salt; formation of salts from acid and basic drug molecules. | Amir Tabatabei |
| PHARM 201 | Y1 | Fall | 2023-10-13 | Lecture | Salts and solubility | Inorganic salts; organic salts; salts and their influence on drug-drug and drug-food interactions. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2023-10-16 | Lecture | Salts and solubility | Solubility of salts and their partition coefficient; therapeutic use of salts based on their water solubility; the balance between water and lipid solubility. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2023-10-18 | Lecture | Salts and solubility | Strategies for optimizing drug solubility; relationship between solubility and drug metabolism. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2023-10-20 | Lecture | Drug binding interactions | Drug binding interactions and their relationship with potency. | Khaled Barakat |
| PHARM 201 | Y1 | Fall | 2023-10-23 | Lecture | Drug binding interactions | Covalent bonds; non-covalent bonds; ionic bonds. | Khaled Barakat |
| PHARM 201 | Y1 | Fall | 2023-10-24 | Seminar/case session | Seminar 2 | Importance of pKa in drug therapy | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2023-10-25 | Lecture | Drug binding interactions | Ion-dipole and dipole-dipole; interactions. | Khaled Barakat |
| PHARM 201 | Y1 | Fall | 2023-10-27 | Lecture | Drug binding interactions | Hydrogen bonds; van der Waals interactions; hydrophobic bonding. | Khaled Barakat |
| PHARM 201 | Y1 | Fall | 2023-10-30 | Lecture | Stereochemistry | Conformational isomers; definition of the active conformation in drug; molecules; conformational restriction. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2023-11-01 | Lecture | Stereochemistry | Stereochemistry: chirality and asymmetry; enantiomers. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2023-11-03 | Lecture | Stereochemistry | Pharmacological implications of enantiomeric mixtures; diastereomers. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2023-11-06 | Lecture | Stereochemistry | Geometric isomers; pharmacological implications of diastereomeric mixtures. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2023-11-07 | Seminar/case session | Seminar 3 | Salts and solubility in drug therapy | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2023-11-08 | Lecture | Drug metabolism | Drug metabolism: General concepts. | Ayman El-Kadi |
| PHARM 201 | Y1 | Fall | 2023-11-10 | Lecture | Drug metabolism | Factors affecting drug metabolism; Phase I and Phase II metabolism. | Ayman El-Kadi |
| PHARM 201 | Y1 | Fall | 2023-11-15 | Lecture | Drug metabolism | Oxidation reactions by the cytochrome P450 (CYP450) family of enzymes. | Ayman El-Kadi |
| PHARM 201 | Y1 | Fall | 2023-11-17 | Lecture | Drug metabolism | Oxidation reactions by the cytochrome P450 (CYP450) family of enzymes | Ayman El-Kadi |
| PHARM 201 | Y1 | Fall | 2023-11-20 | Lecture | Drug metabolism | Reduction reactions by the cytochrome P450 (CYP450) family of enzymes. | Ayman El-Kadi |
| PHARM 201 | Y1 | Fall | 2023-11-22 | Lecture | Drug metabolism | Hydrolysis reactions; conjugation reactions. | Ayman El-Kadi |
| PHARM 201 | Y1 | Fall | 2023-11-24 | Lecture | Drug metabolism | Relationship between drug metabolism and pharmacological activity. | Ayman El-Kadi |
| PHARM 201 | Y1 | Fall | 2023-11-27 | Lecture | Structure-Activity Relationships and Classical Strategies in Drug Design | Structure-Activity Relationships (SAR): general description; examples of SARs; SAR and pharmacological activity. | Khaled Barakat |
| PHARM 201 | Y1 | Fall | 2023-11-28 | Seminar/case session | Seminar 4 | Drug metabolism | Ayman El-Kadi |
| PHARM 201 | Y1 | Fall | 2023-11-29 | Lecture | Structure-Activity Relationships and Classical Strategies in Drug Design | SAR and binding interactions; SARs and the absorption, distribution, metabolism and excretion (ADME) process. | Khaled Barakat |
| PHARM 201 | Y1 | Fall | 2023-12-01 | Lecture | Structure-Activity Relationships and Classical Strategies in Drug Design | SAR, drug interactions and adverse; drug reactions; molecular modification; conformational restriction; variation of functional groups. | Khaled Barakat |
| PHARM 201 | Y1 | Fall | 2023-12-04 | Lecture | Structure-Activity Relationships and Classical Strategies in Drug Design | Isosters and bioisosteres; homologation; chain branching; prodrugs. | Khaled Barakat |
| PHARM 201 | Y1 | Fall | 2023-12-06 | Lecture | Course review and final remarks | Course review | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2023-12-18 | Final exam | Final exam | Final exam | Teaching assistant |
| PHARM 202 | Y1 | Winter | 2024-01-08 | Lecture | Lecture 1 | Introduction | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-01-10 | Lecture | Lecture 2 | Compounding | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-01-12 | Lecture | Lecture 3 | USP 795 | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-01-12 | Seminar/case session | Seminar Lab introduction | Introduction | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-01-15 | Laboratory | Lab Sign-in-A | Sign in | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-01-15 | Lecture | Lecture 4 | USP 795 | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-01-17 | Laboratory | Lab sign-in-B | Sign in | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-01-17 | Lecture | Lecture 5 | Solubility | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2024-01-19 | Lecture | Lecture 6 | Solubility | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2024-01-19 | Seminar/case session | Seminar Equipment and Procedures | Equipment and accuracy | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-01-22 | Lecture | Lecture 7 | Pharm. Solutions | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-01-24 | Lecture | Lecture 8 | Pharm Waters | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-01-26 | Lecture | Lecture 9 | Suspensions | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2024-01-26 | Seminar/case session | Seminar Solubility | Solubility | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2024-01-29 | Laboratory | Lab Solubility-A | Solubility | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2024-01-29 | Lecture | Lecture 10 | Suspensions | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2024-01-31 | Laboratory | Lab Solubility-B | Solubility | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2024-01-31 | Lecture | Lecture 11 | Suspensions | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2024-02-02 | Lecture | Lecture 12 | Suspensions | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2024-02-02 | Seminar/case session | Seminar Suspensions | Suspension | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-02-05 | Laboratory | Lab Suspensions-A | Suspension | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-02-05 | Lecture | Lecture 13 | Emulsions | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2024-02-07 | Laboratory | Lab Suspsnsion-B | Suspension | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-02-07 | Lecture | Lecture 14 | Emulsions | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2024-02-09 | Lecture | Lecture 15 | Emulsions | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2024-02-09 | Seminar/case session | Seminar Emulsions | Emulsion | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-02-12 | Laboratory | Lab Emulsions-A | Emulsion | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-02-12 | Lecture | Lecture 16 | Emulsions | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2024-02-14 | Laboratory | Lab Emulsions-B | Emulsion | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-02-14 | Lecture | Lecture 17 | Semisolids | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2024-02-16 | Lecture | Lecture 18 | Semisolids | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2024-02-16 | Seminar/case session | Seminar Semisolids | Semisolids | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-02-26 | Laboratory | Lab Semisolids-1A | Semisolids | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-02-26 | Lecture | Lecture 19 | Colloids | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2024-02-28 | Laboratory | Lab Semisolids-1B | Semisolids | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-02-28 | Lecture | Lecture 20 | Colloids | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2024-03-01 | Lecture | Lecture 21 | Powders | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-03-04 | Laboratory | Lab Semisolids-2A | Semisolids | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-03-04 | Lecture | Lecture 22 | Capsules | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-03-06 | Laboratory | Lab Semisolids-2B | Semisoids | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-03-06 | Lecture | Lecture 23 | Suppository bases | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-03-08 | Lecture | Lecture 24 | Inserts, Suppositories | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-03-08 | Seminar/case session | Seminar Capsules | Powder and Capsules | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-03-11 | Laboratory | Lab Capsules-A | Capsules | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-03-11 | Lecture | Lecture 25 | Tablets | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-03-13 | Laboratory | Lab Capsules-B | Capsules | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-03-13 | Lecture | Lecture 26 | Tablets | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-03-15 | Lecture | Lecture 27 | Routes of Administration | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2024-03-15 | Seminar/case session | Seminar Suppositories | Suppositories | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-03-18 | Laboratory | Lab Suppositories-A | Suppositories | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-03-18 | Lecture | Lecture 28 | Routes of Administration | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2024-03-20 | Laboratory | Lab Suppositories-B | Suppositories | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-03-20 | Lecture | Lecture 29 | Routes of Administration | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2024-03-22 | Seminar/case session | Compounding review | Compounding | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-03-22 | Lecture | Lecture 30 | Routes of Administration | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2024-03-25 | Lecture | Lecture 31 | Routes of Administration | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2024-03-27 | Lecture | Lecture 32 | Container | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-04-02 | Other exam/test | Lab Exam-A | Lab Exam | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-04-02 | Other exam/test | Lab Exam-B | Lab Exam | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-04-03 | Lecture | Lecture 33 | Aerosols | Martin |
| PHARM 202 | Y1 | Winter | 2024-04-05 | Lecture | Lecture 34 | Aerosols | Martin |
| PHARM 202 | Y1 | Winter | 2024-04-08 | Laboratory | Lab Cleaning | Lab Cleaning | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-04-08 | Lecture | Lecture 35 | Aerosols | Martin |
| PHARM 202 | Y1 | Winter | 2024-04-10 | Laboratory | Lab Cleaning | Lab Cleaning | — |
| PHARM 202 | Y1 | Winter | 2024-04-10 | Lecture | Lecture 36 | Container | Loebenberg |
| PHARM 202 | Y1 | Winter | 2024-04-10 | Lecture | Lecture 36 | Aerosols | Martin |
| PHARM 202 | Y1 | Winter | 2024-04-12 | Lecture | Lecture 37 | Hot topics in Pharmaceutical Sciences | Loebenberg |
| PHARM 203 | Y1 | Fall | 2023-09-06 | Lecture | 1. Molecular Aspects of Drug Action | Receptor types, ion channels, enzymes, & transporters as drug targets | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-09-08 | Lecture | 2. General Principles of Drug Action | Receptors, Specificity, Drug-Receptor Interactions (Agonists, Antagonists, Partial Agonists, Efficacy, Inverse Agonists, Allosteric Modulation), Concentration response, Intro to Pharmacokinetics | Dr. Andrew Holt |
| PHARM 203 | Y1 | Fall | 2023-09-11 | Lecture | 3. General Principles of Drug Action | Receptors, Specificity, Drug-Receptor Interactions (Agonists, Antagonists, Partial Agonists, Efficacy, Inverse Agonists, Allosteric Modulation) , Concentration response, Intro to Pharmacokinetics | Dr. Andrew Holt |
| PHARM 203 | Y1 | Fall | 2023-09-13 | Lecture | 4. General Principles of Drug Action | Receptors, Specificity, Drug-Receptor Interactions (Agonists, Antagonists, Partial Agonists, Efficacy, Inverse Agonists, Allosteric Modulation) , Concentration response, Intro to Pharmacokinetics | Dr. Andrew Holt |
| PHARM 203 | Y1 | Fall | 2023-09-15 | Lecture | 5. General Principles of Drug Action | Receptors, Specificity, Drug-Receptor Interactions (Agonists, Antagonists, Partial Agonists, Efficacy, Inverse Agonists, Allosteric Modulation) , Concentration response, Intro to Pharmacokinetics | Dr. Andrew Holt |
| PHARM 203 | Y1 | Fall | 2023-09-18 | Lecture | 6. General Principles of Drug Action | Receptors, Specificity, Drug-Receptor Interactions (Agonists, Antagonists, Partial Agonists, Efficacy, Inverse Agonists, Allosteric Modulation), Concentration response, Intro to Pharmacokinetics | Dr. Andrew Holt |
| PHARM 203 | Y1 | Fall | 2023-09-20 | Lecture | 7. Chemical Mediators | Acetylcholine, Muscarinic/Nicotinic Action, Cholinergic Autonomic Transmission | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-09-22 | Lecture | 8. Chemical Mediators | Cholinergic Transmission & Noradrenergic Transmission | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-09-25 | Lecture | 9. Chemical Mediators | Catecholamines: Adrenoceptors, Noradrenergic Autonomic Transmission | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-09-27 | Lecture | 10. Chemical Mediators | Amino Acid mediators - histamine, 5-HT | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-09-29 | Lecture | 11. Chemical Mediators | Peptide/Protein mediators - Bradykinin, Neuropeptides, Cytokines and Chemokines | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-10-02 | Lecture | 12. Chemical Mediators | Eicosanoids & Cannabinoids | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-10-04 | Lecture | 13. Chemical Mediators | Nitric Oxide & H2S | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-10-06 | Lecture | 14. Chemical Mediators | Purines & Amino acids and other neurotransmitters | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-10-11 | Lecture | 15. Chemical Mediators | Amino acids and other neurotransmitters - glutamate, aspartate, dopamine, GABA, glycine | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-10-13 | Midterm exam | 16. Midterm | Material encompassed within lectures 1-14 inclusive | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-10-16 | Lecture | 17. CNS Pharmacology | General Anaesthetics | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-10-18 | Lecture | 18. CNS Pharmacology | Local anaesthetics | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-10-20 | Lecture | 19. CNS Pharmacology | Analgesics | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-10-23 | Lecture | 20. CNS Pharmacology | Anxiolytic and Hypnotic Drugs | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-10-25 | Lecture | 21. CNS Pharmacology | Neurodegenerative Diseases and their Pharmacology - Parkinson's | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-10-27 | Lecture | 22. CNS Pharmacology | Neurodegenerative Diseases and their Pharmacology - Alzheimer's, Huntington's | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-10-30 | Lecture | 23. CNS Pharmacology | Antipsychotic Drugs | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-11-01 | Lecture | 24. CNS Pharmacology | Antiepileptic drugs | Dr. Sherif Mahmoud |
| PHARM 203 | Y1 | Fall | 2023-11-03 | Lecture | 25. CNS Pharmacology | Antidepressant drugs | Dr. Sherif Mahmoud |
| PHARM 203 | Y1 | Fall | 2023-11-06 | Lecture | 26. CNS Pharmacology | Psychomotor stimulants and hallucinogenics | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-11-08 | Midterm exam | 27. Midterm review | Midterm review | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-11-10 | Lecture | 28. Cardiovascular Pharmacology | Vascular Function, Vasoactive Drugs (Vasoconstrictors & Vasodilators) | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-11-15 | Lecture | 29. Cardiovascular Pharmacology | Drugs for Treating Hypertension | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-11-17 | Lecture | 30. Cardiovascular Pharmacology | Drugs for Treating Heart Failure | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-11-20 | Lecture | 31. Cardiovascular Pharmacology | Drugs for Treating Pulmonary Hypertension, Shock & Hypotensive States | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-11-22 | Lecture | 32. Cardiovascular Pharmacology | Antidysrhythmic Drugs - Class I (Na Channel Blockers), Class II (b-Adrenoceptor Antagonists), Class III (K Channel Blockers), Class IV (Ca Channel Blockers) | Dr. John Seubert |
| PHARM 203 | Y1 | Fall | 2023-11-24 | Lecture | 33. Cardiovascular Pharmacology | Antidysrhythmic Drugs - Class I (Na Channel Blockers), Class II (b-Adrenoceptor Antagonists), Class III (K Channel Blockers), Class IV (Ca Channel Blockers) | Dr. John Seubert |
| PHARM 203 | Y1 | Fall | 2023-11-27 | Lecture | 34. Cardiovascular Pharmacology | Drugs that Increase Cardiac Contractility and Anti-Anginal Drugs | Dr. John Seubert |
| PHARM 203 | Y1 | Fall | 2023-11-29 | Lecture | 35. Cardiovascular Pharmacology | Atherosclerosis and Lipid-Lowering Drugs | Dr. John Seubert |
| PHARM 203 | Y1 | Fall | 2023-12-01 | Lecture | 36. Cardiovascular Pharmacology | Anti-Platelet Drugs | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-12-04 | Lecture | 37. Cardiovascular Pharmacology | Anti-Platelet Drugs & Anticoagulants | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-12-06 | Lecture | 38. Cardiovascular Pharmacology | Anticoagulants & Fibrinolytics | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2023-12-08 | Lecture | 39. CNS & CV Pharmacology | Course review | Dr. Paul Jurasz |
| PHARM 204 | Y1 | Fall | 2023-09-06 | Lecture | Introduction & Overview of gross anatomy | Description of the course content and assessment. General gross anatomy and terminology | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-09-08 | Lecture | Cellular anatomy | Cellular structure and function, the lipid bilayer and what it contains. Cell adhesion mechanisms-cell junctions including gap junctions, tight junctions. membrane transporters. The electrochemical gradient and redox potential of the cell. Endocytosis | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-09-11 | Lecture | Cell membrane components | Membrane protein functions, important functions of the nucleus, including replication, transcription, & translation. Protein processing (Golgi) | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-09-13 | Lecture | Cell membrane components | Plasma membrane receptors -signaling mechanisms of receptor activation (TK, Gproteins). | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-09-15 | Lecture | Tissue structure and organization | Layers of tissue (epithelial, connective) -supporting tissue structures | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-09-18 | Lecture | Neurons: introduction to the nervous system | CNS vs PNS, function & structure of a neuron. Neuroglia, membrane potential, action potential, and ion channels | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-09-20 | Lecture | Autonomic nervous system (ANS) | Neurotransmitter of pre-and postganglionic neurons:Acetylcholine, noradrenaline: Synthesis and Mechanisms of action. Adrenal medulla:adrenaline, noradrenaline, dopamine. Concept of nonadrenergic-noncholinergic (NANC). Cholinergic receptors, and application to pharmacy Adrenergic receptors, and application to pharmacy. Receptor Distribution | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-09-22 | Lecture | Pain (nociception) | Pain categories, nociceptors, first/second pain -anterolateral pathways (fibres) Referral pain withdrawal reflexes, pain neurotransmitters, afferent pathways of pain | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-09-25 | Lecture | Pain | Inflammatory pain pathophysiology of pain. Neuropathic pain as an example -Central sensitization following peripheral nerve injury | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-09-27 | Lecture | Neurology: neuroanatomy and the CNS | Neuron morphology, glia of CNS, glia of PNS. Cerebrum, diencephalon, brainstem, cerebellum Brain protection. Meninges -Ventricles; Production and flow of cerebrospinal fluid. Blood-brain barrier | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-09-29 | Lecture | Cerebrum and Diencephalon | Overview -cortical structure -white matter -Diencephalon: Structure (and function) of the epi-, hypo-, thalamus | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-10-02 | Lecture | Neurology, brainstem and sensory physiology | Anatomy of key regions: Midbrain, pons, medulla oblongata; cerebral aqueduct, cerebral peduncles, superior and inferior colliculi Brainstem functions: -Cerebellum structure & function; motor learning Cranial nerves. Sensory physiology: Sensory information, sensation, perception. Receptor modalities, sensory receptors, afferent-receptor configurations -Receptive field, receptor potential, adaptation. Coding intensity, modality, and location of a sensory stimulus | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-10-04 | Lecture | Neurology: Sensory physiology | Sensory physiology: Somatic sensation: Receptors, pathways, primary somatosensory cortex. Motor control: Alpha-motor neurons as the final common pathway. Hierarchical control. Feedback control. Cerebellar damage. Proprioceptors, local feedback, spinal reflexes | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-10-06 | Lecture | Neurology: Motor Control Blood supply; Cerebral perfusion pressure and blood flow | Motor control: -Concepts of how motor system works: hierarchical control; Alphamotor neurons as the final common pathway. Cerebellum and feedback, cerebellar damage) -Local feedback. Monosynaptic reflex (includes terminology: agonist, synergist, antagonist -Motor cortices (primary motor, premotor, supplementary motor area) -Motor tracts Blood supply, Intracranial pressure, cerebral perfusion pressure, cerebral blood flow | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-10-09 | No class | Thanksgiving (NO CLASS) | Thanksgiving (NO CLASS) | — |
| PHARM 204 | Y1 | Fall | 2023-10-11 | Lecture | Neurology: Higher CNS function; Basal ganglia | Neurotransmitters -ACh, biogenic amines, amino acid neurotransmitters also neuropeptides, purines, others. Synthesis, receptors, reuptake and/or metabolism of select neurotransmitters, major roles -Alzheimer?s, myasthenia gravis, depression Basal ganglia, Parkinson?s, Anatomy, Basic functioning of healthy basal ganglia -Parkinson?s: Symptoms and basal ganglia function. Pharmacological and surgical treatments as examples to reinforce concepts regarding the physiological function of the CNS, and points of pharmaceutical intervention at the synapse | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-10-13 | Lecture | Cardiology: Anatomy of the heart; Electrical activity of the heart | Gross anatomy Electrical activity -Pacemaker cell vs. conducting fibre; Bachmann?s bundle and intermodal pathways, fibrous skeleton; rates of autorhymicity -Action potentials of pacemaker and contractile cells -Effects of ANS on rate (with mechanisms) and contractility (without mechanisms) -ECG and case study | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-10-16 | Lecture | Cardiology: blood flow 1 | Anatomy-Major Systemic Arteries and Veins Haemodynamics -Arterial and venous system blood vessel walls, characteristics summary. Driving force in the cardiovascular system (MAP) central venous pressure). Regulation of arteriolar resistance: Intrinsic mechanisms: local factors; Extrinsic mechanisms neuroendocrine, to regulate MAP | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-10-18 | Lecture | Cardiology: blood flow 2 | Venomotor tone and venous return and effects of Blood volume and venomotor tone on venous pressure and therefore MAP -Thermoregulation and arteriolar R -Coronary and skeletal muscles and vasodilation by Beta-2, note re: Beta-2 Rs on vascular smooth muscle cells ? beta-blockers and MAP. Regulation of MAP. Baroreceptor reflex regulation of blood pressure. Angiotensin II, ADH increase MAP | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-10-20 | Midterm exam | MIDTERM EXAM | Lectures 1-18 (up to Cardiology: blood flow 2) | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-10-23 | Lecture | Pulmonary | Anatomy- airways, resp epithelium. Mechanics. Blood flow -Sites of intervention. COPD. ARDS cause and consequences (wrt patient care) | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-10-25 | Lecture | GI (1/2) | GI tract anatomy: -oral cavity and teeth. Review of wall of GI tract + stomach wall + small intestine regional differences -diagnostic imaging for GI and liver. Liver blood flow and tissue substructure wrt to drug metabolism | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-10-27 | Lecture | GI (2/2) | GI: small intestine regional differences -diagnostic imaging for GI and liver. Liver blood flow and tissue substructure wrt to drug metabolism | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-10-27 | Midterm exam | MIDTERM REVIEW | MIDTERM REVIEW | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-10-30 | Lecture | Bone & Joint 1 | The skeletal system: osseous tissue and bone structure -Bone functions, histology, structure. Intramembranous ossification -Endochondral ossification | Dr. Doschak |
| PHARM 204 | Y1 | Fall | 2023-11-01 | Lecture | Bone & Joint 2 | Cartilage histology, growth, and composition. Basic multicellular unit (BMU). Bone resorption and formation -RANK / RANKLigand / OPG System | Dr. Doschak |
| PHARM 204 | Y1 | Fall | 2023-11-03 | Lecture | Bone & Joint 3 | Bone elongation: epiphyseal plate. Appositional growth. Formation of an osteon. Bone blood supply and innervation | Dr. Doschak |
| PHARM 204 | Y1 | Fall | 2023-11-06 | Lecture | Bone & Joint 4 | Joint classification -synovial joint characteristics. The knee joint. Aging and joints -sites of therapy in bone and joint | Dr. Doschak |
| PHARM 204 | Y1 | Fall | 2023-11-08 | Lecture | MSK (B & J - 5) | Skeletal muscle: structure -fibres and molecular makeup | Dr. Doschak |
| PHARM 204 | Y1 | Fall | 2023-11-10 | Lecture | MSK (B & J - 6) | Skeletal muscle: force generation (contraction). NMJ and its role (above). twitch summation, types of contraction (concentric, isometric, eccentric) | Dr. Doschak |
| PHARM 204 | Y1 | Fall | 2023-11-15 | Lecture | MSK (B & J - 7) | Skeletal: anatomy Smooth: anatomy, contraction | Dr. Doschak |
| PHARM 204 | Y1 | Fall | 2023-11-17 | Lecture | Integumetary system 1 | Skin: Epidermis, Dermis. Hypodermis; Skin colour; Blood supply and innervation -Hair, Nails, Sebaceous glands and follicles, Sweat glands | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-11-20 | Lecture | Integumetary system 2 | Sun/UV effects -interface with other systems (e.g., immune). Effects of aging interactions of therapeutics | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-11-22 | Lecture | Eye, Ear, Nose & Throat (EENT) | Eye anatomy: -flow of aqueous humor. Retina, macular degeneration -sites of drug action. Ear anatomy: -sound conduction, cochlea, site of drug action. Nose, pharynx, Paranasal sinuses, Larynx, Olfaction | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-11-24 | Lecture | Endocrine 1 | Fundamentals: amines, steroids, peptides. Energy metabolism -actions and regulation of insulin and glucagon. ANS in glucose homeostasis -secretion disorders of the hypothalamuspituitary axis -Cushing?s disease (cortisol effects) | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-11-27 | Lecture | Endocrine 2 | Thyroid gland and parathyroid. -Basic function of and tissue organization. -Use of diagnostic imaging for visualization | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-11-29 | Lecture | Renal 1 | Gross anatomy, blood supply and innervation to the kidneys. Renal corpuscle -key sites and actions of the nephron. | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-12-01 | Lecture | Renal 2 | Sodium on bp, blood volument, water effects -K+: direct effect of K+ on Na+/K+-ATPase -use of agents for diagnostic imaging | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-12-04 | Lecture | Reproductive 1 | Male reproductive system -Female reproductive system | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-12-06 | Lecture | Reproductive 2 | Ovulation and menstrual cycle -Sexual response and therapeutics -lactation and mammary glands | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-12-08 | Lecture | Reproductive 3 | Embryogenesis, fetal development. The placenta and blood exchange with mother Fetal development and the care in considering therapeutics | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2023-12-14 | Final exam | FINAL EXAM | FINAL EXAM | — |
| PHARM 233 | Y1 | Winter | 2024-01-08 | Lecture | 1. Pharmacogenomics 1 | Introduction Pharmacogenomics (PGx), The Basis for Precision Medicine, Overview PharmGkB, CPIC Websites, effect of environment, ethnicity , pollutants etc | D. Hamdy |
| PHARM 233 | Y1 | Winter | 2024-01-10 | Lecture | 2. Pharmacogenomics 2 | Classical and non-classical PGx (Genetics: DNA, RNA, transcription, translation, genetic variability, SNP, CNV, addition, deletion) | D. Hamdy |
| PHARM 233 | Y1 | Winter | 2024-01-12 | Lecture | 3. Pharmacogenomics 3 | Introduction to common Transporters, CYP P450 and Receptors alleles, Relationship between PK-PD-PGX and dose adjustments | D. Hamdy |
| PHARM 233 | Y1 | Winter | 2024-01-15 | Lecture | 4. Pharmacogenomics 4 | Basic techniques for genetic testing and diseases related to genes. Examples on PGX Pt. Case management using pharmGKB | D. Hamdy |
| PHARM 233 | Y1 | Winter | 2024-01-17 | Lecture | 5. GI Pharmacology 1 | Antiemetic Agents | J. Ussher |
| PHARM 233 | Y1 | Winter | 2024-01-19 | Lecture | 6. GI Pharmacology 2 | Agents for Neutralizing Gastric Acid Secretion | J. Ussher |
| PHARM 233 | Y1 | Winter | 2024-01-22 | Lecture | 7. GI Pharmacology 3 | Agents that Modulate Gastric Motility, Antidiarrheal Agents and Agents for Chronic Bowel Disease | J. Ussher |
| PHARM 233 | Y1 | Winter | 2024-01-24 | Lecture | 8. Respiratory Pharmacology | Drugs for COPD, Drugs for Asthma: Bronchodilators & Anti inflammatories | J. Ussher |
| PHARM 233 | Y1 | Winter | 2024-01-26 | Lecture | 9. Skin Pharmacology | Antiinflammatories & Other Agents for Skin Disorders | J. Ussher |
| PHARM 233 | Y1 | Winter | 2024-01-29 | Lecture | 10. Obesity Pharmacology & Pharmacotherapy 1 | Non-Pharmacological Approaches, Central Acting Agents, Gut HormoneBased Agents, and Medical Devices | J. Ussher |
| PHARM 233 | Y1 | Winter | 2024-01-31 | Lecture | 11. Obesity Pharmacology & Pharmacotherapy 2 | Non-Pharmacological Approaches, Central Acting Agents, Gut HormoneBased Agents, and Medical Devices | J. Ussher |
| PHARM 233 | Y1 | Winter | 2024-02-02 | Lecture | 12. Renal Pharmacology 1 | Diuretics | K. Gopal |
| PHARM 233 | Y1 | Winter | 2024-02-07 | Lecture | 13. Renal Pharmacology 2 | Agents for Renal Failure and Urinary Tract Infections | K. Gopal |
| PHARM 233 | Y1 | Winter | 2024-02-09 | Lecture | 14. Endocrine Pharmacology 1 | Type 1 Diabetes (Insulin and Insulin Analogues) | J. Ussher |
| PHARM 233 | Y1 | Winter | 2024-02-12 | Lecture | 15. Endocrine Pharmacology 2 | Type 2 Diabetes (Metformin, Sulfonylureas, and Thiazolidinediones) | J. Ussher |
| PHARM 233 | Y1 | Winter | 2024-02-14 | Lecture | 16. Endocrine Pharmacology 3 | Type 2 Diabetes (Incretin Based Therapies & SGLT2 Inhibitors) | J. Ussher |
| PHARM 233 | Y1 | Winter | 2024-02-16 | Lecture | 17. Anemia Pharmacology | Hematinic Agents | A. El-Kadi |
| PHARM 233 | Y1 | Winter | 2024-02-26 | Lecture | 18. Hematopoietic & Bone Pharmacology 1 | Agents for Osteoporosis and Osteoarthritis | A. El-Kadi |
| PHARM 233 | Y1 | Winter | 2024-02-28 | Lecture | 19. Hematopoietic & Bone Pharmacology 2 | Agents for Rheumatoid Arthritis, Gout and Hyperuricemia | A. El-Kadi |
| PHARM 233 | Y1 | Winter | 2024-03-01 | Lecture | 20. Endocrine and Reproductive Pharmacology 4 | Other Endocrine Disorders (Agents for Thyroid Disorders) | J. Ussher |
| PHARM 233 | Y1 | Winter | 2024-03-04 | Lecture | 21. Endocrine & Reproductive Pharmacology 5 | Other Endocrine Disorders (Agents for Addison's Disease, Cushing Syndrome) and Hormonal Therapies | J. Ussher |
| PHARM 233 | Y1 | Winter | 2024-03-06 | Lecture | 22. Endocrine Pharmacology 6 | Other Endocrine Disorders (Agents for Addison's Disease, Cushing Syndrome) and Hormone Replacement Therapy | J. Ussher |
| PHARM 233 | Y1 | Winter | 2024-03-08 | Lecture | 23. Microbial Pharmacology 1 | Bacterial Cell Wall Agents (Sulfonamides, Beta-Lactam Antibiotics, Glycopeptides, Polymixins, etc.) | A. Tabataei-Dakhili |
| PHARM 233 | Y1 | Winter | 2024-03-13 | Lecture | 24. Microbial Pharmacology 2 | Bacterial protein synthesis inhibitors (Tetracyclines, Aminoglycosides, etc.) | A. Tabataei-Dakhili |
| PHARM 233 | Y1 | Winter | 2024-03-15 | Lecture | 25. Microbial Pharmacology 3 | Antihelminthic Agents | A. Tabatabaei-Dakhili |
| PHARM 233 | Y1 | Winter | 2024-03-18 | Lecture | 26. Microbial Pharmacology 4 | Antimycobacterial Agents | J. Ussher |
| PHARM 233 | Y1 | Winter | 2024-03-19 | Lecture | 27. Microbial Pharmacology 5 | Antimalarial Agents | J. Ussher |
| PHARM 233 | Y1 | Winter | 2024-03-20 | Lecture | 28. Microbial Pharmacology 6 | Agents for Other Protozoal Infections (Trypanosomiasis, Leishmaniasis, Giardiasis Toxoplasmosis, etc.) | A. Tabatabaei-Dakhili |
| PHARM 233 | Y1 | Winter | 2024-03-22 | Lecture | 29. Microbial Pharmacology 7 | Antifungal Agents | K. Gopal |
| PHARM 233 | Y1 | Winter | 2024-03-25 | Lecture | 30. Cancer Chemotherapy 1 | Alkylating Agents, Antimetabolites and Cytotoxic Antibiotics | G. Sutendra |
| PHARM 233 | Y1 | Winter | 2024-03-27 | Lecture | 31. Cancer Chemotherapy 2 | Plant Derivatives, Hormone-Based Agents and Protein Kinase Inhibitors | G. Sutendra |
| PHARM 233 | Y1 | Winter | 2024-04-03 | Lecture | 32. Cancer Chemotherapy 3 | Immune Therapies for Cancer, Immunosuppressants, and Other Immunotherapies | G. Sutendra |
| PHARM 233 | Y1 | Winter | 2024-04-03 | Lecture | 33. Viral Pharmacology 1 | Agents for Hepatitis | A. Siraki |
| PHARM 233 | Y1 | Winter | 2024-04-05 | Lecture | 34. Viral Pharmacology 2 | Agents for HIV/AIDS | A. Siraki |
| PHARM 233 | Y1 | Winter | 2024-04-08 | Lecture | 35. Viral Pharmacology 3 | Alkylating Agents, Antimetabolites and Cytotoxic Antibiotics | A. Siraki |
| PHARM 233 | Y1 | Winter | 2024-04-10 | Lecture | 36. Miscellaneous Topics in Pharmacology 1 | Lifestyle Drug Uses & Drugs in Sport | J. Ussher |
| PHARM 233 | Y1 | Winter | 2024-04-12 | Lecture | 37. Miscellaneous Topics in Pharmacology 2 | Role of Pharmacology in Drug Development | J. Ussher |
| PHARM 302 | Y2 | Fall | 2023-09-06 | Lecture | Introduction: Overview of topics covered in the course | Introduction | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2023-09-08 | Lecture | Aseptic compounding techniques | Aseptic compounding techniques | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2023-09-11 | Lecture | Aseptic compounding techniques | Aseptic compounding techniques | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2023-09-13 | Lecture | Aseptic compounding techniques | Aseptic compounding techniques | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2023-09-15 | Lecture | Aseptic compounding techniques | Aseptic compounding techniques | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2023-09-15 | Seminar/case session | Pre lab Seminar Sterile compounding/Dissolution | Aseptic Compounding, Transdermal Dosage Forms, Dissolution Testing | TA |
| PHARM 302 | Y2 | Fall | 2023-09-18 | Lecture | Aseptic compounding techniques | Aseptic compounding techniques | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2023-09-18 | Laboratory | Lab- Sterile Compounding; Dissolution | Aseptic compounding techniques, Dissolution testing | TA |
| PHARM 302 | Y2 | Fall | 2023-09-20 | Lecture | Aseptic compounding techniques | Aseptic compounding techniques | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2023-09-20 | Laboratory | Lab-Sterile Compounding; Dissolution | Aseptic Compounding, Transdermal Dosage Forms, Dissolution Testing | TA |
| PHARM 302 | Y2 | Fall | 2023-09-22 | Lecture | Aseptic compounding techniques | Aseptic compounding techniques | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2023-09-22 | Laboratory | Lab-Sterile Compounding; Dissolution | Lab-Sterile Compounding; Dissolution | — |
| PHARM 302 | Y2 | Fall | 2023-09-25 | Laboratory | Lab- Sterile Compounding; Dissolution | Aseptic Compounding, Transdermal Dosage Forms, Dissolution Testing | TA |
| PHARM 302 | Y2 | Fall | 2023-09-25 | Lecture | Parenteral Products (TPN) | Parenteral Products | Jolayne Dahmer |
| PHARM 302 | Y2 | Fall | 2023-09-27 | Laboratory | Lab-Sterile Compounding; Dissolution | Aseptic Compounding, Transdermal Dosage Forms, Dissolution Testing | TBD |
| PHARM 302 | Y2 | Fall | 2023-09-27 | Lecture | Parenteral Products (LVP) | Parenteral Products | Ron Marcinoski |
| PHARM 302 | Y2 | Fall | 2023-09-29 | Lecture | Eye/Ear/Nose/Throat dosage | BioPharmaceutics | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2023-09-29 | Laboratory | Lab-Sterile Compounding; Dissolution | Aseptic Compounding, Transdermal Dosage Forms, Dissolution Testing | TA |
| PHARM 302 | Y2 | Fall | 2023-10-04 | Lecture | Eye/Ear/Nose/Throat dosage forms | BioPharmaceutics | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2023-10-04 | Laboratory | Lab- Sterile Compounding; Dissolution | Aseptic Compounding, Transdermal Dosage Forms, Dissolution Testing | TA |
| PHARM 302 | Y2 | Fall | 2023-10-06 | Lecture | Biopharmaceutics | Ophthalmic dosage forms and ENTs | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2023-10-06 | Laboratory | Lab-Sterile Compounding; Dissolution | Aseptic Compounding, Transdermal Dosage Forms, Dissolution Testing | TA |
| PHARM 302 | Y2 | Fall | 2023-10-11 | Lecture | Biopharmaceutics | Ophthalmic dosage forms and ENTs | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2023-10-11 | Laboratory | Lab-Sterile Compounding; Dissolution | Aseptic Compounding, Transdermal Dosage Forms, Dissolution Testing | TAs |
| PHARM 302 | Y2 | Fall | 2023-10-13 | Lecture | Biopharmaceutics | BioPharmaceutics | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2023-10-16 | Lecture | Biopharmaceutics | BioPharmaceutics | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2023-10-16 | Laboratory | Lab- Sterile Compounding; Dissolution | Aseptic Compounding, Transdermal Dosage Forms, Dissolution Testing | TA |
| PHARM 302 | Y2 | Fall | 2023-10-18 | Lecture | Controlled drug delivery systems | Controlled drug delivery systems | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2023-10-18 | Laboratory | Lab- Sterile Compounding; Dissolution | Aseptic Compounding, Transdermal Dosage Forms, Dissolution Testing | TA |
| PHARM 302 | Y2 | Fall | 2023-10-20 | Lecture | Controlled drug delivery systems | Controlled drug delivery systems | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2023-10-20 | Laboratory | Lab- Sterile Compounding; Dissolution | Aseptic Compounding, Transdermal Dosage Forms, Dissolution Testing | TA |
| PHARM 302 | Y2 | Fall | 2023-10-23 | Lecture | Transdermal Delivery Systems | TDS | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2023-10-27 | Seminar/case session | Pre lab seminar transdermal | Pre lab seminar transdermal | TA |
| PHARM 302 | Y2 | Fall | 2023-10-27 | Lecture | Transdermal Delivery Systems | TDS | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2023-10-30 | Lecture | Drug stability and expiration date | Drug stability and expiration date | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2023-10-30 | Laboratory | Lab-Transdermal | Aseptic Compounding, Transdermal Dosage Forms, Dissolution Testing | TA |
| PHARM 302 | Y2 | Fall | 2023-11-01 | Lecture | Drug stability and expiration date | Drug stability and expiration date | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2023-11-01 | Laboratory | Lab-Transdermal | Lab-Transdermal | TAs |
| PHARM 302 | Y2 | Fall | 2023-11-03 | Lecture | Drug stability and expiration date | Drug stability and expiration date | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2023-11-03 | Laboratory | Lab-Transdermal | Lab-Transdermal | — |
| PHARM 302 | Y2 | Fall | 2023-11-06 | Lecture | Drug stability and expiration date | Drug stability and expiration date | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2023-11-06 | Laboratory | Lab-Transdermal | Lab-Transdermal | TAs |
| PHARM 302 | Y2 | Fall | 2023-11-08 | Laboratory | Lab-Transdermal | Lab-Transdermal | TA |
| PHARM 302 | Y2 | Fall | 2023-11-08 | Lecture | Nano-Medicine | Nano-Medicine | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2023-11-10 | Laboratory | Lab-Transdermal | Lab-Transdermal | TA |
| PHARM 302 | Y2 | Fall | 2023-11-10 | Lecture | Nano-Medicine | Nano Medicine | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2023-11-15 | Lecture | Pharmaceutical Biotechnology | Pharmaceutical Biotechnology | Dr Doschak |
| PHARM 302 | Y2 | Fall | 2023-11-17 | Lecture | Pharmaceutical Biotechnology | Pharmaceutical Biotechnology | Dr Doschak |
| PHARM 302 | Y2 | Fall | 2023-11-20 | Laboratory | Biopharmaceutics-Simulation | Biopharmaceutics | TA |
| PHARM 302 | Y2 | Fall | 2023-11-20 | Lecture | Pharmaceutical Biotechnology | Pharmaceutical Biotechnology | Dr Doschak |
| PHARM 302 | Y2 | Fall | 2023-11-22 | Laboratory | Biopharmaceutics-Simulation | Biopharmaceutics | TA |
| PHARM 302 | Y2 | Fall | 2023-11-22 | Lecture | Pharmaceutical Biotechnology | Pharmaceutical Biotechnology | Dr Doschak |
| PHARM 302 | Y2 | Fall | 2023-11-24 | Laboratory | Biopharmaceutics-Simulation | Biopharmaceutics | TA |
| PHARM 302 | Y2 | Fall | 2023-11-24 | Lecture | Pharmaceutical Biotechnology: Protein Delivery | Pharmaceutical Biotechnology: Protein Delivery | Dr Wishart |
| PHARM 302 | Y2 | Fall | 2023-11-26 | Lecture | Pharmaceutical Biotechnology: Protein Delivery | Pharmaceutical Biotechnology: protein Delivery | Dr Wishart |
| PHARM 302 | Y2 | Fall | 2023-11-29 | Lecture | Gene Therapy | Gene Therapy | Diana Diaz Dussan |
| PHARM 302 | Y2 | Fall | 2023-12-01 | Lecture | Gene Therapy | Gene Therapy | Diana Diaz-Dussan |
| PHARM 302 | Y2 | Fall | 2023-12-04 | Lecture | Regulatory Science | Regulatory science | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2023-12-06 | Lecture | Regulatory Science | Regulatory science | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2023-12-08 | Lecture | Hot Topics in Pharmaceutics | Hot Topics in Pharmaceutics | Dr Lavasanifar |
| PHARM 303 | Y2 | Fall | 2023-09-06 | Lecture | Lecture 1 | Introduction, Kinetics of Transport | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-09-08 | Lecture | Lecture 2 | Kinetics of Transport, Kinetics of iv bolus Doses | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-09-11 | Lecture | Lecture 3 | See Above | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-09-13 | Lecture | Lecture 4 | See Above | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-09-15 | Lecture | Lecture 5 | Kinetics of iv bolus Doses | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-09-18 | Lecture | Lecture 6 | Compartmental Concepts | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-09-20 | Lecture | Lecture 7 | See Above | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-09-22 | Lecture | Lecture 8 | See Above | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-09-25 | Lecture | Lecture 9 | Clearance additivity, 2 compartment mode | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-09-27 | Lecture | Lecture 10 | Multiple compartment model | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-09-29 | Lecture | Lecture 11 | Oral absorption and bioequivalence | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-10-01 | Lecture | Lecture 22 | Drug clearance | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-10-02 | Midterm exam | MIDTERM | MIDTERM | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-10-04 | Lecture | Lecture 12 | See Above | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-10-06 | Lecture | Lecture 13 | Oral absorption | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-10-11 | Lecture | Lecture 14 | Bioequivalence | TBA |
| PHARM 303 | Y2 | Fall | 2023-10-13 | Lecture | Lecture 15 | IV infusion | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-10-16 | Lecture | Lecture 16 | See Above | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-10-18 | Lecture | Lecture 17 | Multiple dose PK | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-10-20 | Lecture | Lecture 18 | See above | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-10-23 | Lecture | Lecture 19 | PK-PD relationship | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-10-25 | Lecture | Lecture 19 | Drug distribution | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-10-27 | Lecture | Lecture 20 | Drug distribution | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-10-30 | Lecture | Lecture 21 | Drug distribution, Drug clearance | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-11-03 | Lecture | Lecture 23 | Drug distribution, Drug clearance | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-11-06 | Midterm exam | Midterm 2 | Midterm 2 | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-11-08 | Lecture | Lecture 24 | Drug clearance | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-11-10 | Lecture | Lecture 25 | See Above | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-11-15 | Lecture | Lecture 26 | See Above | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-11-17 | Lecture | Lecture 27 | Clearance | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-11-20 | Lecture | Lecture 28 | Nonlinear elimination | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-11-22 | Lecture | Lecture 29 | Pharmacokinetic based drug interactions | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-11-24 | Lecture | Lecture 31 | Clinical factors affecting pharmacokinetics | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-11-27 | Lecture | Lecture 32 | Clinical variables affecting PK | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-11-29 | Lecture | Lecture 33 | Effects of age on pharmacokinetics | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-12-01 | Lecture | Lecture 34 | Effects of age on pharmacokinetics | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-12-04 | Lecture | Lecture 35 | Drugs in pregnancy and lactation | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-12-06 | Lecture | Lecture 36 | Drugs in pregnancy and lactation | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-12-08 | Lecture | Lecture 37 | Other patient-specific changes in drug PK | Tony Kiang |
| PHARM 303 | Y2 | Fall | 2023-12-18 | Final exam | FINAL | FINAL | Dion Brocks |
| PHARM 310 | Y2 | Fall | 2023-09-07 | Lecture | Aby structure and B-Cell diversity | Antibodies: structure, classes, diversity | M. Doschak |
| PHARM 310 | Y2 | Fall | 2023-09-12 | Lecture | Immunoassays and ELISA & Cell Mediated Immunity (1/2) | Point-of-Care (POC) testing, Antigen recognition by T-lymphocytes, Development of lymphocytes | M. Doschak |
| PHARM 310 | Y2 | Fall | 2023-09-14 | Lecture | Cell-mediated Immunity (2/2) | Antigen recognition by T-lymphocytes, Development of lymphocytes, T-cell mediated immunity | M. Doschak |
| PHARM 310 | Y2 | Fall | 2023-09-19 | Midterm exam | Midterm exam | Midterm exam | M. Doschak |
| PHARM 310 | Y2 | Fall | 2023-09-21 | Lecture | Humoral Immunity and Complement | Development of B-lymphocytes, Immunity mediated by B cells and antibodies | M. Doschak |
| PHARM 310 | Y2 | Fall | 2023-09-26 | Lecture | Body’s Defense Against Infection & Immune Disorders (1/2) | Immune responses against infection, Innate immune responses, Adaptive immune responses, Allergy and hypersensitivity | M. Doschak |
| PHARM 310 | Y2 | Fall | 2023-09-28 | Lecture | Allergy, Hypersensitivity and Immune Disorders | Autoimmune disease | M. Doschak |
| PHARM 310 | Y2 | Fall | 2023-10-05 | Lecture | Vaccines | How vaccines work, Vaccine types, Related current topics: COVID vaccines | M. Doschak |
| PHARM 310 | Y2 | Fall | — | Lecture | Elements of the Immune System | Innate & Acquired Immunity: specificity and memory, Cells and organs of immune system, Clonal selection theory | — |
| PHARM 401 | Y3 | Winter | 2024-01-08 | Lecture | 1. Introduction to the course. | Introduction | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2024-01-10 | Lecture | 2. Toxicology | General principles of toxicology. What is toxicity? | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2024-01-12 | Lecture | 3. Adverse Drug Reactions | Types of ADR (A-F) | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2024-01-15 | Lecture | 4. Toxicological Patient Assessment | What is unique to tox patients | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2024-01-17 | Lecture | 5. Toxicological Patient Assessment | Toxidromes; Antidotes | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2024-01-19 | Lecture | 6. Mechanisms of cell death and tissue repair | Mechanisms of cell death and tissue repair | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2024-01-22 | Lecture | 7. Antihistamines and Decongestants | Toxicity from OTC drugs, e.g. Benadryl | Dr. Ahmed Essa |
| PHARM 401 | Y3 | Winter | 2024-01-22 | Lecture | 8. What Is In Your Medicine Cabinet? | Are there hazards to worry about – such as aspirin, NSAIDs, acetaminophen | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2024-01-24 | Lecture | 9. Dietary Supplements/Stings/Bites | Concerns with supplements, Things that bite | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2024-01-26 | Lecture | 10. Radiation Toxicity | Sources, signs, mechanisms, toxidromes | Dr. Arno Siraki |
| PHARM 401 | Y3 | Winter | 2024-01-29 | Lecture | 11. Immunotoxicity | Toxic Responses of the Immune System | Dr. Arno Siraki |
| PHARM 401 | Y3 | Winter | 2024-01-31 | Lecture | 12. Genotoxicity and Carcinogenicity of Drugs | Mechanisms, theory and practical examples | Dr. Ayman El-Kadi |
| PHARM 401 | Y3 | Winter | 2024-02-02 | Lecture | 13. Forensic Toxicology | Forensic death investigation from a toxicology perspective, including the problem of changing drug and alcohol concentrations after death. Several unusual toxicology related deaths will be reviewed. | Dr. Graham Jones |
| PHARM 401 | Y3 | Winter | 2024-02-05 | Other exam/test | 14. Term Exam 1 | Lectures 1-13 | — |
| PHARM 401 | Y3 | Winter | 2024-02-07 | Lecture | 15. Organ Toxicity | 15. Organ Toxicity | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2024-02-09 | Lecture | 16. Organ Toxicity | 16. Organ Toxicity | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2024-02-12 | Lecture | 17. Anticoaggulatant Toxicity | Warfarin toxicity, DOAC, Management of high INR? | Dr. Tammy Bungard |
| PHARM 401 | Y3 | Winter | 2024-02-14 | Lecture | 18. Cancer Survivorship | Chemotoxicity, long-term survival management, Exploring safety measures to prevent devastating accidental chemotherapy toxicities | Dr. Tara Leslie |
| PHARM 401 | Y3 | Winter | 2024-02-16 | Lecture | 19. Chemotherapy Safety | Oncology – chemotherapeutic toxicity/safety | Dr. Tara Leslie |
| PHARM 401 | Y3 | Winter | 2024-02-26 | Lecture | 20. Toxicological Patient Decontamination | Poison decontamination | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2024-02-28 | Lecture | 21. Special Populations Geriatrics | Toxicological concerns in geriatric populations | Dr. Cheryl Sadowski |
| PHARM 401 | Y3 | Winter | 2024-03-01 | Lecture | 22. Special Populations MAiD | Introduction, what is involved, what drugs, regimen/combinations, potential outcomes | Dr. Terri Schindel |
| PHARM 401 | Y3 | Winter | 2024-03-04 | Lecture | 23. Special Populations Pediatrics | Toxicological concerns for reproduction, perinatal and pediatric populations | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2024-03-06 | Lecture | 24. Case - Special Populations | Group work on case – Special populations | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2024-03-08 | Quiz | 25. Case Debrief/Quiz 1 | Quiz (eClass on Case 1) | Dr. Sandra Trkulja/Dr. Cheryl Sadowski |
| PHARM 401 | Y3 | Winter | 2024-03-11 | Lecture | 26. Special Topics in Advanced Pharmacology | Biologics – Mechanisms, pharmacokinetics, pharmacodynamics, and therapeutics of polyclonal antibodies (e.g. antithymocyte globulin) | Dr. Tony Kiang |
| PHARM 401 | Y3 | Winter | 2024-03-13 | Lecture | 27. Special Topics in Advanced Pharmacology | Transplant biologics, Biologics – Mechanisms, pharmacokinetics, pharmacodynamics, and therapeutics of monoclonal antibodies (e.g. anti-CD3, anti-CD52, anti-CD20, and anti-CD25) | Dr. Tony Kiang |
| PHARM 401 | Y3 | Winter | 2024-03-15 | Lecture | 28. Special Topics in Advanced Pharmacology | Pharmacological principles of cell and gene-based therapy (e.g. tisagenlecleucel for B-cell leukemia and voretigene neparvovec-rzyl for inherited retinal dystrophies) | Dr. Tony Kiang |
| PHARM 401 | Y3 | Winter | 2024-03-18 | Lecture | 29. Restarting Medications After Overdose | Tools to assist with deciding on restarting medications | Matt Mink (TBD) |
| PHARM 401 | Y3 | Winter | 2024-03-20 | Other exam/test | 30. Term Exam 2 | Lecture 14-24 | — |
| PHARM 401 | Y3 | Winter | 2024-03-22 | Lecture | 31. Drugs of Abuse 1 | Stimulants | Dr. Essi Salokangas |
| PHARM 401 | Y3 | Winter | 2024-03-25 | Lecture | 32. Drugs of Abuse 2 | CNS Depressants | Dr. Candace Necyk |
| PHARM 401 | Y3 | Winter | 2024-03-25 | Lecture | 33. Drugs of Abuse 3 | Hallicinogens | Dr. Candace Necyk |
| PHARM 401 | Y3 | Winter | 2024-03-27 | Lecture | 34. Drugs of Abuse 4 | Toxic Alcohols | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2024-04-03 | Lecture | 35. Drugs of Abuse 5 | Harmful Hookah, Cannabis, Vaping and e-cigarettes | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2024-04-05 | Lecture | 36. Case - Drugs of Abuse | Group work on case – drugs of abuse | Dr. John Seubert/Dr. Essi Salokangas |
| PHARM 401 | Y3 | Winter | 2024-04-08 | Quiz | 37. Case Debrief/Quiz 2 | Quiz 2 (eClass on Case 2) | Dr. Essi Salokangas |
| PHARM 401 | Y3 | Winter | 2024-04-10 | Lecture | 38. Drugs that are necessary but carry a risk of toxicity | Post-marketing Surveillance, Black Box Warnings | Dr. Arno Siraki |
| PHARM 401 | Y3 | Winter | 2024-04-12 | Lecture | 39. Deliberate Poisonings | Toxicologic misfortunes and deliberate poisonings. | Dr. John Seubert |
Assessment Information
| PHARM 201 | Y1 | Final exam | Final exam | — | — |
| PHARM 201 | Y1 | Unit assessment 1 - Functional groups, characteristics and roles. | Quiz | — | — |
| PHARM 201 | Y1 | Unit assessment 2 - Acidic and basic functional groups. | Quiz | — | — |
| PHARM 201 | Y1 | Unit assessment 3 - Problems with pH and pKa. | Quiz | — | — |
| PHARM 201 | Y1 | Unit assessment 4 - Salts and solubility. | Quiz | — | — |
| PHARM 201 | Y1 | Unit assessment 5 - Drug binding interactions. | Quiz | — | — |
| PHARM 201 | Y1 | Unit assessment 6 - Stereochemistry. | Quiz | — | — |
| PHARM 201 | Y1 | Unit assessment 7 - Drug metabolism. | Quiz | — | — |
| PHARM 201 | Y1 | Unit assessment 8 - SAR and drug design strategies. | Quiz | — | — |
| PHARM 202 | Y1 | Lab Report Capsules | Assignment/written work | 2% | — |
| PHARM 202 | Y1 | Lab Report Emulsions | Assignment/written work | 2% | — |
| PHARM 202 | Y1 | Lab Report Semisolids 1+2 | Assignment/written work | 2% | — |
| PHARM 202 | Y1 | Lab Report Solubility | Assignment/written work | 2% | — |
| PHARM 202 | Y1 | Lab Report Suppositories | Assignment/written work | 2% | — |
| PHARM 202 | Y1 | Lab Report Suspensions | Assignment/written work | 2% | — |
| PHARM 202 | Y1 | Final | Final exam | 40% | — |
| PHARM 202 | Y1 | Midterm | Midterm exam | 40% | — |
| PHARM 202 | Y1 | Lab Exam | Other exam/test | 8% | — |
| PHARM 203 | Y1 | Final | Final exam | 65% | — |
| PHARM 203 | Y1 | Midterm | Midterm exam | 35% | — |
| PHARM 204 | Y1 | Online Assignments | Assignment/written work | 10% | — |
| PHARM 204 | Y1 | Final | Final exam | 55% | — |
| PHARM 204 | Y1 | Midterm | Midterm exam | 30% | — |
| PHARM 204 | Y1 | In class Quizzes | Quiz | 5% | — |
| PHARM 233 | Y1 | Final | Final exam | 50% | — |
| PHARM 233 | Y1 | Midterm 1 | Midterm exam | 25% | — |
| PHARM 233 | Y1 | Midterm 2 | Midterm exam | 25% | — |
| PHARM 302 | Y2 | Hot Topic Assignment | Assignment/written work | 5% | — |
| PHARM 302 | Y2 | Lab reports (four) | Assignment/written work | 10% | — |
| PHARM 302 | Y2 | Final | Final exam | 40% | — |
| PHARM 302 | Y2 | Lab Quiz | Other exam/test | 5% | — |
| PHARM 302 | Y2 | Mid term | Other exam/test | 40% | — |
| PHARM 303 | Y2 | Assignments | Assignment/written work | 13% | — |
| PHARM 303 | Y2 | Final | Final exam | 42% | — |
| PHARM 303 | Y2 | Midterm examination 1 | Midterm exam | 20% | — |
| PHARM 303 | Y2 | Midterm examination 2 | Midterm exam | 23% | — |
| PHARM 303 | Y2 | Class Participation | Participation/professionalism | 2% | — |
| PHARM 310 | Y2 | Final | Final exam | 60% | — |
| PHARM 310 | Y2 | Midterm | Midterm exam | 40% | — |
| PHARM 401 | Y3 | Final | Final exam | 30% | — |
| PHARM 401 | Y3 | Term Exam 1 | Other exam/test | 30% | — |
| PHARM 401 | Y3 | Term Exam 2 | Other exam/test | 30% | — |
| PHARM 401 | Y3 | Case 1 - Quiz (eClass) | Quiz | 5% | — |
| PHARM 401 | Y3 | Case 2 - Quiz (eClass) | Quiz | 5% | — |
Use these searchable records to verify the course, session and assessment evidence behind the curriculum portrait. The browser supports inspection and verification rather than additional curriculum analysis.
Course Information
| PHARM 201 — PHARM 201 - Medicinal Chemistry | Y1 | Fall | 36 | 4 | 0 | Final exam (1); Midterm exam (1); Quiz (4) | — |
| PHARM 202 — PHARM 202 - Pharmaceutics 1 | Y1 | Winter | 37 | 10 | 18 | Assignment/written work (6); Final exam (1); Midterm exam (1); Other exam/test (1) | — |
| PHARM 203 — PHARM 203 - Pharmacology 1 | Y1 | Fall | 38 | 0 | 0 | Final exam (1); Midterm exam (1) | — |
| PHARM 204 — PHARM 204 - Anatomy/Physiology for Pharmacy | Y1 | Fall | 37 | 0 | 0 | Assignment/written work (1); Final exam (1); Midterm exam (1); Quiz (1) | — |
| PHARM 233 — PHARM 233 - Pharmacology 2 | Y1 | Winter | 37 | 0 | 0 | Final exam (1); Midterm exam (2) | — |
| PHARM 302 — PHARM 302 - Pharmaceutics 2 | Y2 | Fall | 37 | 2 | 21 | Assignment/written work (2); Final exam (1); Other exam/test (1) | — |
| PHARM 303 — PHARM 303 - Pharmacokinetics | Y2 | Fall | 37 | 0 | 0 | Assignment/written work (1); Final exam (1); Midterm exam (2) | — |
| PHARM 310 — PHARM 310 - Immunology and Biotechnology | Y2 | Fall | 8 | 0 | 0 | Final exam (1); Midterm exam (1) | — |
| PHARM 401 — PHARM 401 - Toxicology | Y3 | Winter | 33 | 1 | 0 | Final exam (1); Other exam/test (3); Quiz (2) | — |
Session Information
| PHARM 201 | Y1 | Fall | 2024-09-06 | Lecture | Functional groups - characteristics and roles | Definition of a functional group; relevant functional groups in drug molecules. | Khaled Barakat |
| PHARM 201 | Y1 | Fall | 2024-09-06 | Lecture | Functional groups - characteristics and roles | Course overview | Khaled Barakat |
| PHARM 201 | Y1 | Fall | 2024-09-09 | Lecture | Functional groups - characteristics and roles | Physical chemical properties associated to functional groups in drug molecules. | Khaled Barakat |
| PHARM 201 | Y1 | Fall | 2024-09-11 | Lecture | Functional groups - characteristics and roles | Electronic and inductive effects. | Khaled Barakat |
| PHARM 201 | Y1 | Fall | 2024-09-13 | Lecture | Functional groups - characteristics and roles | Steric effects; solubility effects; binding interactions. | Khaled Barakat |
| PHARM 201 | Y1 | Fall | 2024-09-16 | Lecture | Acidic and basic functional groups | Most common types of acidic and basic functional groups in drug molecules. | Amir Tabatabei |
| PHARM 201 | Y1 | Fall | 2024-09-17 | Seminar/case session | Seminar 1 | Clinical relevance of organic functional groups in drug therapy | Amir Tabatabei |
| PHARM 201 | Y1 | Fall | 2024-09-18 | Lecture | Acidic and basic functional groups | Physiologically relevant acidic and basic functional groups. | Amir Tabatabei |
| PHARM 201 | Y1 | Fall | 2024-09-20 | Lecture | Acidic and basic functional groups | Therapeutic significance of acidic and basic groups. | Amir Tabatabei |
| PHARM 201 | Y1 | Fall | 2024-09-23 | Lecture | Acidic and basic functional groups | Correlating the presence (or absence) of acidic / basic groups to therapeutic effects. | Amir Tabatabei |
| PHARM 201 | Y1 | Fall | 2024-09-23 | Lecture | Problems involving pH and pKa | pH and pKa: principles and applications in clinical practice; using the Henderson-Hasselbach equation. | Amir Tabatabei |
| PHARM 201 | Y1 | Fall | 2024-09-25 | Lecture | Problems involving pH and pKa | Importance of pH and pKa in drug therapy; influence of pH and pKa on the solubility of a drug molecule. | Amir Tabatabei |
| PHARM 201 | Y1 | Fall | 2024-09-27 | Lecture | Problems involving pH and pKa | Relationship between pH and pKa on the duration of action of drug molecules; influence of pH and pKa on drug binding interactions (drug potency). | Amir Tabatabei |
| PHARM 201 | Y1 | Fall | 2024-10-02 | Lecture | Problems involving pH and pKa | Predicting chemical antagonism between drug molecules using their pKa values. | Amir Tabatabei |
| PHARM 201 | Y1 | Fall | 2024-10-04 | Lecture | Problems involving pH and pKa | Drug interactions based on pH and their pKa values. | Amir Tabatabei |
| PHARM 201 | Y1 | Fall | 2024-10-07 | Lecture | Salts and solubility | Salts and solubility of drug molecules; definition of salt; formation of salts from acid and basic drug molecules. | Amir Tabatabei |
| PHARM 201 | Y1 | Fall | 2024-10-08 | Seminar/case session | Seminar 2 | Importance of pKa in drug therapy | Amir Tabatabei |
| PHARM 201 | Y1 | Fall | 2024-10-09 | Lecture | Salts and solubility | Inorganic salts; organic salts; salts and their influence on drug-drug and drug-food interactions. | Amir Tabatabei |
| PHARM 201 | Y1 | Fall | 2024-10-11 | Lecture | Salts and solubility | Solubility of salts and their partition coefficient; therapeutic use of salts based on their water solubility; the balance between water and lipid solubility. | Amir Tabatabei |
| PHARM 201 | Y1 | Fall | 2024-10-16 | Lecture | Salts and solubility | Strategies for optimizing drug solubility; relationship between solubility and drug metabolism. | Amir Tabatabei |
| PHARM 201 | Y1 | Fall | 2024-10-18 | Lecture | Drug metabolism | Drug metabolism: General concepts. | Ayman El-Kadi |
| PHARM 201 | Y1 | Fall | 2024-10-21 | Lecture | Drug metabolism | Factors affecting drug metabolism; Phase I and Phase II metabolism. | Ayman El-Kadi |
| PHARM 201 | Y1 | Fall | 2024-10-22 | Seminar/case session | Seminar 3 | Salts and solubility in drug therapy | Amir Tabatabei |
| PHARM 201 | Y1 | Fall | 2024-10-23 | Lecture | Drug metabolism | Oxidation reactions by the cytochrome P450 (CYP450) family of enzymes. | Ayman El-Kadi |
| PHARM 201 | Y1 | Fall | 2024-10-28 | Lecture | Drug metabolism | Reduction reactions by the cytochrome P450 (CYP450) family of enzymes. | Ayman El-Kadi |
| PHARM 201 | Y1 | Fall | 2024-10-30 | Lecture | Drug metabolism | Hydrolysis reactions; conjugation reactions. | Ayman El-Kadi |
| PHARM 201 | Y1 | Fall | 2024-11-01 | Lecture | Drug metabolism | Relationship between drug metabolism and pharmacological activity. | Ayman El-Kadi |
| PHARM 201 | Y1 | Fall | 2024-11-04 | Lecture | Stereochemistry | Conformational isomers; definition of the active conformation in drug; molecules; conformational restriction. | Amir Tabatabei |
| PHARM 201 | Y1 | Fall | 2024-11-06 | Lecture | Stereochemistry | Stereochemistry: chirality and asymmetry; enantiomers. | Amir Tabatabei |
| PHARM 201 | Y1 | Fall | 2024-11-13 | Lecture | Stereochemistry | Pharmacological implications of enantiomeric mixtures; diastereomers. | Amir Tabatabei |
| PHARM 201 | Y1 | Fall | 2024-11-15 | Lecture | Stereochemistry | Geometric isomers; pharmacological implications of diastereomeric mixtures. | Amir Tabatabei |
| PHARM 201 | Y1 | Fall | 2024-11-18 | Lecture | Drug binding interactions | Drug binding interactions and their relationship with potency. | Khaled Barakat |
| PHARM 201 | Y1 | Fall | 2024-11-20 | Lecture | Drug binding interactions | Covalent bonds; non-covalent bonds; ionic bonds. | Khaled Barakat |
| PHARM 201 | Y1 | Fall | 2024-11-22 | Lecture | Drug binding interactions | Ion-dipole and dipole-dipole; interactions. | Khaled Barakat |
| PHARM 201 | Y1 | Fall | 2024-11-25 | Lecture | Drug binding interactions | Hydrogen bonds; van der Waals interactions; hydrophobic bonding. | Khaled Barakat |
| PHARM 201 | Y1 | Fall | 2024-11-27 | Lecture | Structure-Activity Relationships and Classical Strategies in Drug Design | Structure-Activity Relationships (SAR): general description; examples of SARs; SAR and pharmacological activity. | Khaled Barakat |
| PHARM 201 | Y1 | Fall | 2024-11-28 | Seminar/case session | Seminar 4 | Drug metabolism | Ayman El-Kadi |
| PHARM 201 | Y1 | Fall | 2024-11-29 | Lecture | Structure-Activity Relationships and Classical Strategies in Drug Design | SAR and binding interactions; SARs and the absorption, distribution, metabolism, and excretion (ADME) process. | Khaled Barakat |
| PHARM 201 | Y1 | Fall | 2024-12-02 | Lecture | Structure-Activity Relationships and Classical Strategies in Drug Design | Isosters and bioisosteres; homologation; chain branching; prodrugs. | Khaled Barakat |
| PHARM 201 | Y1 | Fall | 2024-12-02 | Lecture | Structure-Activity Relationships and Classical Strategies in Drug Design | SAR, drug interactions and adverse drug reactions, molecular modification, conformational restriction, variation of functional groups. | Khaled Barakat |
| PHARM 202 | Y1 | Winter | 2025-01-06 | Lecture | Lecture 1 | Introduction | Loebenberg |
| PHARM 202 | Y1 | Winter | 2025-01-08 | Lecture | Lecture 2 | Compounding | Loebenberg |
| PHARM 202 | Y1 | Winter | 2025-01-10 | Lecture | Lecture 3 | USP 795 | Loebenberg |
| PHARM 202 | Y1 | Winter | 2025-01-10 | Seminar/case session | Seminar Lab introduction | Introduction | Loebenberg/Sanaee |
| PHARM 202 | Y1 | Winter | 2025-01-13 | Laboratory | Lab Sign-in-A | Sign in | Loebenberg/Sanaee |
| PHARM 202 | Y1 | Winter | 2025-01-13 | Lecture | Lecture 4 | USP 795 | Loebenberg |
| PHARM 202 | Y1 | Winter | 2025-01-15 | Laboratory | Lab sign-in-B | Sign in | Loebenberg/Sanaee |
| PHARM 202 | Y1 | Winter | 2025-01-15 | Lecture | Lecture 5 | Solubility | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2025-01-17 | Lecture | Lecture 6 | Solubility | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2025-01-17 | Seminar/case session | Seminar Equipment and Procedures | Equipment and accuracy | Loebenberg/Sanaee |
| PHARM 202 | Y1 | Winter | 2025-01-20 | Lecture | Lecture 7 | Pharm. Solutions | Loebenberg |
| PHARM 202 | Y1 | Winter | 2025-01-22 | Lecture | Lecture 8 | Pharm Waters | Loebenberg |
| PHARM 202 | Y1 | Winter | 2025-01-24 | Lecture | Lecture 9 | Suspensions | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2025-01-24 | Seminar/case session | Seminar Solubility | Solubility | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2025-01-27 | Laboratory | Lab Solubility-A | Solubility | Lavasanifar/Sanaee |
| PHARM 202 | Y1 | Winter | 2025-01-27 | Lecture | Lecture 10 | Suspensions | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2025-01-29 | Laboratory | Lab Solubility-B | Solubility | Lavasanifar/Sanaee |
| PHARM 202 | Y1 | Winter | 2025-01-29 | Lecture | Lecture 11 | Suspensions | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2025-01-31 | Lecture | Lecture 12 | Suspensions | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2025-01-31 | Seminar/case session | Seminar Suspensions | Suspension | Loebenberg/Sanaee |
| PHARM 202 | Y1 | Winter | 2025-02-03 | Laboratory | Lab Suspensions-A | Suspension | Loebenberg/Sanaee |
| PHARM 202 | Y1 | Winter | 2025-02-03 | Lecture | Lecture 13 | Emulsions | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2025-02-05 | Laboratory | Lab Suspsnsion-B | Suspension | Loebenberg/Sanaee |
| PHARM 202 | Y1 | Winter | 2025-02-05 | Lecture | Lecture 14 | Emulsions | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2025-02-07 | Lecture | Lecture 15 | Emulsions | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2025-02-07 | Seminar/case session | Seminar Emulsions | Emulsion | Loebenberg/Sanaee |
| PHARM 202 | Y1 | Winter | 2025-02-10 | Laboratory | Lab Emulsions-A | Emulsion | Loebenberg/Sanaee |
| PHARM 202 | Y1 | Winter | 2025-02-10 | Lecture | Lecture 16 | Emulsions | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2025-02-12 | Laboratory | Lab Emulsions-B | Emulsion | Loebenberg/Sanaee |
| PHARM 202 | Y1 | Winter | 2025-02-12 | Lecture | Lecture 17 | Semisolids | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2025-02-14 | Lecture | Lecture 18 | Semisolids | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2025-02-14 | Seminar/case session | Seminar Semisolids | Semisolids | Loebenberg/Sanaee |
| PHARM 202 | Y1 | Winter | 2025-02-24 | Laboratory | Lab Semisolids-1A | Semisolids | Loebenberg/Sanaee |
| PHARM 202 | Y1 | Winter | 2025-02-24 | Lecture | Lecture 19 | Colloids | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2025-02-25 | Midterm exam | Midterm | Midterm | Raimar Loebenberg, Afsaneh Lavasanifar, Forughalsadat Sanaee |
| PHARM 202 | Y1 | Winter | 2025-02-26 | Laboratory | Lab Semisolids-1B | Semisolids | Loebenberg/Sanaee |
| PHARM 202 | Y1 | Winter | 2025-02-26 | Lecture | Lecture 20 | Colloids | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2025-02-28 | Lecture | Lecture 21 | Powders | Loebenberg |
| PHARM 202 | Y1 | Winter | 2025-02-28 | Seminar/case session | Seminar SOP | Seminar SOP | Loebenberg/Sanaee |
| PHARM 202 | Y1 | Winter | 2025-03-03 | Laboratory | Lab Semisolids-2A | Semisolids | Loebenberg/Sanaee |
| PHARM 202 | Y1 | Winter | 2025-03-03 | Lecture | Lecture 22 | Capsules | Loebenberg |
| PHARM 202 | Y1 | Winter | 2025-03-05 | Laboratory | Lab Semisolids-2B | Semisoids | Loebenberg/Sanaee |
| PHARM 202 | Y1 | Winter | 2025-03-05 | Lecture | Lecture 23 | Suppository bases | Loebenberg |
| PHARM 202 | Y1 | Winter | 2025-03-07 | Lecture | Lecture 24 | Inserts, Suppositories | Loebenberg |
| PHARM 202 | Y1 | Winter | 2025-03-07 | Seminar/case session | Seminar Capsules | Powder and Capsules | Loebenberg/Sanaee |
| PHARM 202 | Y1 | Winter | 2025-03-10 | Laboratory | Lab Capsules-A | Capsules | Loebenberg/Sanaee |
| PHARM 202 | Y1 | Winter | 2025-03-10 | Lecture | Lecture 25 | Tablets | Loebenberg |
| PHARM 202 | Y1 | Winter | 2025-03-12 | Laboratory | Lab Capsules-B | Capsules | Loebenberg/Sanaee |
| PHARM 202 | Y1 | Winter | 2025-03-12 | Lecture | Lecture 26 | Tablets | Loebenberg |
| PHARM 202 | Y1 | Winter | 2025-03-14 | Lecture | Lecture 27 | Routes of Administration | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2025-03-14 | Seminar/case session | Seminar Suppositories | Suppositories | Loebenberg/Sanaee |
| PHARM 202 | Y1 | Winter | 2025-03-17 | Laboratory | Lab Suppositories-A | Suppositories | Loebenberg/Sanaee |
| PHARM 202 | Y1 | Winter | 2025-03-17 | Lecture | Lecture 28 | Routes of Administration | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2025-03-19 | Laboratory | Lab Suppositories-B | Suppositories | Loebenberg/Sanaee |
| PHARM 202 | Y1 | Winter | 2025-03-19 | Lecture | Lecture 29 | Routes of Administration | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2025-03-21 | Seminar/case session | Compounding review | Compounding | Loebenberg/Sanaee |
| PHARM 202 | Y1 | Winter | 2025-03-21 | Lecture | Lecture 30 | Routes of Administration | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2025-03-24 | Lecture | Lecture 31 | Routes of Administration | Lavasanifar |
| PHARM 202 | Y1 | Winter | 2025-03-26 | Lecture | Lecture 32 | Container | Loebenberg |
| PHARM 202 | Y1 | Winter | 2025-03-28 | Lecture | Lecture 33 | Aerosols | Martin |
| PHARM 202 | Y1 | Winter | 2025-03-31 | Lecture | Lecture 34 | Aerosols | Martin |
| PHARM 202 | Y1 | Winter | 2025-04-01 | Other exam/test | Lab Exam-A | Lab Exam | Loebenberg |
| PHARM 202 | Y1 | Winter | 2025-04-01 | Other exam/test | Lab Exam-B | Lab Exam | Loebenberg |
| PHARM 202 | Y1 | Winter | 2025-04-02 | Lecture | Lecture 35 | Aerosols | Martin |
| PHARM 202 | Y1 | Winter | 2025-04-04 | Lecture | Lecture 36 | Aerosols | Martin |
| PHARM 202 | Y1 | Winter | 2025-04-07 | Laboratory | Lab Cleaning | Lab Cleaning | Loebenberg/Sanaee |
| PHARM 202 | Y1 | Winter | 2025-04-07 | Lecture | Lecture 37 | Hot topics in Pharmaceutical Sciences | Loebenberg |
| PHARM 202 | Y1 | Winter | 2025-04-09 | Laboratory | Lab Cleaning | Lab Cleaning | Loebenberg/Sanaee |
| PHARM 203 | Y1 | Fall | 2024-09-04 | Lecture | 1. Molecular Aspects of Drug Action | Receptor types, ion channels, enzymes, & transporters as drug targets | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2024-09-06 | Lecture | 2. Molecular Aspects of Drug Action | Receptor types, ion channels, enzymes, & transporters as drug targets | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2024-09-09 | Lecture | 3. General Principles of Drug Action | Receptors, Specificity, Drug-Receptor Interactions (Agonists, Antagonists, Partial Agonists, Efficacy, Inverse Agonists, Allosteric Modulation) , Concentration response, Intro to Pharmacokinetics | Dr. Andrew Holt |
| PHARM 203 | Y1 | Fall | 2024-09-11 | Lecture | 4. General Principles of Drug Action | Receptors, Specificity, Drug-Receptor Interactions (Agonists, Antagonists, Partial Agonists, Efficacy, Inverse Agonists, Allosteric Modulation) , Concentration response, Intro to Pharmacokinetics | Dr. Andrew Holt |
| PHARM 203 | Y1 | Fall | 2024-09-13 | Lecture | 5. General Principles of Drug Action | Receptors, Specificity, Drug-Receptor Interactions (Agonists, Antagonists, Partial Agonists, Efficacy, Inverse Agonists, Allosteric Modulation) , Concentration response, Intro to Pharmacokinetics | Dr. Andrew Holt |
| PHARM 203 | Y1 | Fall | 2024-09-16 | Lecture | 6. General Principles of Drug Action | Receptors, Specificity, Drug-Receptor Interactions (Agonists, Antagonists, Partial Agonists, Efficacy, Inverse Agonists, Allosteric Modulation), Concentration response, Intro to Pharmacokinetics | Dr. Andrew Holt |
| PHARM 203 | Y1 | Fall | 2024-09-18 | Lecture | 7. General Principles of Drug Action | Concentration response, Intro to Pharmacokinetics | Dr. Andrew Holt |
| PHARM 203 | Y1 | Fall | 2024-09-20 | Lecture | 8. General Principles of Drug Action | Concentration response, Intro to Pharmacokinetics | Dr. Andrew Holt |
| PHARM 203 | Y1 | Fall | 2024-09-23 | Lecture | 9. Chemical Mediators | Cholinergic/Autonomic Transmission | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2024-09-25 | Lecture | 10. Chemical Mediators | Acetylcholine, nicotinic/muscarinic action | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2024-09-27 | Lecture | 11. Chemical Mediators | Noradrenergic autonomic transmission, Catecholamines, adrenoreceptors | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2024-10-02 | Lecture | 12. Chemical Mediators | Amino acid mediators: Histamine, 5-HT | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2024-10-04 | Lecture | 13. Chemical Mediators | Peptide & Protein mediators | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2024-10-07 | Lecture | 14. Chemical Mediators | Eicosanoids & cannabinoids | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2024-10-09 | Lecture | 15. Chemical Mediators | NO & H2S | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2024-10-11 | Lecture | 16. Chemical mediators | Purines; Amino acids & other neurotransmitters | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2024-10-16 | Lecture | 17. CNS Pharmacology | Amino acids & other neurotransmitters | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2024-10-18 | Midterm exam | 18. Midterm | Materials encompassed in lectures 1 - 16 | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2024-10-21 | Lecture | 19. CNS Pharmacology | General anaesthetics | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2024-10-23 | Lecture | 20. CNS Pharmacology | Local anaesthetics | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2024-10-25 | Lecture | 21. CNS Pharmacology | Analgesics | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2024-10-28 | Lecture | 22. CNS Pharmacology | Anxiolytic & Hyponotic drugs | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2024-10-30 | Lecture | 23. CNS Pharmacology | Parkinson's Dis. Pharmacology | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2024-11-01 | Lecture | 24. CNS Pharmacology | Alzheimer's dis. & Huntington's dis. pharmacology | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2024-11-04 | Lecture | 25. CNS Pharmacology | Antiepileptic drug | Dr. Sherif Mahmoud |
| PHARM 203 | Y1 | Fall | 2024-11-04 | Lecture | 26. CNS Pharmacology | Antidepressant drugs | Dr. Sherif Mahmoud |
| PHARM 203 | Y1 | Fall | 2024-11-06 | Lecture | 27. CNS Pharmacology | Antipsychotic drugs | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2024-11-13 | Lecture | 28. CNS Pharmacology | Psychomotor stimulants & hallucinogenics | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2024-11-15 | Lecture | 29. Cardiovascular Pharmacology | Antidysrhythmic drugs | Dr. John Seubert |
| PHARM 203 | Y1 | Fall | 2024-11-18 | Lecture | 30. Cardiovascular Pharmacology | Antidysrhythmic drugs | Dr. John Seubert |
| PHARM 203 | Y1 | Fall | 2024-11-20 | Lecture | 31. Cardiovascular Pharmacology | Drugs that Increase Cardiac Contractility and Anti-Anginal Drugs | Dr. John Seubert |
| PHARM 203 | Y1 | Fall | 2024-11-22 | Lecture | 32. Cardiovascular Pharmacology | Atherosclerosis and Lipid-Lowering Drugs | Dr. John Seubert |
| PHARM 203 | Y1 | Fall | 2024-11-25 | Lecture | 33. Cardiovascular Pharmacology | Vascular Function, Vasoactive Drugs (Vasoconstrictors & Vasodilators) | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2024-11-27 | Lecture | 34. Cardiovascular Pharmacology | Drugs for Treating Hypertension | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2024-11-29 | Lecture | 35. Cardiovascular Pharmacology | Drugs for Treating Heart Failure | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2024-12-02 | Lecture | 36. Cardiovascular Pharmacology | Drugs for Treating Pulmonary Hypertension, Shock & Hypotensive States | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2024-12-04 | Lecture | 37. Cardiovascular Pharmacology | Anti-platelet drugs | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2024-12-06 | Lecture | 38. Cardiovascular Pharmacology | Anticoagulants & Fibrinolytics, Anti-platelet drugs & Anticoagulants | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2024-12-09 | Lecture | 39. Cardiovascular Pharmacology | Anticoagulants & Fibrinolytics | Dr. Paul Jurasz |
| PHARM 204 | Y1 | Fall | 2024-09-04 | Lecture | Introduction & Overview of gross anatomy | Description of the course content and assessment. General gross anatomy and terminology | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-09-06 | Lecture | Cellular anatomy | Cellular structure and function, the lipid bilayer and what it contains. Cell adhesion mechanisms-cell junctions including gap junctions, tight junctions. membrane transporters. The electrochemical gradient and redox potential of the cell. Endocytosis | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-09-09 | Lecture | Cell membrane components | Membrane protein functions, important functions of the nucleus, including replication, transcription, & translation. Protein processing (Golgi) | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-09-11 | Lecture | Cell membrane components | Plasma membrane receptors -signaling mechanisms of receptor activation (TK, Gproteins). | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-09-13 | Lecture | Tissue structure and organization | Layers of tissue (epithelial, connective) -supporting tissue structures | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-09-16 | Lecture | Neurons: introduction to the nervous system | CNS vs PNS, function & structure of a neuron. Neuroglia, membrane potential, action potential, and ion channels | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-09-18 | Lecture | Autonomic nervous system (ANS) | Neurotransmitter of pre-and postganglionic neurons:Acetylcholine, noradrenaline: Synthesis and Mechanisms of action. Adrenal medulla:adrenaline, noradrenaline, dopamine. Concept of nonadrenergic-noncholinergic (NANC). Cholinergic receptors, and application to pharmacy Adrenergic receptors, and application to pharmacy. Receptor Distribution | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-09-20 | Lecture | Pain (nociception) | Pain categories, nociceptors, first/second pain -anterolateral pathways (fibres) Referral pain withdrawal reflexes, pain neurotransmitters, afferent pathways of pain | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-09-23 | Lecture | Pain | Inflammatory pain pathophysiology of pain. Neuropathic pain as an example -Central sensitization following peripheral nerve injury | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-09-25 | Lecture | Neurology: neuroanatomy and the CNS | Neuron morphology, glia of CNS, glia of PNS. Cerebrum, diencephalon, brainstem, cerebellum Brain protection. Meninges -Ventricles; Production and flow of cerebrospinal fluid. Blood-brain barrier | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-09-27 | Lecture | Cerebrum and Diencephalon | Overview -cortical structure -white matter -Diencephalon: Structure (and function) of the epi-, hypo-, thalamus | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-10-02 | Lecture | Neurology, brainstem and sensory physiology | Anatomy of key regions: Midbrain, pons, medulla oblongata; cerebral aqueduct, cerebral peduncles, superior and inferior colliculi Brainstem functions: -Cerebellum structure & function; motor learning Cranial nerves. Sensory physiology: Sensory information, sensation, perception. Receptor modalities, sensory receptors, afferent-receptor configurations -Receptive field, receptor potential, adaptation. Coding intensity, modality, and location of a sensory stimulus | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-10-04 | Lecture | Neurology: Sensory physiology | Sensory physiology: Somatic sensation: Receptors, pathways, primary somatosensory cortex. Motor control: Alpha-motor neurons as the final common pathway. Hierarchical control. Feedback control. Cerebellar damage. Proprioceptors, local feedback, spinal reflexes | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-10-07 | Lecture | Neurology: Motor Control Blood supply; Cerebral perfusion pressure and blood flow | Motor control: -Concepts of how motor system works: hierarchical control; Alphamotor neurons as the final common pathway. Cerebellum and feedback, cerebellar damage) -Local feedback. Monosynaptic reflex (includes terminology: agonist, synergist, antagonist -Motor cortices (primary motor, premotor, supplementary motor area) -Motor tracts Blood supply, Intracranial pressure, cerebral perfusion pressure, cerebral blood flow | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-10-09 | Lecture | Neurology: Higher CNS function; Basal ganglia | Neurotransmitters -ACh, biogenic amines, amino acid neurotransmitters also neuropeptides, purines, others. Synthesis, receptors, reuptake and/or metabolism of select neurotransmitters, major roles -Alzheimer?s, myasthenia gravis, depression Basal ganglia, Parkinson?s, Anatomy, Basic functioning of healthy basal ganglia -Parkinson?s: Symptoms and basal ganglia function. Pharmacological and surgical treatments as examples to reinforce concepts regarding the physiological function of the CNS, and points of pharmaceutical intervention at the synapse | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-10-11 | Lecture | Cardiology: Anatomy of the heart; Electrical activity of the heart | Gross anatomy Electrical activity -Pacemaker cell vs. conducting fibre; Bachmann?s bundle and intermodal pathways, fibrous skeleton; rates of autorhymicity -Action potentials of pacemaker and contractile cells -Effects of ANS on rate (with mechanisms) and contractility (without mechanisms) -ECG and case study | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-10-14 | No class | Thanksgiving (NO CLASS) | Thanksgiving (NO CLASS) | Dr. Arno G. Siraki, Dr. Michael Doschak |
| PHARM 204 | Y1 | Fall | 2024-10-16 | Lecture | Cardiology: blood flow 1 | Anatomy-Major Systemic Arteries and Veins Haemodynamics -Arterial and venous system blood vessel walls, characteristics summary. Driving force in the cardiovascular system (MAP) central venous pressure). Regulation of arteriolar resistance: Intrinsic mechanisms: local factors; Extrinsic mechanisms neuroendocrine, to regulate MAP | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-10-18 | Lecture | Cardiology: blood flow 2 | Venomotor tone and venous return and effects of Blood volume and venomotor tone on venous pressure and therefore MAP -Thermoregulation and arteriolar R -Coronary and skeletal muscles and vasodilation by Beta-2, note re: Beta-2 Rs on vascular smooth muscle cells ? beta-blockers and MAP. Regulation of MAP. Baroreceptor reflex regulation of blood pressure. Angiotensin II, ADH increase MAP | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-10-21 | Midterm exam | MIDTERM EXAM | Lectures 1-18 (up to Cardiology: blood flow 2) | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-10-23 | Lecture | Pulmonary | Anatomy- airways, resp epithelium. Mechanics. Blood flow -Sites of intervention. COPD. ARDS cause and consequences (wrt patient care) | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-10-25 | Lecture | GI (1/2) | GI tract anatomy: -oral cavity and teeth. Review of wall of GI tract + stomach wall + small intestine regional differences -diagnostic imaging for GI and liver. Liver blood flow and tissue substructure wrt to drug metabolism | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-10-28 | Lecture | GI (2/2) | GI: small intestine regional differences -diagnostic imaging for GI and liver. Liver blood flow and tissue substructure wrt to drug metabolism | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-10-30 | Lecture | Bone & Joint 1 | The skeletal system: osseous tissue and bone structure -Bone functions, histology, structure. Intramembranous ossification -Endochondral ossification | Dr. Doschak |
| PHARM 204 | Y1 | Fall | 2024-11-01 | Lecture | Bone & Joint 2 | Cartilage histology, growth, and composition. Basic multicellular unit (BMU). Bone resorption and formation -RANK / RANKLigand / OPG System | Dr. Doschak |
| PHARM 204 | Y1 | Fall | 2024-11-04 | Lecture | Bone & Joint 3 | Bone elongation: epiphyseal plate. Appositional growth. Formation of an osteon. Bone blood supply and innervation | Dr. Doschak |
| PHARM 204 | Y1 | Fall | 2024-11-06 | Lecture | Bone & Joint 4 | Joint classification -synovial joint characteristics. The knee joint. Aging and joints -sites of therapy in bone and joint | Dr. Doschak |
| PHARM 204 | Y1 | Fall | 2024-11-13 | Lecture | MSK (B & J - 5) | Skeletal muscle: structure -fibres and molecular makeup | Dr. Doschak |
| PHARM 204 | Y1 | Fall | 2024-11-15 | Lecture | MSK (B & J - 6) | Skeletal muscle: force generation (contraction). NMJ and its role (above). twitch summation, types of contraction (concentric, isometric, eccentric) | Dr. Doschak |
| PHARM 204 | Y1 | Fall | 2024-11-18 | Lecture | MSK (B & J - 7) | Skeletal: anatomy Smooth: anatomy, contraction | Dr. Doschak |
| PHARM 204 | Y1 | Fall | 2024-11-20 | Lecture | Integumetary system 1 | Skin: Epidermis, Dermis. Hypodermis; Skin colour; Blood supply and innervation -Hair, Nails, Sebaceous glands and follicles, Sweat glands | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-11-22 | Lecture | Integumetary system 2 | Sun/UV effects -interface with other systems (e.g., immune). Effects of aging interactions of therapeutics | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-11-25 | Lecture | Eye, Ear, Nose & Throat (EENT) | Eye anatomy: -flow of aqueous humor. Retina, macular degeneration -sites of drug action. Ear anatomy: -sound conduction, cochlea, site of drug action. Nose, pharynx, Paranasal sinuses, Larynx, Olfaction | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-11-27 | Lecture | Endocrine 1 | Fundamentals: amines, steroids, peptides. Energy metabolism -actions and regulation of insulin and glucagon. ANS in glucose homeostasis -secretion disorders of the hypothalamuspituitary axis -Cushing?s disease (cortisol effects) | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-11-29 | Lecture | Endocrine 2 | Thyroid gland and parathyroid. -Basic function of and tissue organization. -Use of diagnostic imaging for visualization | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-12-02 | Lecture | Renal 1 | Gross anatomy, blood supply and innervation to the kidneys. Renal corpuscle -key sites and actions of the nephron. | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-12-04 | Lecture | Renal 2 | Sodium on bp, blood volument, water effects -K+: direct effect of K+ on Na+/K+-ATPase -use of agents for diagnostic imaging | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-12-06 | Lecture | Reproductive 1 | Male reproductive system -Female reproductive system | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-12-08 | Lecture | Reproductive 2 | Ovulation and menstrual cycle -Sexual response and therapeutics -lactation and mammary glands | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2024-12-15 | Final exam | FINAL EXAM | FINAL EXAM | Dr. Arno G. Siraki, Dr. Michael Doschak |
| PHARM 233 | Y1 | Winter | 2025-01-06 | Lecture | 1. Pharmacogenomics Lecture 1 | Introduction Pharmacogenomics (PGx), The Basis for Precision Medicine, Overview PharmGkB, CPIC Websites, effect of environment, ethnicity , pollutants etc | D. Hamdy |
| PHARM 233 | Y1 | Winter | 2025-01-08 | Lecture | 2. Pharmacogenomics Lecture 2 | Classical and non-classical PGx (Genetics: DNA, RNA, transcription, translation, genetic variability, SNP, CNV, addition, deletion) | D. Hamdy |
| PHARM 233 | Y1 | Winter | 2025-01-10 | Lecture | 3. Pharmacogenomics Lecture 3 | Introduction to common Transporters, CYP P450 and Receptors alleles, Relationship between PK-PD-PGX and dose adjustments | D. Hamdy |
| PHARM 233 | Y1 | Winter | 2025-01-13 | Lecture | 4. Pharmacogenomics Lecture 4 | Basic techniques for genetic testing and diseases related to genes. Examples on PGX Pt. Case management using pharmGKB | D. Hamdy |
| PHARM 233 | Y1 | Winter | 2025-01-15 | Lecture | 5. GI Pharmacology Lecture 1 | Antiemetic Agents | J. Ussher |
| PHARM 233 | Y1 | Winter | 2025-01-17 | Lecture | 6. GI Pharmacology Lecture 2 | Agents for Neutralizing Gastric Acid Secretion | J. Ussher |
| PHARM 233 | Y1 | Winter | 2025-01-20 | Lecture | 7. GI Pharmacology Lecture 3 | Agents that Modulate Gastric Motility, Antidiarrheal Agents and Agents for Chronic Bowel Disease | J. Ussher |
| PHARM 233 | Y1 | Winter | 2025-01-22 | Lecture | 8. Respiratory Pharmacology | Drugs for COPD, Drugs for Asthma: Bronchodilators & Anti inflammatories | J. Ussher |
| PHARM 233 | Y1 | Winter | 2025-01-24 | Lecture | 9. Skin Pharmacology | Antiinflammatories & Other Agents for Skin Disorders | J. Ussher |
| PHARM 233 | Y1 | Winter | 2025-01-27 | Lecture | 10. Obesity Pharmacology & Pharmacotherapy Lecture 1 | Non-Pharmacological Approaches, Central Acting Agents, Gut HormoneBased Agents, and Medical Devices | J. Ussher |
| PHARM 233 | Y1 | Winter | 2025-01-29 | Lecture | 11. Obesity Pharmacology & Pharmacotherapy Lecture 2 | Non-Pharmacological Approaches, Central Acting Agents, Gut HormoneBased Agents, and Medical Devices | J. Ussher |
| PHARM 233 | Y1 | Winter | 2025-01-31 | Lecture | 12. Endocrine Pharmacology Lecture 1 | Type 1 Diabetes (Insulin and Insulin Analogues) | J. Ussher |
| PHARM 233 | Y1 | Winter | 2025-02-05 | Lecture | 13. Endocrine Pharmacology Lecture 2 | Type 2 Diabetes (Metformin, Sulfonylureas, and Thiazolidinediones) | J. Ussher |
| PHARM 233 | Y1 | Winter | 2025-02-07 | Lecture | 14. Endocrine Pharmacology Lecture 3 | Type 2 Diabetes (Incretin Based Therapies & SGLT2 Inhibitors) | J. Ussher |
| PHARM 233 | Y1 | Winter | 2025-02-10 | Lecture | 15. Endocrine Pharmacology Lecture 4 | Other Endocrine Disorders (Agents for Thyroid Disorders) | J. Ussher |
| PHARM 233 | Y1 | Winter | 2025-02-12 | Lecture | 16. Endocrine Pharmacology Lecture 5 | Other Endocrine Disorders (Agents for Addison's Disease, Cushing Syndrome) and Hormone Replacement Therapy | J. Ussher |
| PHARM 233 | Y1 | Winter | 2025-02-14 | Lecture | 17. Endocrine (Reproductive) Pharmacology Lecture 6 | Other Endocrine Disorders (Agents for Addison's Disease, Cushing Syndrome) and Hormonal Therapies | J. Ussher |
| PHARM 233 | Y1 | Winter | 2025-02-24 | Lecture | 18. Renal Pharmacology Lecture 1 | Diuretics | K. Gopal |
| PHARM 233 | Y1 | Winter | 2025-02-26 | Lecture | 19. Renal Pharmacology Lecture 2 | Agents for Renal Failure and Urinary Tract Infections | K. Gopal |
| PHARM 233 | Y1 | Winter | 2025-02-28 | Lecture | 20. Anemia Pharmacology | Hematinic Agents | A. El-Kadi |
| PHARM 233 | Y1 | Winter | 2025-03-03 | Lecture | 21. Hematopoietic & Bone Pharmacology Lecture 1 | Agents for Osteoporosis and Osteoarthritis | A. El-Kadi |
| PHARM 233 | Y1 | Winter | 2025-03-05 | Lecture | 22. Hematopoietic & Bone Pharmacology Lecture 2 | Agents for Rheumatoid Arthritis, Gout and Hyperuricemia | A. El-Kadi |
| PHARM 233 | Y1 | Winter | 2025-03-06 | Lecture | 23. Microbial Pharmacology Lecture 1 | Bacterial Cell Wall Agents (Sulfonamides, Beta-Lactam Antibiotics, Glycopeptides, Polymixins, etc.) | A. Tabataei-Dakhili |
| PHARM 233 | Y1 | Winter | 2025-03-07 | Lecture | 24. Microbial Pharmacology Lecture 2 | Bacterial protein synthesis inhibitors (Tetracyclines, Aminoglycosides, etc.) | A. Tabataei-Dakhili |
| PHARM 233 | Y1 | Winter | 2025-03-12 | Lecture | 25. Microbial Pharmacology Lecture 3 | Antihelminthic Agents | A. Tabatabaei-Dakhili |
| PHARM 233 | Y1 | Winter | 2025-03-14 | Lecture | 26. Microbial Pharmacology Lecture 4 | Antimycobacterial Agents | J. Ussher |
| PHARM 233 | Y1 | Winter | 2025-03-17 | Lecture | 27. Microbial Pharmacology Lecture 5 | Antifungal Agents | J. Ussher |
| PHARM 233 | Y1 | Winter | 2025-03-19 | Lecture | 28. Microbial Pharmacology Lecture 6 | Antifungal Agents | A. Tabatabaei Dakhili |
| PHARM 233 | Y1 | Winter | 2025-03-21 | Lecture | 29. Microbial Pharmacology Lecture 7 | Agents for Other Protozoal Infections (Trypanosomiasis, Leishmaniasis, Giardiasis Toxoplasmosis, etc.) | A. Tabatabaei-Dakhili |
| PHARM 233 | Y1 | Winter | 2025-03-24 | Lecture | 30. Cancer Chemotherapy Lecture 1 | Alkylating Agents, Antimetabolites and Cytotoxic Antibiotics | G. Sutendra |
| PHARM 233 | Y1 | Winter | 2025-03-26 | Lecture | 31. Cancer Chemotherapy Lecture 2 | Plant Derivatives, Hormone-Based Agents and Protein Kinase Inhibitors | G. Sutendra |
| PHARM 233 | Y1 | Winter | 2025-03-28 | Lecture | 32. Cancer Chemotherapy Lecture 3 | Immune Therapies for Cancer, Immunosuppressants, and Other Immunotherapies | G. Sutendra |
| PHARM 233 | Y1 | Winter | 2025-03-31 | Lecture | 33. Viral Pharmacology Lecture 1 | Agents for Herpes | A. Siraki |
| PHARM 233 | Y1 | Winter | 2025-04-02 | Lecture | 34. Viral Pharmacology lecture 2 | Agents for Influenza | A. Siraki |
| PHARM 233 | Y1 | Winter | 2025-04-04 | Lecture | 35. Viral Pharmacology Lecture 3 | Agents for HIV/AIDS | A. Siraki |
| PHARM 233 | Y1 | Winter | 2025-04-07 | Lecture | 36. Miscellaneous Topics in Pharmacology Lecture 1 | Lifestyle Drug Uses & Drugs in Sport | J. Ussher |
| PHARM 233 | Y1 | Winter | 2025-04-09 | Lecture | 37. Miscellaneous Topics in Pharmacology Lecture 2 | Role of Pharmacology in Drug Development | J. Ussher |
| PHARM 302 | Y2 | Fall | 2024-09-04 | Lecture | Introduction: Overview of topics covered in the course | Introduction | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2024-09-06 | Lecture | Aseptic compounding techniques | Aseptic compounding techniques | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2024-09-09 | Lecture | Aseptic compounding techniques | Aseptic compounding techniques | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2024-09-11 | Lecture | Aseptic compounding techniques | Aseptic compounding techniques | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2024-09-13 | Lecture | Aseptic compounding techniques | Aseptic compounding techniques | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2024-09-13 | Seminar/case session | Pre lab Seminar Sterile compounding/Dissolution | Aseptic Compounding, Transdermal Dosage Forms, Dissolution Testing | TA |
| PHARM 302 | Y2 | Fall | 2024-09-16 | Lecture | Aseptic compounding techniques | Aseptic compounding techniques | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2024-09-16 | Laboratory | Lab- Sterile Compounding; Dissolution | Aseptic compounding techniques, Dissolution testing | TA |
| PHARM 302 | Y2 | Fall | 2024-09-18 | Lecture | Aseptic compounding techniques | Aseptic compounding techniques | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2024-09-18 | Laboratory | Lab-Sterile Compounding; Dissolution | Aseptic Compounding, Transdermal Dosage Forms, Dissolution Testing | TA |
| PHARM 302 | Y2 | Fall | 2024-09-20 | Lecture | Aseptic compounding techniques | Aseptic compounding techniques | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2024-09-20 | Laboratory | Lab-Sterile Compounding; Dissolution | Lab-Sterile Compounding; Dissolution | Afsaneh Lavasanifar, Michael Doschak , Raimar Loebenberg |
| PHARM 302 | Y2 | Fall | 2024-09-23 | Laboratory | Lab- Sterile Compounding; Dissolution | Aseptic Compounding, Transdermal Dosage Forms, Dissolution Testing | TA |
| PHARM 302 | Y2 | Fall | 2024-09-23 | Lecture | Parenteral Products (TPN) | Parenteral Products | Afsaneh Lavasanifar, Michael Doschak , Raimar Loebenberg |
| PHARM 302 | Y2 | Fall | 2024-09-25 | Laboratory | Lab-Sterile Compounding; Dissolution | Aseptic Compounding, Transdermal Dosage Forms, Dissolution Testing | TBD |
| PHARM 302 | Y2 | Fall | 2024-09-25 | Lecture | Parenteral Products (LVP) | Parenteral Products | Dana Lyons |
| PHARM 302 | Y2 | Fall | 2024-09-27 | Lecture | Eye/Ear/Nose/Throat dosage | BioPharmaceutics | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2024-09-27 | Laboratory | Lab-Sterile Compounding; Dissolution | Aseptic Compounding, Transdermal Dosage Forms, Dissolution Testing | TA |
| PHARM 302 | Y2 | Fall | 2024-10-02 | Lecture | Eye/Ear/Nose/Throat dosage forms | BioPharmaceutics | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2024-10-04 | Lecture | Biopharmaceutics | Ophthalmic dosage forms and ENTs | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2024-10-07 | Lecture | Biopharmaceutics | Ophthalmic dosage forms and ENTs | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2024-10-07 | Laboratory | Lab-Sterile Compounding; Dissolution | Aseptic Compounding, Transdermal Dosage Forms, Dissolution Testing | TAs |
| PHARM 302 | Y2 | Fall | 2024-10-09 | Lecture | Biopharmaceutics | BioPharmaceutics | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2024-10-09 | Laboratory | Lab- Sterile Compounding; Dissolution | Aseptic Compounding, Transdermal Dosage Forms, Dissolution Testing | TA |
| PHARM 302 | Y2 | Fall | 2024-10-11 | Lecture | Biopharmaceutics | BioPharmaceutics | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2024-10-11 | Laboratory | Lab-Sterile Compounding; Dissolution | Aseptic Compounding, Transdermal Dosage Forms, Dissolution Testing | TA |
| PHARM 302 | Y2 | Fall | 2024-10-16 | Lecture | Controlled drug delivery systems | Controlled drug delivery systems | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2024-10-16 | Laboratory | Lab- Sterile Compounding; Dissolution | Aseptic Compounding, Transdermal Dosage Forms, Dissolution Testing | TA |
| PHARM 302 | Y2 | Fall | 2024-10-18 | Lecture | Controlled drug delivery systems | Controlled drug delivery systems | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2024-10-18 | Laboratory | Lab- Sterile Compounding; Dissolution | Aseptic Compounding, Transdermal Dosage Forms, Dissolution Testing | TA |
| PHARM 302 | Y2 | Fall | 2024-10-21 | Laboratory | Lab- Sterile Compounding; Dissolution | Aseptic Compounding, Transdermal Dosage Forms, Dissolution Testing | TA |
| PHARM 302 | Y2 | Fall | 2024-10-21 | Lecture | Transdermal Delivery Systems | TDS | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2024-10-25 | Seminar/case session | Pre lab seminar transdermal | Pre lab seminar transdermal | TA |
| PHARM 302 | Y2 | Fall | 2024-10-25 | Lecture | Transdermal Delivery Systems | TDS | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2024-10-28 | Lecture | Drug stability and expiration date | Drug stability and expiration date | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2024-10-28 | Laboratory | Lab-Transdermal | Aseptic Compounding, Transdermal Dosage Forms, Dissolution Testing | TA |
| PHARM 302 | Y2 | Fall | 2024-10-30 | Lecture | Drug stability and expiration date | Drug stability and expiration date | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2024-10-30 | Laboratory | Lab-Transdermal | Lab-Transdermal | TAs |
| PHARM 302 | Y2 | Fall | 2024-11-01 | Lecture | Drug stability and expiration date | Drug stability and expiration date | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2024-11-01 | Laboratory | Lab-Transdermal | Lab-Transdermal | Afsaneh Lavasanifar, Michael Doschak , Raimar Loebenberg |
| PHARM 302 | Y2 | Fall | 2024-11-04 | Lecture | Drug stability and expiration date | Drug stability and expiration date | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2024-11-04 | Laboratory | Lab-Transdermal | Lab-Transdermal | TAs |
| PHARM 302 | Y2 | Fall | 2024-11-06 | Laboratory | Lab-Transdermal | Lab-Transdermal | TA |
| PHARM 302 | Y2 | Fall | 2024-11-06 | Lecture | Nano-Medicine | Nano-Medicine | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2024-11-13 | Lecture | Nano-Medicine | Nano Medicine | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2024-11-15 | Laboratory | Lab-Transdermal | Lab-Transdermal | TA |
| PHARM 302 | Y2 | Fall | 2024-11-15 | Lecture | Pharmaceutical Biotechnology | Pharmaceutical Biotechnology | Dr Doschak |
| PHARM 302 | Y2 | Fall | 2024-11-18 | Laboratory | Biopharmaceutics-Simulation | Biopharmaceutics | TA |
| PHARM 302 | Y2 | Fall | 2024-11-18 | Lecture | Pharmaceutical Biotechnology | Pharmaceutical Biotechnology | Dr Doschak |
| PHARM 302 | Y2 | Fall | 2024-11-20 | Laboratory | Biopharmaceutics-Simulation | Biopharmaceutics | TA |
| PHARM 302 | Y2 | Fall | 2024-11-20 | Lecture | Pharmaceutical Biotechnology | Pharmaceutical Biotechnology | Dr Doschak |
| PHARM 302 | Y2 | Fall | 2024-11-22 | Laboratory | Biopharmaceutics-Simulation | Biopharmaceutics | TA |
| PHARM 302 | Y2 | Fall | 2024-11-22 | Lecture | Pharmaceutical Biotechnology | Pharmaceutical Biotechnology | Dr Doschak |
| PHARM 302 | Y2 | Fall | 2024-11-25 | Lecture | Pharmaceutical Biotechnology: Protein Delivery | Pharmaceutical Biotechnology: Protein Delivery | Dr Wishart |
| PHARM 302 | Y2 | Fall | 2024-11-27 | Lecture | Pharmaceutical Biotechnology: Protein Delivery | Pharmaceutical Biotechnology: protein Delivery | Dr Wishart |
| PHARM 302 | Y2 | Fall | 2024-11-29 | Lecture | Gene Therapy | Gene Therapy | Diana Diaz Dussan |
| PHARM 302 | Y2 | Fall | 2024-12-02 | Lecture | Gene Therapy | Gene Therapy | Diana Diaz-Dussan |
| PHARM 302 | Y2 | Fall | 2024-12-04 | Lecture | Regulatory Science | Regulatory science | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2024-12-06 | Lecture | Regulatory Science | Regulatory science | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2024-12-09 | Lecture | Hot Topics in Pharmaceutics | Hot Topics in Pharmaceutics | Dr Lavasanifar |
| PHARM 303 | Y2 | Fall | 2024-09-04 | Lecture | Lecture 1 | Introduction, Kinetics of Transport | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-09-06 | Lecture | Lecture 2 | Kinetics of Transport, Kinetics of iv bolus Doses | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-09-09 | Lecture | Lecture 3 | See Above | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-09-11 | Lecture | Lecture 4 | See Above | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-09-13 | Lecture | Lecture 5 | Kinetics of iv bolus Doses | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-09-16 | Lecture | Lecture 6 | Compartmental Concepts | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-09-18 | Lecture | Lecture 7 | See Above | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-09-20 | Lecture | Lecture 8 | See Above | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-09-23 | Lecture | Lecture 9 | Clearance additivity, 2 compartment mode | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-09-25 | Lecture | Lecture 10 | Multiple compartment model | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-09-27 | Lecture | Lecture 11 | Oral absorption and bioequivalence | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-10-02 | Midterm exam | Midterm #1 | Midterm #1 | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-10-04 | Lecture | Lecture 12 | See Above | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-10-07 | Lecture | Lecture 13 | Oral absorption | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-10-09 | Lecture | Lecture 14 | Bioequivalence | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-10-11 | Lecture | Lecture 15 | IV infusion | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-10-16 | Lecture | Lecture 16 | See Above | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-10-17 | Lecture | Lecture 17 | See Above | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-10-18 | Lecture | Lecture 18 | Multiple dose PK | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-10-21 | Lecture | Lecture 19 | See Above | Hamdah Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-10-23 | Lecture | Lecture 20 | PK-PD relationship | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-10-25 | Lecture | Lecture 21 | Drug distribution | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-10-28 | Lecture | Lecture 22 | Drug distribution | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-10-30 | Lecture | Lecture 23 | Drug distribution, Drug clearance | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-11-01 | Midterm exam | Midterm #2 | Midterm #2 | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-11-04 | Lecture | Lecture 24 | See Above | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-11-06 | Lecture | Lecture 25 | Drug clearance | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-11-13 | Lecture | Lecture 26 | See Above | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-11-15 | Lecture | Lecture 27 | See Above | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-11-18 | Lecture | Lecture 28 | Clearance | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-11-20 | Lecture | Lecture 29 | Nonlinear elimination | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-11-22 | Lecture | Lecture 30 | Pharmacokinetic based drug interactions | Dr. Al Nebaihi |
| PHARM 303 | Y2 | Fall | 2024-11-25 | Lecture | Lecture 31 | Clinical factors affecting pharmacokinetics | Dr. Kiang |
| PHARM 303 | Y2 | Fall | 2024-11-27 | Lecture | Lecture 32 | Clinical variables affecting PK | Dr. Kiang |
| PHARM 303 | Y2 | Fall | 2024-11-29 | Lecture | Lecture 33 | Effects of age on pharmacokinetics | Dr. Kiang |
| PHARM 303 | Y2 | Fall | 2024-12-02 | Lecture | Lecture 34 | Effects of age on pharmacokinetics | Dr. Kiang |
| PHARM 303 | Y2 | Fall | 2024-12-04 | Lecture | Lecture 35 | Drugs in pregnancy and lactation | Dr. Kiang |
| PHARM 303 | Y2 | Fall | 2024-12-06 | Lecture | Lecture 36 | Drugs in pregnancy and lactation | Dr. Kiang |
| PHARM 303 | Y2 | Fall | 2024-12-09 | Lecture | Lecture 37 | Other patient- specific changes in drug PK | Dr. Kiang |
| PHARM 303 | Y2 | Fall | 2024-12-18 | Final exam | Final Exam | Final Exam | Dr. Hamdah Al Nebaihi |
| PHARM 310 | Y2 | Fall | 2024-09-03 | Lecture | Elements of the Immune System | Innate & Acquired Immunity: specificity and memory, Cells and organs of immune system, Clonal selection theory | M. Doschak |
| PHARM 310 | Y2 | Fall | 2024-09-05 | Lecture | Aby structure and B-Cell diversity | Antibodies: structure, classes, diversity | M. Doschak |
| PHARM 310 | Y2 | Fall | 2024-09-10 | Lecture | Immunoassays and ELISA & Cell Mediated Immunity (1/2) | Point-of-Care (POC) testing, Antigen recognition by T-lymphocytes, Development of lymphocytes | M. Doschak |
| PHARM 310 | Y2 | Fall | 2024-09-12 | Lecture | Cell-mediated Immunity (2/2) | Antigen recognition by T-lymphocytes, Development of lymphocytes, T-cell mediated immunity | M. Doschak |
| PHARM 310 | Y2 | Fall | 2024-09-17 | Midterm exam | Midterm exam | Midterm exam | M. Doschak |
| PHARM 310 | Y2 | Fall | 2024-09-19 | Lecture | Humoral Immunity and Complement | Development of B-lymphocytes, Immunity mediated by B cells and antibodies | M. Doschak |
| PHARM 310 | Y2 | Fall | 2024-09-24 | Lecture | Body’s Defense Against Infection & Immune Disorders (1/2) | Immune responses against infection, Innate immune responses, Adaptive immune responses, Allergy and hypersensitivity | M. Doschak |
| PHARM 310 | Y2 | Fall | 2024-09-26 | Lecture | Allergy, Hypersensitivity and Immune Disorders | Autoimmune disease | M. Doschak |
| PHARM 310 | Y2 | Fall | 2024-10-01 | Lecture | Vaccines | How vaccines work, Vaccine types, Related current topics: COVID vaccines | M. Doschak |
| PHARM 401 | Y3 | Winter | 2025-01-06 | Lecture | 1. Introduction to the course and toxicology | Introduction | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2025-01-08 | Lecture | 2. Adverse Drug Reactions | Types of ADR (A-F) | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2025-01-10 | Lecture | 3. Toxicological Assessment | What is unique to tox patients | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2025-01-13 | Lecture | 4. Toxidromes | Toxidromes; Antidotes | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2025-01-15 | Lecture | 5. Toxicological Decontaminations | Poison decontamination | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2025-01-16 | Lecture | 6. Mechanisms of cell death and tissue repair | Mechanisms of cell death and tissue repair | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2025-01-17 | Lecture | 7. Antihistamines and Decongestants | Toxicity from OTC drugs | Dr. Ahmed Essa |
| PHARM 401 | Y3 | Winter | 2025-01-20 | Lecture | 8. What Is In Your Medicine Cabinet? | Are there hazards to worry about – such as aspirin, NSAIDs, acetaminophen | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2025-01-22 | Lecture | 9. Dietary Supplements/Stings/Bites | Concerns with supplements, Things that bite | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2025-01-24 | Lecture | 10. Radiation Toxicity | Sources, signs, mechanisms, toxidromes | Dr. Arno Siraki |
| PHARM 401 | Y3 | Winter | 2025-01-27 | Lecture | 11. Immunotoxicity | Toxic Responses of the Immune System | Dr. Arno Siraki |
| PHARM 401 | Y3 | Winter | 2025-01-29 | Lecture | 12. Genotoxicity and Carcinogenicity of Drugs | Mechanisms, theory and practical examples | Dr. Ayman El-Kadi |
| PHARM 401 | Y3 | Winter | 2025-01-31 | Lecture | 13. Organ Toxicity | Selected topics | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2025-02-03 | Lecture | 14. Forensic Toxicology | Forensic death investigation from a toxicology perspective, including the problem of changing drug and alcohol concentrations after death. Several unusual toxicology related deaths will be reviewed. | Dr. Graham Jones |
| PHARM 401 | Y3 | Winter | 2025-02-05 | Other exam/test | 15. Term Exam 1 | Lectures 1-14 | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2025-02-07 | Seminar/case session | 16. Case 1 - Cardiotoxicity (LQTc) | Group work on case - Cardiotox | Drs. John Seubert, Sheri Koshman, Tara Leslie, Ann Thompson |
| PHARM 401 | Y3 | Winter | 2025-02-10 | Quiz | 17. Case Debrief/eQuiz1 | Quiz (eCLass on Case 1) | Drs. Sheri Koshman, Tara Leslie, Ann Thompson |
| PHARM 401 | Y3 | Winter | 2025-02-12 | Lecture | 18. Cancer Survivorship | Chemotoxicity, long-term survival management, Exploring safety measures to prevent devastating accidental chemotherapy toxicities | Dr. Tara Leslie |
| PHARM 401 | Y3 | Winter | 2025-02-14 | Lecture | 19. Chemotherapy Safety | Oncology – chemotherapeutic toxicity/safety | Dr. Tara Leslie |
| PHARM 401 | Y3 | Winter | 2025-02-24 | Lecture | 20. Anticoagulant Toxicity | Warfarin toxicity, DOAC, management of high INR | Dr. Tammy Bungard |
| PHARM 401 | Y3 | Winter | 2025-02-26 | Lecture | 21. Special Populations MAiD | Introduction, what is involved, what drugs, regimen/combinations, potential outcomes | Dr. Terri Schindel |
| PHARM 401 | Y3 | Winter | 2025-02-28 | Lecture | 22. Special Populations Geriatrics | Toxicological concerns in geriatric populations | Dr. Cheryl Sadowski |
| PHARM 401 | Y3 | Winter | 2025-03-03 | Lecture | 23. Special Populations Pediatrics | Toxicological concerns for reproduction, perinatal and pediatric populations | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2025-03-05 | Lecture | 24. Case 2 - Special Populations | Group work on case – Special populations | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2025-03-07 | Quiz | 25. Case Debrief/Quiz 2 | Quiz (eClass on Case 2) | Dr. Sandra Trkulja/Dr. Cheryl Sadowski |
| PHARM 401 | Y3 | Winter | 2025-03-10 | Lecture | 26. Special Topics in Advanced Pharmacology | Biologics – Mechanisms, pharmacokinetics, pharmacodynamics, and therapeutics of polyclonal antibodies (e.g. antithymocyte globulin) | Dr. Tony Kiang |
| PHARM 401 | Y3 | Winter | 2025-03-12 | Lecture | 27. Special Topics in Advanced Pharmacology | Transplant biologics, Biologics – Mechanisms, pharmacokinetics, pharmacodynamics, and therapeutics of monoclonal antibodies (e.g. anti-CD3, anti-CD52, anti-CD20, and anti-CD25) | Dr. Tony Kiang |
| PHARM 401 | Y3 | Winter | 2025-03-14 | Lecture | 28. Special Topics in Advanced Pharmacology | Pharmacological principles of cell and gene-based therapy (e.g. tisagenlecleucel for B-cell leukemia and voretigene neparvovec-rzyl for inherited retinal dystrophies) | Dr. Tony Kiang |
| PHARM 401 | Y3 | Winter | 2025-03-17 | Lecture | 29. Restarting Medications After Overdose | Tools to assist with deciding on restarting medications | Dr. Riley Hartmann |
| PHARM 401 | Y3 | Winter | 2025-03-19 | Other exam/test | 30. Term Exam 2 | Lectures 16-25 | Dr. John M. Seubert |
| PHARM 401 | Y3 | Winter | 2025-03-21 | Lecture | 31. Drugs of Abuse 1 - Stimulants | Stimulants | Dr. Essi Salokangas |
| PHARM 401 | Y3 | Winter | 2025-03-24 | Lecture | 32. Drugs of Abuse 2 - CNS Depressants | CNS Depressants | Dr. Candace Necyk |
| PHARM 401 | Y3 | Winter | 2025-03-26 | Lecture | 33. Drugs of Abuse 3 - Hallucinogens | Hallicinogens | Dr. Candace Necyk |
| PHARM 401 | Y3 | Winter | 2025-03-28 | Lecture | 34. Drugs of Abuse 4 Toxic Alcohols | Toxic Alcohols | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2025-03-31 | Lecture | 35. Drugs of Abuse 5 - Vaping | Harmful Hookah, Cannabis, Vaping and e-cigarettes | Dr. John Seubert |
| PHARM 401 | Y3 | Winter | 2025-04-02 | Lecture | 36. Case 3 - Drugs of Abuse | Group work on case – drugs of abuse | Dr. John Seubert/Dr. Essi Salokangas |
| PHARM 401 | Y3 | Winter | 2025-04-04 | Quiz | 37. Case Debrief/Quiz 2 | Quiz 2 (eClass on Case 2) | Dr. Essi Salokangas |
| PHARM 401 | Y3 | Winter | 2025-04-07 | Lecture | 38. Drugs that are necessary but carry a risk of toxicity | Post-marketing Surveillance, Black Box Warnings | Dr. Arno Siraki |
| PHARM 401 | Y3 | Winter | 2025-04-09 | Lecture | 39. Deliberate Poisonings | Toxicologic misfortunes and deliberate poisonings. | Dr. John Seubert |
Assessment Information
| PHARM 201 | Y1 | Final Exam | Final exam | 45.0% | — |
| PHARM 201 | Y1 | Midterm Exam | Midterm exam | 35.0% | — |
| PHARM 201 | Y1 | Assessment 1 - Functional Groups in therapy, ACidic and basic functional groups | Quiz | 5.0% | — |
| PHARM 201 | Y1 | Assessment 2 - Calculations involving pH and pKa, Salts and water solubility in therapy | Quiz | 5.0% | — |
| PHARM 201 | Y1 | Assessment 3 - Drug metabolism, Stereochemistry | Quiz | 5.0% | — |
| PHARM 201 | Y1 | Assessment 4 - Drug binding interactions; Structure-activity relationships; Classical strategies in drug design. | Quiz | 0.0% | — |
| PHARM 202 | Y1 | Lab Report Capsules | Assignment/written work | 2.0% | — |
| PHARM 202 | Y1 | Lab Report Emulsions | Assignment/written work | 2.0% | — |
| PHARM 202 | Y1 | Lab Report Semisolids 1+2 | Assignment/written work | 2.0% | — |
| PHARM 202 | Y1 | Lab Report Solubility | Assignment/written work | 2.0% | — |
| PHARM 202 | Y1 | Lab Report Suppositories | Assignment/written work | 2.0% | — |
| PHARM 202 | Y1 | Lab Report Suspensions | Assignment/written work | 2.0% | — |
| PHARM 202 | Y1 | Final | Final exam | 40.0% | — |
| PHARM 202 | Y1 | Midterm | Midterm exam | 40.0% | — |
| PHARM 202 | Y1 | Lab Exam | Other exam/test | 8.0% | — |
| PHARM 203 | Y1 | Final | Final exam | 65.0% | — |
| PHARM 203 | Y1 | Midterm | Midterm exam | 35.0% | — |
| PHARM 204 | Y1 | Online Assignments | Assignment/written work | 10.0% | — |
| PHARM 204 | Y1 | Final | Final exam | 55.0% | — |
| PHARM 204 | Y1 | Midterm | Midterm exam | 30.0% | — |
| PHARM 204 | Y1 | In class Quizzes | Quiz | 5.0% | — |
| PHARM 233 | Y1 | Final | Final exam | 50.0% | — |
| PHARM 233 | Y1 | Midterm 1 | Midterm exam | 24.0% | — |
| PHARM 233 | Y1 | Midterm 2 | Midterm exam | 26.0% | — |
| PHARM 302 | Y2 | Hot Topic Assignment | Assignment/written work | 5.0% | — |
| PHARM 302 | Y2 | Lab reports (four) | Assignment/written work | 10.0% | — |
| PHARM 302 | Y2 | Final | Final exam | 42.5% | — |
| PHARM 302 | Y2 | Mid term | Other exam/test | 42.5% | — |
| PHARM 303 | Y2 | Assignments | Assignment/written work | 15.0% | — |
| PHARM 303 | Y2 | Final | Final exam | 42.0% | — |
| PHARM 303 | Y2 | Midterm examination 1 | Midterm exam | 20.0% | — |
| PHARM 303 | Y2 | Midterm examination 1 | Midterm exam | 20.0% | — |
| PHARM 303 | Y2 | Midterm examination 2 | Midterm exam | 23.0% | — |
| PHARM 303 | Y2 | Class Participation | Participation/professionalism | 2.0% | — |
| PHARM 310 | Y2 | Final | Final exam | 60.0% | — |
| PHARM 310 | Y2 | Midterm | Midterm exam | 40.0% | — |
| PHARM 401 | Y3 | Final Term Exam | Final exam | 30.0% | — |
| PHARM 401 | Y3 | Case 3 - Quiz (eClass) | Other exam/test | 5.0% | — |
| PHARM 401 | Y3 | Term Exam 1 | Other exam/test | 30.0% | — |
| PHARM 401 | Y3 | Term Exam 2 | Other exam/test | 25.0% | — |
| PHARM 401 | Y3 | Case 1 - Quiz (eClass) | Quiz | 5.0% | — |
| PHARM 401 | Y3 | Case 2 - Quiz (eClass) | Quiz | 5.0% | — |
Use these searchable records to verify the course, session and assessment evidence behind the curriculum portrait. The browser supports inspection and verification rather than additional curriculum analysis.
Course Information
| PHARM 201 — PRINCIPLES OF MEDICINAL CHEMISTRY | Y1 | Fall | 38 | 5 | 0 | Final exam (1); Midterm exam (1); Participation/professionalism (1) | Introduces students to fundamental principles in Medicinal Chemistry necessary to understand the relationship between drug structure and drug action. The clinical relevance of Medicinal Chemistry will be explored through an examination of drug structure, properties, classification, metabolism, and selected design/development strategies. (Restricted to Pharmacy students). |
| PHARM 202 — Pharmaceutics 1 | Y1 | Winter | 37 | 9 | 9 | Assignment/written work (1); Final exam (1); Midterm exam (1); Other exam/test (1); Quiz (1) | 3 units (fi 6) (second term, 3-1S-2) Introduces students to the principles of pharmaceutical dosage forms. This course will focus on factors affecting the physical and chemical behavior of drug products, the rationale underlying their formulation, and compounding techniques of pharmaceutical preparations. (Restricted to Pharmacy students) |
| PHARM 203 — INTRO TO PHARMACOLOGY 1 | Y1 | Fall | 38 | 0 | 0 | Final exam (1); Midterm exam (1) | Introduces students to fundamental principles of pharmacology that will form the basis for future pharmacotherapy courses. Core concepts of pharmacology, including theoretical aspects of drug-receptor interaction, dose-dependence of drug action, and the effects of drugs on nervous and cardiovascular systems will be covered. |
| PHARM 204 — Anatomy and Physiology for Pharmacy | Y1 | Fall | 29 | 0 | 0 | Assignment/written work (1); Final exam (1); Midterm exam (1); Quiz (1) | ★ 3 (fi 6) (first term, 3-1s-0) Provides students with a fundamental understanding of human anatomy relevant to pharmacy practice using a system-based approach. Core concepts include human anatomy and anatomical function including physiology and pathophysiology within the context of drug action. |
| PHARM 233 — Introduction to Pharmacology 2 | Y1 | Winter | 36 | 0 | 0 | Final exam (1); Midterm exam (2) | Building on pharmacology fundamentals introduced in Pharm 203, students will continue learning fundamental principles of pharmacology that affect other organ systems, as well as core concepts on the mechanisms of action for drugs including those used in the treatment of various diseases. |
| PHARM 302 — Pharmaceutics 2 | Y2 | Fall | 38 | 0 | 0 | Assignment/written work (3); Final exam (1); Midterm exam (1) | The overall goal of PharmSci 3: Pharmaceutics II is for students to develop the fundamental knowledge of the physicochemical and biological factors that affect the manufacturing, compounding, application and behaviour of drug products and pharmaceutical dosage forms. The course also explores the rationale underlying, as well as the standards governing, the formulation and quality control of pharmaceutical preparations. The emphasis of Pharmaceutics 2 is on advanced dosage forms, biologicals as pharmaceuticals, and more complex compounding practices |
| PHARM 303 — ESSENTIALS OF PHARMACOKINETICS | Y2 | Fall | 39 | 0 | 0 | Assignment/written work (1); Final exam (1); Midterm exam (2) | 3 (fi 6) (first term, 3-0-0) Provides students with fundamental knowledge of pharmacokinetic concepts and their application in devising appropriate patient-specific dosing regimens. Clinical relevance of pharmacokinetics will be explored through the examination of disease states and drug interactions that affect drug concentrations in the body. (Restricted to Pharmacy students.) |
| PHARM 310 — IMMUNOLOGY AND BIOTECHNOLOGY | Y2 | Fall | 8 | 0 | 0 | Final exam (1); Midterm exam (1) | ★ 1 (fi 2)(EITHER, 1-0-0) This course provides students with an understanding of immunology, molecular biology, and biotechnical processes and point of care tests that support therapeutic and diagnostic application in patient care. |
| PHARM 401 — Toxicology | Y3 | Winter | 34 | 0 | 0 | Final exam (1); Midterm exam (2); Quiz (3) | 3 (fi 6) (second term, 3-0-0) Provides students with fundamental knowledge of toxicology of prescription and non- prescription medications and drugs of abuse, as well as select specialized topics in pharmacology. Clinical relevance of toxicology, including pharmacogenomic concepts, will be explored through the examination of drug toxicity to specific target organs and approaches to managing poisoning and adverse drug reactions. (Restricted to Pharmacy students.) |
Session Information
| PHARM 201 | Y1 | Fall | 2025-09-03 | Lecture | Course introduction. | History and evolution of Medicinal Chemistry in clinical practice. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-09-05 | Lecture | Functional groups - characteristics and roles | Definition of a functional group; relevant functional groups in drug molecules. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-09-08 | Lecture | Functional groups - characteristics and roles | Physical chemical properties associated to functional groups in drug molecules. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-09-10 | Lecture | Functional groups - characteristics and roles | Electronic and inductive effects. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-09-12 | Lecture | Functional groups - characteristics and roles | Steric effects; solubility effects; binding interactions. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-09-15 | Lecture | Acidic and basic functional groups | Most common types of acidic and basic functional groups in drug molecules. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-09-16 | Seminar/case session | Seminar 1 | Functional groups, reactivity. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-09-17 | Lecture | Acidic and basic functional groups | Physiologically relevant acidic and basic functional groups. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-09-19 | Lecture | Acidic and basic functional groups | Therapeutic significance of acidic and basic groups. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-09-22 | Lecture | Acidic and basic functional groups | Correlating the presence (or absence) of acidic / basic groups to therapeutic effects. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-09-23 | Lecture | Problems involving pH and pKa | pH and pKa: principles and applications in clinical practice; using the Henderson-Hasselbach equation. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-09-24 | Lecture | Problems involving pH and pKa | Importance of pH and pKa in drug therapy; influence of pH and pKa on the solubility of a drug molecule. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-09-26 | Lecture | Problems involving pH and pKa | Relationship between pH and pKa on the duration of action of drug molecules; influence of pH and pKa on drug binding interactions (drug potency). | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-09-29 | Lecture | Problems involving pH and pKa | Predicting chemical antagonism between drug molecules using their pKa values. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-10-01 | Lecture | Problems involving pH and pKa | Drug interactions based on pH and their pKa values. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-10-03 | Lecture | Salts and solubility | Salts and solubility of drug molecules; definition of salt; formation of salts from acid and basic drug molecules. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-10-06 | Lecture | Salts and solubility | Inorganic salts; organic salts; salts and their influence on drug-drug and drug-food interactions. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-10-07 | Seminar/case session | Seminar 2 | Problems with pH and pKa; salts and solubility. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-10-08 | Lecture | Salts and solubility | Solubility of salts and their partition coefficient; therapeutic use of salts based on their water solubility; the balance between water and lipid solubility. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-10-10 | Lecture | Salts and solubility | Strategies for optimizing drug solubility; relationship between solubility and drug metabolism. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-10-15 | Lecture | Drug binding interactions | Drug binding interactions and their relationship with potency. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-10-20 | Lecture | Drug binding interactions | Covalent bonds; non-covalent bonds; ionic bonds. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-10-21 | Seminar/case session | Seminar 3 | Drug binding interactions; stereochemistry. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-10-22 | Lecture | Drug binding interactions | Ion-dipole and dipole-dipole interactions. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-10-24 | Lecture | Drug binding interactions | Hydrogen bonds; van der Waals interactions; hydrophobic bonding. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-10-27 | Lecture | Stereochemistry | Stereochemistry: chirality and asymmetry; enantiomers. | Amir Tabatabaei |
| PHARM 201 | Y1 | Fall | 2025-10-29 | Lecture | Stereochemistry | Pharmacological implications of enantiomeric mixtures; diastereomers. | Amir Tabatabaei |
| PHARM 201 | Y1 | Fall | 2025-10-31 | Lecture | Stereochemistry | Geometric isomers; pharmacological implications of diastereomeric mixtures. | Amir Tabatabaei |
| PHARM 201 | Y1 | Fall | 2025-11-03 | Lecture | Stereochemistry | Conformational isomers; definition of the active conformation in drug molecules; conformational restriction. | Amir Tabatabaei |
| PHARM 201 | Y1 | Fall | 2025-11-04 | Seminar/case session | Seminar (No seminar) | No seminar | *** |
| PHARM 201 | Y1 | Fall | 2025-11-05 | Lecture | Drug metabolism (1) | Drug metabolism: General concepts. | Ayman El-Kadi |
| PHARM 201 | Y1 | Fall | 2025-11-07 | Lecture | Drug metabolism (2) | Factors affecting drug metabolism; Phase I and Phase II metabolism. | Ayman El-Kadi |
| PHARM 201 | Y1 | Fall | 2025-11-17 | Lecture | Drug metabolism (3) | Oxidation reactions by the cytochrome P450 (CYP450) family of enzymes. | Ayman El-Kadi |
| PHARM 201 | Y1 | Fall | 2025-11-19 | Lecture | Drug metabolism (4) | Oxidation reactions by the cytochrome P450 (CYP450) family of enzymes. | Ayman El-Kadi |
| PHARM 201 | Y1 | Fall | 2025-11-21 | Lecture | Drug metabolism (5) | Reduction reactions by the cytochrome P450 (CYP450) family of enzymes. | Ayman El-Kadi |
| PHARM 201 | Y1 | Fall | 2025-11-24 | Lecture | Drug metabolism (6) | Hydrolysis reactions; conjugation reactions. | Ayman El-Kadi |
| PHARM 201 | Y1 | Fall | 2025-11-25 | Seminar/case session | Seminar 4 | Drug metabolism | Ayman El-Kadi |
| PHARM 201 | Y1 | Fall | 2025-11-26 | Lecture | Drug metabolism (7) | Relationship between drug metabolism and pharmacological activity. | Ayman El-Kadi |
| PHARM 201 | Y1 | Fall | 2025-11-28 | Lecture | Structure-Activity Relationships and Classical Strategies in Drug Design | Structure-Activity Relationships (SAR): general description; examples of SARs; SAR and pharmacological activity. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-12-01 | Lecture | Structure-Activity Relationships and Classical Strategies in Drug Design | SARs and the absorption, distribution, metabolism and excretion (ADME) process. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-12-03 | Lecture | Structure-Activity Relationships and Classical Strategies in Drug Design | SAR, drug interactions and adverse drug reactions; molecular modification. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-12-05 | Lecture | Classical Strategies in Drug Design | Isosters and bioisosteres; homologation; chain branching; prodrugs. | Carlos Velazquez |
| PHARM 201 | Y1 | Fall | 2025-12-08 | Lecture | Course review | Course review (all book chapters and seminars). | Carlos Velazquez |
| PHARM 202 | Y1 | Winter | 2026-01-05 | Lecture | Introducion: Overview of topics covered in this course | Introducion: Overview of topics covered in this course | F. Sanaee |
| PHARM 202 | Y1 | Winter | 2026-01-07 | Lecture | Compounding | Compounding | R. Loebenberg |
| PHARM 202 | Y1 | Winter | 2026-01-09 | Seminar/case session | Accuracy-Risk Assessment | Accuracy-Risk Assessment | R. Loebenberg; F. Sanaee |
| PHARM 202 | Y1 | Winter | 2026-01-09 | Lecture | USP 795-1 | USP 795-1 | R. Loebenberg |
| PHARM 202 | Y1 | Winter | 2026-01-12 | Laboratory | Sign in/ Accuracy | Sign in/ Accuracy | R. Loebenberg; F. Sanaee; A. Lavasanifar |
| PHARM 202 | Y1 | Winter | 2026-01-12 | Lecture | USP 795-2 | USP 795-2 | R. Loebenberg |
| PHARM 202 | Y1 | Winter | 2026-01-14 | Lecture | Solubility-1 | Solubility-1 | A. Lavasanifar |
| PHARM 202 | Y1 | Winter | 2026-01-16 | Lecture | Solubility-2 | Solubility-2 | A. Lavasanifar |
| PHARM 202 | Y1 | Winter | 2026-01-19 | Lecture | Pharmaceuical Soluions | Pharmaceuical Soluions | R. Loebenberg |
| PHARM 202 | Y1 | Winter | 2026-01-21 | Lecture | Pharma Waters | Pharma Waters | R. Loebenberg |
| PHARM 202 | Y1 | Winter | 2026-01-23 | Seminar/case session | Soluion | Soluion | R. Loebenberg; F. Sanaee |
| PHARM 202 | Y1 | Winter | 2026-01-23 | Lecture | Suspensions-1 | Suspensions-1 | A. Lavasanifar |
| PHARM 202 | Y1 | Winter | 2026-01-26 | Lecture | Suspensions-2 | Suspensions-2 | A. Lavasanifar |
| PHARM 202 | Y1 | Winter | 2026-01-28 | Laboratory | Soluions/Solubility Suspensions | Soluions/Solubility Suspensions | F. Sanaee |
| PHARM 202 | Y1 | Winter | 2026-01-28 | Lecture | Suspensions-3 | Suspensions-3 | A. Lavasanifar |
| PHARM 202 | Y1 | Winter | 2026-01-30 | Lecture | Emulsions-1 | Emulsions-1 | A. Lavasanifar |
| PHARM 202 | Y1 | Winter | 2026-01-30 | Seminar/case session | Suspension | Suspension | A. Lavasanifar; F. Sanaee |
| PHARM 202 | Y1 | Winter | 2026-02-02 | Lecture | Soluions-Suspensions Review | Soluions-Suspensions Review | F. Sanaee |
| PHARM 202 | Y1 | Winter | 2026-02-02 | Laboratory | Suspensions | Suspensions | R. Loebenberg; F. Sanaee |
| PHARM 202 | Y1 | Winter | 2026-02-04 | Quiz | 1 | 1 | — |
| PHARM 202 | Y1 | Winter | 2026-02-04 | Lecture | Emulsions-2 | Emulsions-2 | A. Lavasanifar |
| PHARM 202 | Y1 | Winter | 2026-02-06 | Seminar/case session | Emulsion | Emulsion | R. Loebenberg; F. Sanaee |
| PHARM 202 | Y1 | Winter | 2026-02-06 | Lecture | Emulsions-3 | Emulsions-3 | A. Lavasanifar |
| PHARM 202 | Y1 | Winter | 2026-02-09 | Laboratory | Emulsions | Emulsions | R. Loebenberg; F. Sanaee |
| PHARM 202 | Y1 | Winter | 2026-02-09 | Lecture | Semisolids-1 | Semisolids-1 | A. Lavasanifar |
| PHARM 202 | Y1 | Winter | 2026-02-11 | Lecture | Semisolids-2 | Semisolids-2 | A. Lavasanifar |
| PHARM 202 | Y1 | Winter | 2026-02-13 | Lecture | Colloids-1 | Colloids-1 | A. Lavasanifar |
| PHARM 202 | Y1 | Winter | 2026-02-13 | Seminar/case session | Semisolid | Semisolid | R. Loebenberg; F. Sanaee |
| PHARM 202 | Y1 | Winter | 2026-02-18 | Quiz | 2 | 2 | — |
| PHARM 202 | Y1 | Winter | 2026-02-23 | Lecture | Colloids-2 | Colloids-2 | A. Lavasanifar |
| PHARM 202 | Y1 | Winter | 2026-02-23 | Laboratory | Semisolids-1 | Semisolids-1 | R. Loebenberg; F. Sanaee |
| PHARM 202 | Y1 | Winter | 2026-02-24 | Midterm exam | Midterm | Midterm | PharmaceuQcs Team |
| PHARM 202 | Y1 | Winter | 2026-02-25 | Lecture | Semisolids-Colloids Review | Semisolids-Colloids Review | F. Sanaee |
| PHARM 202 | Y1 | Winter | 2026-02-27 | Lecture | Powders | Powders | R. Loebenberg |
| PHARM 202 | Y1 | Winter | 2026-02-27 | Seminar/case session | SOP/QA | SOP/QA | R. Loebenberg; F. Sanaee |
| PHARM 202 | Y1 | Winter | 2026-03-02 | Lecture | Capsules | Capsules | R. Loebenberg |
| PHARM 202 | Y1 | Winter | 2026-03-02 | Laboratory | Semisolids-2 | Semisolids-2 | R. Loebenberg; F. Sanaee |
| PHARM 202 | Y1 | Winter | 2026-03-04 | Lecture | Tablets-1 | Tablets-1 | R. Loebenberg |
| PHARM 202 | Y1 | Winter | 2026-03-06 | Seminar/case session | Capsule | Capsule | R. Loebenberg, F. Sanaee |
| PHARM 202 | Y1 | Winter | 2026-03-06 | Lecture | Tablets-2 | Tablets-2 | R. Loebenberg |
| PHARM 202 | Y1 | Winter | 2026-03-09 | Laboratory | Capsules | Capsules | R. Loebenberg; F. Sanaee |
| PHARM 202 | Y1 | Winter | 2026-03-09 | Lecture | Suppositories Bases | Suppositories Bases | R. Loebenberg |
| PHARM 202 | Y1 | Winter | 2026-03-11 | Lecture | Inserts, Suppositories | Inserts, Suppositories | R. Loebenberg |
| PHARM 202 | Y1 | Winter | 2026-03-12 | Lecture | Routes of Drug Administraion-1 | Routes of Drug Administraion-1 | A. Lavasanifar |
| PHARM 202 | Y1 | Winter | 2026-03-13 | Lecture | Routes of Drug Administraion-2 | Routes of Drug Administraion-2 | A. Lavasanifar |
| PHARM 202 | Y1 | Winter | 2026-03-13 | Seminar/case session | Suppository | Suppository | R. Loebenberg; F. Sanaee |
| PHARM 202 | Y1 | Winter | 2026-03-16 | Quiz | 3 | 3 | — |
| PHARM 202 | Y1 | Winter | 2026-03-16 | Lecture | Routes of Drug Administraion-3 | Routes of Drug Administraion-3 | A. Lavasanifar |
| PHARM 202 | Y1 | Winter | 2026-03-16 | Laboratory | Suppositories | Suppositories | R. Loebenberg; F. Sanaee |
| PHARM 202 | Y1 | Winter | 2026-03-18 | Lecture | Routes of Drug Administraion-4 | Routes of Drug Administraion-4 | A. Lavasanifar |
| PHARM 202 | Y1 | Winter | 2026-03-20 | Seminar/case session | Review | Review | R. Loebenberg; F. Sanaee |
| PHARM 202 | Y1 | Winter | 2026-03-20 | Lecture | Routes of Drug Administraion-5 | Routes of Drug Administraion-5 | A. Lavasanifar |
| PHARM 202 | Y1 | Winter | 2026-03-23 | Lecture | Containers | Containers | R. Loebenberg |
| PHARM 202 | Y1 | Winter | 2026-03-25 | Lecture | Aerosoles-1 | Aerosoles-1 | S. Tavernini |
| PHARM 202 | Y1 | Winter | 2026-03-27 | Lecture | Aerosoles-2 | Aerosoles-2 | S. Tavernini |
| PHARM 202 | Y1 | Winter | 2026-03-30 | Lecture | Aerosoles-3 | Aerosoles-3 | S. Tavernini |
| PHARM 202 | Y1 | Winter | 2026-03-30 | Other exam/test | Lab Exam | Lab Exam | R. Loebenberg; F. Sanaee |
| PHARM 202 | Y1 | Winter | 2026-04-01 | Lecture | Hot Topic in Pharmaceuical Sciences | Hot Topic in Pharmaceuical Sciences | R. Loebenberg |
| PHARM 202 | Y1 | Winter | 2026-04-01 | Laboratory | Lab Cleaning | Lab Cleaning | R. Loebenberg; F. Sanaee |
| PHARM 202 | Y1 | Winter | 2026-04-04 | Quiz | 4 | 4 | — |
| PHARM 202 | Y1 | Winter | — | Lecture | Final | Final | PharmaceuQcs Team |
| PHARM 203 | Y1 | Fall | 2024-11-05 | Lecture | CNS Pharmacology | Psychomotor stimulants & hallucinogenics | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2025-09-03 | Lecture | Molecular Aspects of Drug Action | Receptors, Specificity, Drug-Receptor Interactions | Dr. Andrew Holt |
| PHARM 203 | Y1 | Fall | 2025-09-05 | Lecture | Molecular Aspects of Drug Action | Receptors, Specificity, Drug-Receptor Interactions | Dr. Andrew Holt |
| PHARM 203 | Y1 | Fall | 2025-09-08 | Lecture | General Principles of Drug Action | Receptors, Specificity, Drug-Receptor Interactions (Agonists, Antagonists, Partial Agonists, Efficacy, Inverse Agonists, Allosteric Modulation) , Concentration response, Intro to Pharmacokinetics | Dr. Andrew Holt |
| PHARM 203 | Y1 | Fall | 2025-09-10 | Lecture | General Principles of Drug Action | Receptors, Specificity, Drug-Receptor Interactions (Agonists, Antagonists, Partial Agonists, Efficacy, Inverse Agonists, Allosteric Modulation) , Concentration response, Intro to Pharmacokinetics | Dr. Andrew Holt |
| PHARM 203 | Y1 | Fall | 2025-09-12 | Lecture | General Principles of Drug Action | Receptors, Specificity, Drug-Receptor Interactions (Agonists, Antagonists, Partial Agonists, Efficacy, Inverse Agonists, Allosteric Modulation) , | Dr. Andrew Holt |
| PHARM 203 | Y1 | Fall | 2025-09-15 | Lecture | General Principles of Drug Action | Receptors, Specificity, Drug-Receptor Interactions (Agonists, Antagonists, Partial Agonists, Efficacy, Inverse Agonists, Allosteric Modulation), Concentration response, Intro to Pharmacokinetics | Dr. Andrew Holt |
| PHARM 203 | Y1 | Fall | 2025-09-17 | Lecture | General Principles of Drug Action | Receptor types, ion channels, enzymes, & transporters as drug targets | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2025-09-19 | Lecture | General Principles of Drug Action | Receptor types, ion channels, enzymes, & transporters as drug targets | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2025-09-22 | Lecture | Chemical Mediators | Cholinergic/Autonomic Transmission; | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2025-09-24 | Lecture | Chemical Mediators | Acetylcholine, nicotinic/muscarinic action; Noradrenergic transmission | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2025-09-26 | Lecture | Chemical Mediators | Noradrenergic autonomic transmission, Catecholamines, adrenoreceptors | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2025-09-29 | Lecture | Chemical Mediators | Amino acid mediators: Histamine, 5-HT | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2025-10-01 | Lecture | Chemical Mediators | Peptide & Protein mediators | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2025-10-03 | Lecture | Chemical Mediators | Eicosanoids & cannabinoids | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2025-10-06 | Lecture | Chemical Mediators | NO & H2S | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2025-10-08 | Lecture | Chemical mediators | Purines; Amino acids & other neurotransmitters | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2025-10-10 | Lecture | CNS Pharmacology | Amino acids & other neurotransmitters | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2025-10-15 | Midterm exam | Midterm | Materials encompassed in lectures 1 - 16 | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2025-10-17 | Lecture | CNS Pharmacology | General anaesthetics | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2025-10-20 | Lecture | CNS Pharmacology | Local anaesthetics | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2025-10-22 | Lecture | CNS Pharmacology | Analgesics | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2025-10-24 | Lecture | CNS Pharmacology | Anxiolytic & Hyponotic drugs | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2025-10-27 | Lecture | CNS Pharmacology | Parkinson's Dis. Pharmacology | Dr. Tabatabaei Dakhili |
| PHARM 203 | Y1 | Fall | 2025-10-29 | Lecture | CNS Pharmacology | Alzheimer's dis. & Huntington's dis. pharmacology | Dr. Tabatabaei Dakhili |
| PHARM 203 | Y1 | Fall | 2025-10-31 | Lecture | CNS Pharmacology | Antiepileptic drug | Dr. Sherif Mahmoud |
| PHARM 203 | Y1 | Fall | 2025-11-03 | Lecture | CNS Pharmacology | Antidepressant drugs | Dr. Sherif Mahmoud |
| PHARM 203 | Y1 | Fall | 2025-11-05 | Lecture | CNS Pharmacology | Antipsychotic drugs | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2025-11-07 | Lecture | Cardiovascular Pharmacology | Antidysrhythmic drugs Class I , Class II | Dr. John Seubert |
| PHARM 203 | Y1 | Fall | 2025-11-17 | Lecture | Cardiovascular Pharmacology | Antidysrhythmic drugs Class III, Class IV | Dr. John Seubert |
| PHARM 203 | Y1 | Fall | 2025-11-19 | Lecture | Cardiovascular Pharmacology | Drugs that Increase Cardiac Contractility and Anti-Anginal Drugs | Dr. John Seubert |
| PHARM 203 | Y1 | Fall | 2025-11-21 | Lecture | Cardiovascular Pharmacology | Atherosclerosis and Lipid-Lowering Drugs | Dr. John Seubert |
| PHARM 203 | Y1 | Fall | 2025-11-24 | Lecture | Cardiovascular Pharmacology | Vascular Function, Vasoactive Drugs (Vasoconstrictors & Vasodilators) | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2025-11-26 | Lecture | Cardiovascular Pharmacology | Drugs for Treating Hypertension | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2025-11-28 | Lecture | Cardiovascular Pharmacology | Drugs for Treating Heart Failure | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2025-12-01 | Lecture | Cardiovascular Pharmacology | Drugs for Treating Pulmonary Hypertension, Shock & Hypotensive States | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2025-12-03 | Lecture | Cardiovascular Pharmacology | Anti-platelet drugs | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2025-12-05 | Lecture | Cardiovascular Pharmacology | Anticoagulants & Fibrinolytics, Anti-platelet drugs & Anticoagulants | Dr. Paul Jurasz |
| PHARM 203 | Y1 | Fall | 2025-12-08 | Lecture | Cardiovascular Pharmacology | Anticoagulants & Fibrinolytics | Dr. Paul Jurasz |
| PHARM 204 | Y1 | Fall | 2025-09-03 | Lecture | Introduction & Overview of gross anatomy | Description of the course content and assessment. General gross anatomy and terminology | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-09-05 | Lecture | Cellular anatomy | Cellular structure and function, the lipid bilayer and what it contains. Cell adhesion mechanisms-cell junctions including gap junctions, tight junctions. membrane transporters. The electrochemical gradient and redox potential of the cell. | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-09-08 | Lecture | Cell membrane components | Membrane protein functions, important functions of the nucleus, including replication, transcription, & translation. Protein processing (Golgi) | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-09-10 | Lecture | Cell membrane components | Plasma membrane receptors; signaling mechanisms of receptor activation (TK, G-proteins). | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-09-12 | Quiz | Tissue structure and organization (Quiz #1) | Layers of tissue (epithelial, connective) -supporting tissue structures | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-09-15 | Lecture | Neurons: introduction to the nervous system | CNS vs PNS, function & structure of a neuron. Neuroglia, membrane potential, action potential, and ion channels | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-09-17 | Lecture | Autonomic nervous system (ANS) | Neurotransmitter of pre-and postganglionic neurons: Acetylcholine, noradrenaline: Synthesis and Mechanisms of action. Adrenal medulla hormones. Adrenergic and cholinergic receptors, and brief application to pharmacy. Receptor distribution. | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-09-19 | Lecture | Pain (nociception) | Pain categories, nociceptors, first/second pain -anterolateral pathways (fibres) Referral pain withdrawal reflexes, pain neurotransmitters, afferent pathways of pain | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-09-22 | Other/unspecified | Pain | Inflammatory pain pathophysiology of pain. Neuropathic pain as an example - Central sensitization following peripheral nerve injury | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-09-24 | Quiz | Neurology: neuroanatomy and the CNS (Quiz #2) | Neuron morphology, glia of CNS, glia of PNS. Cerebrum, diencephalon, brainstem, cerebellum Brain protection. Meninges -Ventricles; Production and flow of cerebrospinal fluid. Blood-brain barrier | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-09-26 | Lecture | Cerebrum and Diencephalon | Overview -cortical structure -white matter -Diencephalon: Structure (and function) of the epi-, hypo-, thalamus | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-09-29 | Lecture | Neurology, brainstem and sensory physiology | Anatomy of key regions: Midbrain, pons, medulla oblongata; cerebral aqueduct, cerebral peduncles, superior and inferior colliculi Brainstem functions: -Cerebellum structure & function; motor learning Cranial nerves. Sensory physiology: Sensory information, sensation, perception. Receptor modalities, sensory receptors, afferent-receptor configurations - Receptive field, receptor potential, adaptation. Coding intensity, modality, and location of a sensory stimulus | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-10-01 | Other/unspecified | Neurology: Sensory physiology | Sensory physiology: Somatic sensation: Receptors, pathways, primary somatosensory cortex. Motor control: Alpha-motor neurons as the final common pathway. Hierarchical control. Feedback control. Cerebellar damage. Proprioceptors, local feedback, spinal reflexes | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-10-03 | Other/unspecified | Neurology: Motor Control Blood supply; Cerebral perfusion pressure and blood flow | Motor control: -Concepts of how motor system works: hierarchical control; Alpha-motor neurons as the final common pathway. Cerebellum and feedback, cerebellar damage) -Local feedback. Monosynaptic reflex (includes terminology: agonist, synergist, antagonist -Motor cortices (primary motor, premotor, supplementary motor area) -Motor tracts Blood supply, Intracranial pressure, cerebral perfusion pressure, cerebral blood flow | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-10-06 | Other/unspecified | Neurology: Higher CNS function; Basal ganglia | Neurotransmitters -ACh, biogenic amines, amino acid neurotransmitters also neuropeptides, purines, others. Synthesis, receptors, reuptake and/or metabolism of select neurotransmitters, major roles -Alzheimer?s, myasthenia gravis, depression Basal ganglia, Parkinson?s, Anatomy, Basic functioning of healthy basal ganglia - Parkinson?s: Symptoms and basal ganglia function. Pharmacological and surgical treatments as examples to reinforce concepts regarding the physiological function of the CNS, and points of pharmaceutical intervention at the synapse | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-10-08 | Lecture | Cardiology: Anatomy of the heart; Electrical activity of the heart | Gross anatomy Electrical activity - Pacemaker cell vs. conducting fibre; Bachmann?s bundle and intermodal pathways, fibrous skeleton; rates of autorhymicity -Action potentials of pacemaker and contractile cells -Effects of ANS on rate (with mechanisms) and contractility (without mechanisms) - ECG and case study | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-10-10 | Lecture | Cardiology: blood flow 1 | Anatomy-Major Systemic Arteries and Veins Haemodynamics -Arterial and venous system blood vessel walls, characteristics summary. Driving force in the cardiovascular system (MAP) central venous pressure). Regulation of arteriolar resistance: Intrinsic mechanisms: local factors; Extrinsic mechanisms neuroendocrine, to regulate MAP | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-10-15 | Quiz | Cardiology: blood flow 2 (Quiz #3) | Venomotor tone and venous return and effects of Blood volume and venomotor tone on venous pressure and therefore MAP -Thermoregulation and arteriolar R -Coronary and skeletal muscles and vasodilation by Beta-2, note re: Beta-2 Rs on vascular smooth muscle cells ? beta-blockers and MAP. Regulation of MAP. Baroreceptor reflex regulation of blood pressure. Angiotensin II, ADH increase MAP | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-10-17 | Lecture | Pulmonary | Anatomy- airways, resp epithelium. Mechanics. Blood flow -Sites of intervention. COPD. ARDS cause and consequences (wrt patient care) | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-10-20 | Midterm exam | MIDTERM EXAM | Lectures 1-18 (up to Cardiology: blood flow 2) | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-10-22 | Lecture | GI (1/2) | GI tract anatomy: -oral cavity and teeth. Review of wall of GI tract + stomach wall + small intestine regional differences -diagnostic imaging for GI and liver. Liver blood flow and tissue substructure wrt to drug metabolism | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-10-24 | Lecture | GI (2/2) | GI: small intestine regional differences -diagnostic imaging for GI and liver. Liver blood flow and tissue substructure wrt to drug metabolism | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-10-27 | Lecture | Bone & Joint 1 | The skeletal system: osseous tissue and bone structure -Bone functions, histology, structure. Intramembranous ossification -Endochondral ossification | Dr. Doschak |
| PHARM 204 | Y1 | Fall | 2025-10-29 | Lecture | Bone & Joint 2 | Cartilage histology, growth, and composition. Basic multicellular unit (BMU). Bone resorption and formation -RANK / RANKLigand / OPG System | Dr. Doschak |
| PHARM 204 | Y1 | Fall | 2025-10-31 | Lecture | Bone & Joint 3 | Bone elongation: epiphyseal plate. Appositional growth. Formation of an osteon. Bone blood supply and innervation | Dr. Doschak |
| PHARM 204 | Y1 | Fall | 2025-11-03 | Quiz | Bone & Joint 4 (Quiz #4) | Joint classification -synovial joint characteristics. The knee joint. Aging and joints -sites of therapy in bone and joint | Dr. Doschak |
| PHARM 204 | Y1 | Fall | 2025-11-05 | Lecture | MSK (B & J - 5) | Skeletal muscle: structure -fibres and molecular makeup | Dr. Doschak |
| PHARM 204 | Y1 | Fall | 2025-11-07 | Lecture | MSK (B & J - 6) | Skeletal muscle: force generation (contraction). NMJ and its role (above). twitch summation, types of contraction (concentric, isometric, eccentric) | Dr. Doschak |
| PHARM 204 | Y1 | Fall | 2025-11-17 | Lecture | MSK (B & J - 7) | Skeletal: anatomy Smooth: anatomy, contraction | Dr. Doschak |
| PHARM 204 | Y1 | Fall | 2025-11-19 | Lecture | Integumetary system 1 | Skin: Epidermis, Dermis. Hypodermis; Skin colour; Blood supply and innervation -Hair, Nails, Sebaceous glands and follicles, Sweat glands | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-11-21 | Lecture | Integumetary system 2 | Sun/UV effects -interface with other systems (e.g., immune). Effects of aging interactions of therapeutics | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-11-24 | Lecture | Eye, Ear, Nose & Throat (EENT) | Eye anatomy: -flow of aqueous humor. Retina, macular degeneration -sites of drug action. Ear anatomy: -sound conduction, cochlea, site of drug action. Nose, pharynx, Paranasal sinuses, Larynx, Olfaction | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-11-26 | Lecture | Endocrine 1 | Fundamentals: amines, steroids, peptides. Energy metabolism -actions and regulation of insulin and glucagon. ANS in glucose homeostasis -secretion disorders of the hypothalamuspituitary axis -Cushing?s disease (cortisol effects) | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-11-28 | Lecture | Endocrine 2 | Thyroid gland and parathyroid. -Basic function of and tissue organization. - Use of diagnostic imaging for visualization | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-12-01 | Lecture | Renal 1 | Gross anatomy, blood supply and innervation to the kidneys. Renal corpuscle -key sites and actions of the nephron. | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-12-03 | Lecture | Renal 2 | Sodium on bp, blood volument, water effects -K+: direct effect of K+ on Na+/K+-ATPase -use of agents for diagnostic imaging | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-12-05 | Lecture | Reproductive 1 | Male reproductive system -Female reproductive system | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-12-08 | Lecture | Reproductive 2 | Ovulation and menstrual cycle -Sexual response and therapeutics -lactation and mammary glands | Dr. Siraki |
| PHARM 204 | Y1 | Fall | 2025-12-13 | Final exam | FINAL EXAM | FINAL EXAM | — |
| PHARM 233 | Y1 | Winter | 2026-01-05 | Lecture | Pharmacogenomics 1 | Introduction Pharmacogenomics (PGx), The Basis for Precision Medicine, Overview PharmGkB, CPIC Websites, effect of environment, ethnicity , pollutants etc | Dr. Dalia Hamdy |
| PHARM 233 | Y1 | Winter | 2026-01-07 | Lecture | Pharmacogenomics 2 | Classical and non-classical PGx (Genetics: DNA, RNA, transcription, translation, genetic variability, SNP, CNV, addition, deletion) | Dr. Dalia Hamdy |
| PHARM 233 | Y1 | Winter | 2026-01-09 | Lecture | Pharmacogenomics 3 | Introduction to common Transporters, CYP P450 and Receptors alleles, Relationship between PK-PD-PGX and dose adjustments | Dr. Dalia Hamdy |
| PHARM 233 | Y1 | Winter | 2026-01-12 | Other/unspecified | Pharmacogenomics 4 | Basic techniques for genetic testing and diseases related to genes. Examples on PGX Pt. Case management using pharmGKB | Dr. Dalia Hamdy |
| PHARM 233 | Y1 | Winter | 2026-01-14 | Lecture | GI Pharmacology 1 | Antiemetic Agents | Dr. John Ussher |
| PHARM 233 | Y1 | Winter | 2026-01-16 | Lecture | GI Pharmacology 2 | Agents for Neutralizing Gastric Acid Secretion | Dr. John Ussher |
| PHARM 233 | Y1 | Winter | 2026-01-19 | Lecture | GI Pharmacology 3 | Agents that Modulate Gastric Motility, Antidiarrheal Agents and Agents for Chronic Bowel Disease | Dr. John Ussher |
| PHARM 233 | Y1 | Winter | 2026-01-21 | Lecture | Respiratory Pharmacology | Drugs for Asthma: Bronchodilators & Antiinflammatories; Drugs for COPD | Dr. Mourad Ferdaoussi |
| PHARM 233 | Y1 | Winter | 2026-01-23 | Lecture | Skin Pharmacology | Antiinflammatories & Other Agents for Skin Disorders | Dr. Mourad Ferdaoussi |
| PHARM 233 | Y1 | Winter | 2026-01-26 | Lecture | Obesity Pharmacology & Pharmacotherapy 1 | Non-Pharmacological Approaches, Central Acting Agents, Gut Hormone-Based Agents, and Medical Devices | Dr. John Ussher |
| PHARM 233 | Y1 | Winter | 2026-01-28 | Lecture | Obesity Pharmacology & Pharmacotherapy 2 | Non-Pharmacological Approaches, Central Acting Agents, Gut Hormone-Based Agents, and Medical Devices | Dr. John Ussher |
| PHARM 233 | Y1 | Winter | 2026-01-30 | Lecture | Endocrine Pharmacology 1 | Type 1 Diabetes (Insulin and Insulin Analogues) | Dr. John Ussher |
| PHARM 233 | Y1 | Winter | 2026-02-04 | Lecture | Endocrine Pharmacology 2 | Type 2 Diabetes (Metformin, Sulfonylureas, and Thiazolidinediones) | Dr. John Ussher |
| PHARM 233 | Y1 | Winter | 2026-02-06 | Lecture | Endocrine Pharmacology 3 | Type 2 Diabetes (Incretin Based Therapies & SGLT2 Inhibitors) | Dr. John Ussher |
| PHARM 233 | Y1 | Winter | 2026-02-09 | Lecture | Anemia Pharmacology | Hematinic Agents | Dr. Ayman El-Kadi |
| PHARM 233 | Y1 | Winter | 2026-02-11 | Lecture | Hematopoietic & Bone Pharmacology 1 | Agents for Osteoporosis and Osteoarthritis | Dr. Ayman El-Kadi |
| PHARM 233 | Y1 | Winter | 2026-02-13 | Lecture | Hematopoietic & Bone Pharmacology 2 | Agents for Rheumatoid Arthritis, Gout and Hyperuricemia | Dr. Ayman El-Kadi |
| PHARM 233 | Y1 | Winter | 2026-02-23 | Lecture | Endocrine Pharmacology 4 | Other Endocrine Disorders (Agents for Thyroid Disorders) | Dr. John Ussher |
| PHARM 233 | Y1 | Winter | 2026-02-25 | Lecture | Endocrine Pharmacology 5 | Oral Contraceptives, Agents that Act on the Uterus and Agents for Erectile Dysfunction | Dr. John Ussher |
| PHARM 233 | Y1 | Winter | 2026-02-27 | Lecture | Endocrine Pharmacology 6 | Other Endocrine Disorders (Agents for Addison's Disease, Cushing Syndrome) and Hormonal Therapies | Dr. John Ussher |
| PHARM 233 | Y1 | Winter | 2026-03-02 | Lecture | Renal Pharmacology 1 | Diuretics | Dr. Keshav Gopal |
| PHARM 233 | Y1 | Winter | 2026-03-04 | Lecture | Renal Pharmacology 2 | Agents for Renal Failure and Urinary Tract Infections | Dr. Keshav Gopal |
| PHARM 233 | Y1 | Winter | 2026-03-05 | Lecture | Microbial Pharmacology 1 | Bacterial Cell Wall Agents (Sulfonamides, Beta-Lactam Antibiotics, Glycopeptides, Polymixins, etc.) | Dr. Amirhossein Tabatabaei-Dakhili |
| PHARM 233 | Y1 | Winter | 2026-03-06 | Lecture | Microbial Pharmacology 2 | Bacterial protein synthesis inhibitors (Tetracyclines, Aminoglycosides, etc.) | Dr. Amirhossein Tabatabaei-Dakhili |
| PHARM 233 | Y1 | Winter | 2026-03-11 | Lecture | Microbial Pharmacology 3 | Antihelminthic Agents | Dr. Amirhossein Tabatabaei-Dakhili |
| PHARM 233 | Y1 | Winter | 2026-03-13 | Lecture | Microbial Pharmacology 4 | Antimycobacterial Agents | Dr. John Ussher |
| PHARM 233 | Y1 | Winter | 2026-03-16 | Lecture | Microbial Pharmacology 5 | Antifungal Agents | Dr. John Ussher |
| PHARM 233 | Y1 | Winter | 2026-03-18 | Lecture | Microbial Pharmacology 6 | Antimalarial Agents | Dr. John Ussher |
| PHARM 233 | Y1 | Winter | 2026-03-20 | Lecture | Microbial Pharmacology 7 | Agents for Other Protozoal Infections (Trypanosomiasis, Leishmaniasis, Giardiasis Toxoplasmosis, etc.) | Dr. John Ussher |
| PHARM 233 | Y1 | Winter | 2026-03-23 | Lecture | Viral Pharmacology 1 | Agents for Herpes | Dr. Arno Siraki |
| PHARM 233 | Y1 | Winter | 2026-03-23 | Lecture | Viral Pharmacology 2 | Agents for Influenza | Dr. Arno Siraki |
| PHARM 233 | Y1 | Winter | 2026-03-25 | Lecture | Viral Pharmacology 3 | Agents for Hepatitis & HIV | Dr. Arno Siraki |
| PHARM 233 | Y1 | Winter | 2026-03-27 | Lecture | Cancer Chemotherapy 1 | Alkylating Agents, Antimetabolites and Cytotoxic Antibiotics | Dr. Gopinath Sutendra |
| PHARM 233 | Y1 | Winter | 2026-03-30 | Lecture | Cancer Chemotherapy 2 | Plant Derivatives, Hormone-Based Agents and Protein Kinase Inhibitors | Dr. Gopinath Sutendra |
| PHARM 233 | Y1 | Winter | 2026-04-01 | Lecture | Cancer Chemotherapy 3 | Immune Therapies for Cancer, Immunosuppressants, and Other Immunotherapies | Dr. Gopinath Sutendra |
| PHARM 233 | Y1 | Winter | 2026-04-08 | Lecture | Miscellaneous Topics in Pharmacology 1 | Lifestyle Drug Uses & Drugs in Sport | Dr. John Ussher |
| PHARM 233 | Y1 | Winter | 2026-04-10 | Lecture | Miscellaneous Topics in Pharmacology 2 | Role of Pharmacology in Drug Development | Dr. John Ussher |
| PHARM 302 | Y2 | Fall | 2024-10-10 | Lecture | Controlled drug delivery systems | Controlled drug delivery systems | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2025-09-03 | Lecture | Introduction: Overview of topics covered in the course | Introduction: Overview of topics covered in the course | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2025-09-05 | Lecture | Aseptic compounding techniques | Aseptic compounding techniques | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2025-09-08 | Lecture | Aseptic compounding techniques | Aseptic compounding techniques | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2025-09-12 | Lecture | Aseptic compounding techniques | Aseptic compounding techniques | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2025-09-12 | Lecture | Aseptic compounding techniques | Aseptic compounding techniques | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2025-09-15 | Lecture | Aseptic compounding techniques | Aseptic compounding techniques | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2025-09-17 | Lecture | Aseptic compounding techniques | Aseptic compounding techniques | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2025-09-19 | Lecture | Aseptic compounding techniques | Aseptic compounding techniques | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2025-09-22 | Lecture | Parenteral Products (TPN) | Parenteral Products (TPN) | Sylvia Pasmore |
| PHARM 302 | Y2 | Fall | 2025-09-24 | Lecture | Parenteral Products (LVP) | Parenteral Products (LVP) | Dana Lyons |
| PHARM 302 | Y2 | Fall | 2025-09-26 | Lecture | Eye/Ear/Nose/Throat dosage | Eye/Ear/Nose/Throat dosage | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2025-09-29 | Lecture | Eye/Ear/Nose/Throat dosage forms | Eye/Ear/Nose/Throat dosage forms | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2025-10-01 | Lecture | Biopharmaceutics | Biopharmaceutics | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2025-10-03 | Lecture | Biopharmaceutics | Biopharmaceutics | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2025-10-06 | Lecture | Biopharmaceutics | Biopharmaceutics | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2025-10-08 | Lecture | Biopharmaceutics | Biopharmaceutics | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2025-10-15 | Lecture | Controlled drug delivery systems | Controlled drug delivery systems | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2025-10-17 | Lecture | Transdermal Drug Delivery | Transdermal Drug Delivery | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2025-10-20 | Lecture | Transdermal Drug Delivery | Transdermal Drug Delivery | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2025-10-22 | Lecture | Mid term | Mid term | — |
| PHARM 302 | Y2 | Fall | 2025-10-24 | Lecture | Drug stability and expiration date | Drug stability and expiration date | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2025-10-27 | Lecture | Drug stability and expiration date | Drug stability and expiration date | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2025-10-29 | Lecture | Drug stability and expiration date | Drug stability and expiration date | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2025-10-31 | Lecture | Drug stability and expiration date | Drug stability and expiration date | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2025-11-03 | Lecture | Nano-Medicine | Nano-Medicine | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2025-11-05 | Lecture | Nano-Medicine Biotechnology | Nano-Medicine; Biotechnology | Dr Lavasanifar |
| PHARM 302 | Y2 | Fall | 2025-11-07 | Lecture | Pharmaceutical Biotechnology | Pharmaceutical Biotechnology | Dr Doschak |
| PHARM 302 | Y2 | Fall | 2025-11-17 | Lecture | Pharmaceutical Biotechnology | Pharmaceutical Biotechnology | Dr Doschak |
| PHARM 302 | Y2 | Fall | 2025-11-19 | Lecture | Pharmaceutical Biotechnology | Pharmaceutical Biotechnology | Dr Doschak |
| PHARM 302 | Y2 | Fall | 2025-11-21 | Lecture | Pharmaceutical Biotechnology | Pharmaceutical Biotechnology | Dr Doschak |
| PHARM 302 | Y2 | Fall | 2025-11-24 | Lecture | Pharmaceutical Biotechnology: Protein Delivery | Pharmaceutical Biotechnology: Protein Delivery | Dr Wishart |
| PHARM 302 | Y2 | Fall | 2025-11-26 | Lecture | Pharmaceutical Biotechnology: Protein Delivery | Pharmaceutical Biotechnology: Protein Delivery | Dr Wishart |
| PHARM 302 | Y2 | Fall | 2025-11-28 | Lecture | Gene Therapy | Gene Therapy | Ms. L Sanchez Castillo |
| PHARM 302 | Y2 | Fall | 2025-12-01 | Lecture | Gene Therapy | Gene Therapy | Ms. L Sanchez Castillo |
| PHARM 302 | Y2 | Fall | 2025-12-03 | Lecture | Regulatory Science | Regulatory Science | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2025-12-05 | Lecture | Regulatory Science | Regulatory Science | Dr Loebenberg |
| PHARM 302 | Y2 | Fall | 2025-12-08 | Lecture | Hot Topics in Pharmaceutics | Hot Topics in Pharmaceutics | Dr Lavasanifar; Dr Sanaee |
| PHARM 303 | Y2 | Fall | 2025-09-03 | Lecture | Lecture 1 | Definitions and relevance of pharmacokinetics | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-09-05 | Lecture | Lecture 2 | Kinetics of Transport | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-09-08 | Lecture | Lecture 3 | Compartmental models and rates of transfer | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-09-10 | Lecture | Lecture 4 | One compartment model after iv bolus doses | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-09-12 | Lecture | Lecture 5 | See Above | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-09-15 | Lecture | Lecture 6 | See Above | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-09-17 | Lecture | Lecture 7 | See Above | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-09-19 | Lecture | Lecture 8 | Pharmacokinetic relationships | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-09-22 | Lecture | Lecture 9 | Multiple compartment mode | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-09-24 | Lecture | Lecture 10 | Multiple compartment model | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-09-26 | Lecture | Lecture 11 | See Above | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-09-29 | Lecture | Lecture 12 | Oral absorption | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-10-01 | Midterm exam | Midterm 1 | Examination | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-10-03 | Lecture | Lecture 13 | See above | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-10-06 | Lecture | Lecture 14 | Bioequivalence | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-10-08 | Lecture | Lecture 15 | IV infusion | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-10-10 | Lecture | Lecture 16 | See Above | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-10-13 | Lecture | Thanksgiving | Thanksgiving | No class |
| PHARM 303 | Y2 | Fall | 2025-10-15 | Lecture | Lecture 17 | Multiple dosing | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-10-17 | Lecture | Lecture 18 | See above | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-10-20 | Lecture | Lecture 19 | PK-PD relationship | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-10-22 | Lecture | Lecture 20 | Drug distribution | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-10-24 | Lecture | Lecture 21 | Drug distribution | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-10-27 | Lecture | Lecture 22 | Drug distribution, Drug clearance | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-10-29 | Lecture | Lecture 23 | Drug distribution, Renal clearance | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-10-31 | Lecture | Lecture 24 | Renal clearance | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-11-03 | Midterm exam | Midterm 2 | Examination | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-11-05 | Lecture | Lecture 25 | Hepatic clearance | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-11-07 | Lecture | Lecture 26 | Hepatic clearance | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-11-17 | Lecture | Lecture 27 | Hepatic clearance | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-11-19 | Lecture | Lecture 28 | Hepatic clearance | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-11-21 | Lecture | Lecture 29 | Nonlinear elimination | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-11-24 | Lecture | Lecture 30 | Nonlinear elimination | Dr. Brocks |
| PHARM 303 | Y2 | Fall | 2025-11-26 | Lecture | Lecture 31 | Clinical factors affecting pharmacokinetics | Dr. Kiang |
| PHARM 303 | Y2 | Fall | 2025-11-28 | Lecture | Lecture 32 | Clinical factors affecting pharmacokinetics | Dr. Kiang |
| PHARM 303 | Y2 | Fall | 2025-12-01 | Lecture | Lecture 33 | Clinical factors affecting pharmacokinetics | Dr. Kiang |
| PHARM 303 | Y2 | Fall | 2025-12-03 | Lecture | Lecture 34 | Clinical factors affecting pharmacokinetics | Dr. Kiang |
| PHARM 303 | Y2 | Fall | 2025-12-04 | Lecture | Lecture 35 | Clinical factors affecting pharmacokinetics | Dr. Kiang |
| PHARM 303 | Y2 | Fall | 2025-12-05 | Lecture | Lecture 36 | Clinical factors affecting pharmacokinetics | Dr. Kiang |
| PHARM 303 | Y2 | Fall | 2025-12-08 | Lecture | Lecture 37 | Clinical factors affecting pharmacokinetics | Dr. Kiang |
| PHARM 303 | Y2 | Fall | 2025-12-19 | Other/unspecified | Final | The exam is 2 hrs TBD time and place | Dr. Brocks |
| PHARM 303 | Y2 | Fall | — | Lecture | FALL BREAK | FALL BREAK | — |
| PHARM 310 | Y2 | Fall | 2025-09-02 | Lecture | Elements of the Immune System | Innate & Acquired Immunity: specificity and memory, Cells and organs of immune system, Clonal selection theory | M. Doschak |
| PHARM 310 | Y2 | Fall | 2025-09-04 | Lecture | Aby structure and B-Cell diversity | Antibodies: structure, classes, diversity | M. Doschak |
| PHARM 310 | Y2 | Fall | 2025-09-09 | Lecture | Immunoassays and ELISA | Point-of-Care (POC) testing | M. Doschak |
| PHARM 310 | Y2 | Fall | 2025-09-11 | Lecture | Cell-mediated Immunity | Antigen recognition by T- lymphocytes, Development of lymphocytes, T- cell mediated immunity | M. Doschak |
| PHARM 310 | Y2 | Fall | 2025-09-16 | Lecture | Humoral Immunity and Complement | Immune responses against infection, Innate immunity, Adaptive immunity | M. Doschak |
| PHARM 310 | Y2 | Fall | 2025-09-16 | Midterm exam | Midterm exam | Midterm exam | — |
| PHARM 310 | Y2 | Fall | 2025-09-18 | Lecture | Body’s Defense Against Infection | Development of B-lymphocytes, Immunity mediated by B cells and antibodies | M. Doschak |
| PHARM 310 | Y2 | Fall | 2025-09-23 | Lecture | Vaccines | How vaccines work, Vaccine types, Related current topics: COVID vaccines | M. Doschak |
| PHARM 310 | Y2 | Fall | 2025-09-25 | Lecture | Allergy, Hyper-sensitivity and Immune Disorders | Allergic and hypersensitivity reactions versus Autoimmune conditions | M. Doschak |
| PHARM 310 | Y2 | Fall | 2025-10-02 | Final exam | FINAL exam | FINAL exam | — |
| PHARM 401 | Y3 | Winter | 2026-01-05 | Lecture | Introduction to the course/Toxicology | Introduction to the course/Toxicology | Seubert |
| PHARM 401 | Y3 | Winter | 2026-01-07 | Lecture | Adverse Drug Reactions/Antidotes | Adverse Drug Reactions/Antidotes | Seubert |
| PHARM 401 | Y3 | Winter | 2026-01-09 | Lecture | Toxicological Patient Assessment | Toxicological Patient Assessment | Seubert |
| PHARM 401 | Y3 | Winter | 2026-01-12 | Lecture | Toxidromes | Toxidromes | Seubert |
| PHARM 401 | Y3 | Winter | 2026-01-14 | Lecture | Toxicological _Decontam Mechanisms of cell death and tissure | Toxicological _Decontam Mechanisms of cell death and tissure | Seubert |
| PHARM 401 | Y3 | Winter | 2026-01-14 | Lecture | repair | repair | Seubert |
| PHARM 401 | Y3 | Winter | 2026-01-16 | Lecture | Antihistamines and Decongestants | Antihistamines and Decongestants | Darwesh |
| PHARM 401 | Y3 | Winter | 2026-01-19 | Lecture | What Is In Your Medicine Cabinet? | What Is In Your Medicine Cabinet? | Seubert |
| PHARM 401 | Y3 | Winter | 2026-01-21 | Lecture | Dietary Supplements/Stings/Bites | Dietary Supplements/Stings/Bites | Seubert |
| PHARM 401 | Y3 | Winter | 2026-01-23 | Lecture | Radiation toxicity | Radiation toxicity | Siraki |
| PHARM 401 | Y3 | Winter | 2026-01-26 | Lecture | Immunotoxicity | Immunotoxicity | Siraki |
| PHARM 401 | Y3 | Winter | 2026-01-28 | Lecture | Genotoxicity and Carcinogenicity of Drugs | Genotoxicity and Carcinogenicity of Drugs | El-Kadi |
| PHARM 401 | Y3 | Winter | 2026-01-30 | Lecture | Organ Toxicity | Organ Toxicity | Seubert |
| PHARM 401 | Y3 | Winter | 2026-02-02 | Lecture | Forensic Toxicology | Forensic Toxicology | Jones |
| PHARM 401 | Y3 | Winter | 2026-02-04 | Other exam/test | Term Exam 1 | Term Exam 1 | Seubert |
| PHARM 401 | Y3 | Winter | 2026-02-06 | Lecture | Case 1 - LQTC | Case 1 - LQTC | Leslie/Thompson/Koshman |
| PHARM 401 | Y3 | Winter | 2026-02-09 | Quiz | Case Debrief/Quiz1 | Case Debrief/Quiz1 | Leslie/Thompson/Koshman |
| PHARM 401 | Y3 | Winter | 2026-02-11 | Lecture | Cancer Survivorship | Cancer Survivorship | Leslie |
| PHARM 401 | Y3 | Winter | 2026-02-13 | Lecture | Chemotherapy Safety | Chemotherapy Safety | Leslie |
| PHARM 401 | Y3 | Winter | 2026-02-23 | Lecture | Restarting Medications After Overdose | Restarting Medications After Overdose | Hartmann |
| PHARM 401 | Y3 | Winter | 2026-02-25 | Lecture | Special Populations Geriatrics | Special Populations Geriatrics | Haggarty |
| PHARM 401 | Y3 | Winter | 2026-02-27 | Lecture | Special Populations Pediatrics | Special Populations Pediatrics | Seubert |
| PHARM 401 | Y3 | Winter | 2026-03-02 | Lecture | Special Populations MAiD | Special Populations MAiD | Schindel |
| PHARM 401 | Y3 | Winter | 2026-03-04 | Lecture | Case 2 - Special Populations | Case 2 - Special Populations | Trkulja/Haggarty |
| PHARM 401 | Y3 | Winter | 2026-03-06 | Quiz | Case Debrief/Quiz2 | Case Debrief/Quiz2 | Trkulja/Haggarty |
| PHARM 401 | Y3 | Winter | 2026-03-09 | Lecture | Special Topics in Advanced Pharmacology | Special Topics in Advanced Pharmacology | Kiang |
| PHARM 401 | Y3 | Winter | 2026-03-11 | Lecture | Special Topics in Advanced Pharmacology | Special Topics in Advanced Pharmacology | Kiang |
| PHARM 401 | Y3 | Winter | 2026-03-13 | Lecture | Special Topics in Advanced Pharmacology | Special Topics in Advanced Pharmacology | Kiang |
| PHARM 401 | Y3 | Winter | 2026-03-16 | Lecture | Anticoag Accumulation/Toxicity | Anticoag Accumulation/Toxicity | Bungard |
| PHARM 401 | Y3 | Winter | 2026-03-18 | Other exam/test | Term Exam 2 | Term Exam 2 | Seubert |
| PHARM 401 | Y3 | Winter | 2026-03-20 | Lecture | Drugs of Abuse 1 - Stimulants | Drugs of Abuse 1 - Stimulants | Salokangas |
| PHARM 401 | Y3 | Winter | 2026-03-23 | Lecture | Drugs of Abuse 2- CNS Depressants | Drugs of Abuse 2- CNS Depressants | Necyk |
| PHARM 401 | Y3 | Winter | 2026-03-25 | Lecture | Drugs of Abuse 3 - Hallucinogens | Drugs of Abuse 3 - Hallucinogens | Necyk |
| PHARM 401 | Y3 | Winter | 2026-03-27 | Lecture | Drugs of Abuse 4 - Toxic Alcohols | Drugs of Abuse 4 - Toxic Alcohols | Seubert |
| PHARM 401 | Y3 | Winter | 2026-03-30 | Lecture | Drugs of Abuse 5 - Vaping, eCig | Drugs of Abuse 5 - Vaping, eCig | Seubert |
| PHARM 401 | Y3 | Winter | 2026-04-01 | Lecture | Case 3 - Drugs of Abuse | Case 3 - Drugs of Abuse | Salokangas |
| PHARM 401 | Y3 | Winter | 2026-04-08 | Quiz | Case Debrief/Quiz3 | Case Debrief/Quiz3 | Salokangas |
| PHARM 401 | Y3 | Winter | 2026-04-09 | Lecture | Drugs that are necessary but carry a risk of toxicity | Drugs that are necessary but carry a risk of toxicity | Siraki |
| PHARM 401 | Y3 | Winter | 2026-04-10 | Lecture | Deliberate Poisonings | Deliberate Poisonings | Seubert |
Assessment Information
| PHARM 201 | Y1 | Final Exam | Final exam | 40% | MCQ and short-answer format; covers chapters 6-9; final exam is not cumulative. |
| PHARM 201 | Y1 | Midterm Exam | Midterm exam | 30% | MCQ and short-answer format; covers chapters 2-5. |
| PHARM 201 | Y1 | Seminar participation | Participation/professionalism | 20% | — |
| PHARM 202 | Y1 | Lab Reports | Assignment/written work | 12% | Lab reports due one week after each lab; rubric in Lab Manual. |
| PHARM 202 | Y1 | Final Exam | Final exam | 35% | Computer-based MCQ/written final covering sessions 20-35; not cumulative; in-person in computer lab; calculator and formula sheets available. |
| PHARM 202 | Y1 | Midterm Exam | Midterm exam | 35% | Computer-based MCQ/written midterm covering sessions 1-19; in-person in computer lab; calculator required. |
| PHARM 202 | Y1 | Lab Exam | Other exam/test | 8% | Practical compounding exam assessing preparation of requested dosage form. |
| PHARM 202 | Y1 | Quiz (including Lab’s seminars) | Quiz | 10% | Four computer-based quizzes on Canvas (10-12 Qs), each 2.5%; 5-day window, 30-minute attempt; no repeats. |
| PHARM 203 | Y1 | Final | Final exam | 65% | Multiple choice; computer-based (lectures 16-39 inclusive); closed book; proctored. |
| PHARM 203 | Y1 | Midterm | Midterm exam | 35% | Multiple choice; computer-based (lectures 1-16 inclusive); closed book; proctored. |
| PHARM 204 | Y1 | Online Assignments | Assignment/written work | 10% | Open-book style online assignments with planned date ranges for four assignments (first assignment Sept 8–12). |
| PHARM 204 | Y1 | Final Exam | Final exam | 55% | Final exam is not cumulative (covers Lectures 19-37). Format: multiple choice and anatomical identification. |
| PHARM 204 | Y1 | Midterm Exam | Midterm exam | 30% | Midterm is cumulative, MCQ, covering Lectures 1–18. Date: 2025-10-20. |
| PHARM 204 | Y1 | In-class Quizzes | Quiz | 5% | Several in-class MCQ quizzes (~8-10 MCQs, 10 minutes each) with listed in-class dates for four quizzes. |
| PHARM 233 | Y1 | Winter final (non-cumulative) | Final exam | 50% | Non-cumulative final exam, multiple choice, ~80 questions, covers lectures 23–37; time TBA. |
| PHARM 233 | Y1 | Midterm 1 | Midterm exam | 24% | Multiple choice exam, 40 questions, covers lectures 1–11; outcomes listed. |
| PHARM 233 | Y1 | Midterm 2 (non-cumulative) | Midterm exam | 26% | Non-cumulative multiple choice exam, 44 questions, covers lectures 12–22. |
| PHARM 302 | Y2 | Hazard assessment assignment | Assignment/written work | 2% | — |
| PHARM 302 | Y2 | Hot Topic Assignment | Assignment/written work | 5% | Online pre-class submission and in-class discussion graded as participation; full credit for submission. |
| PHARM 302 | Y2 | Lab reports (five) | Assignment/written work | 23% | Five individual lab reports; sterile/dissolution/stability/transdermal reports = 5% each, simulation = 3%; due within one week of lab; rubric discussed in lab seminar. |
| PHARM 302 | Y2 | Final including labs | Final exam | 35% | Written multiple-choice final (not cumulative) covering sessions 19–37 plus related prelab seminars and labs; calculator allowed. |
| PHARM 302 | Y2 | Midterm including labs | Midterm exam | 35% | Written multiple-choice midterm covering sessions 1–18 plus related prelab seminars and labs. |
| PHARM 303 | Y2 | Assignments | Assignment/written work | 13% | Web-based, individualized short-answer and multiple-choice assignments released through the term; due one week after release; final assignment grade is percent correct across all assignments with allowance to remove up to 20 incorrect answers. |
| PHARM 303 | Y2 | Final | Final exam | 43% | Final exam: 2-hour multiple-choice and short-answer exam; cumulative with emphasis on material since Midterm 2; time/place TBD. |
| PHARM 303 | Y2 | Midterm examination 1 | Midterm exam | 22% | Midterm 1: multiple choice and short answer; described as not cumulative; logistical timing differs from normal class schedule; coverage cutoff given in class. |
| PHARM 303 | Y2 | Midterm examination 2 | Midterm exam | 22% | Midterm 2: written and multiple-choice; cumulative; coverage primarily since Midterm 1 but prior material may be needed; scheduling differs from normal class times. |
| PHARM 310 | Y2 | Final | Final exam | 60% | Final is a written assessment consisting of multiple choice questions. |
| PHARM 310 | Y2 | Midterm | Midterm exam | 40% | Midterm is a written assessment consisting of multiple choice questions. |
| PHARM 401 | Y3 | Final Term Exam | Final exam | 30% | Written multiple-choice computer-based final covering Lectures 26-39 (TBD date). |
| PHARM 401 | Y3 | Term Exam 1 | Midterm exam | 30% | Written multiple-choice computer-based exam covering Lectures 1-14. |
| PHARM 401 | Y3 | Term Exam 2 | Midterm exam | 25% | Written multiple-choice computer-based exam covering Lectures 16-25. |
| PHARM 401 | Y3 | Case 1 - Quiz (eClass) | Quiz | 5% | Written multiple-choice eClass quiz on Cardiotoxicity. |
| PHARM 401 | Y3 | Case 2 - Quiz (eClass) | Quiz | 5% | Written multiple-choice eClass quiz on Special Populations. |
| PHARM 401 | Y3 | Case 3 - Quiz (eClass) | Quiz | 5% | Written multiple-choice eClass quiz on Drugs of Abuse. |
About this Evidence
Where did this information come from, and how was it prepared?
What information is included
This curriculum portrait brings together the curriculum records available for the selected stream and academic cycle. These include course information and learning outcomes, documented sessions and topics, assessment information, and links to the CCAPP and AFPC curriculum frameworks.
The amount of descriptive detail varies across academic cycles because the underlying source material is not identical. Current-cycle records are drawn largely from syllabus information, while some earlier-cycle records come from legacy curriculum data that contain less narrative detail. Missing information is left visible rather than filled in.
How topics are connected to curriculum frameworks
Documented curriculum topics are matched to CCAPP curriculum categories with OpenAI assistance. A topic can be matched to more than one CCAPP category when it clearly relates to more than one area.
CCAPP categories are linked to AFPC professional roles. Those links are used to show the AFPC role patterns in the curriculum portrait. These profiles describe where curriculum content is documented. They do not show instructional time, student achievement, or preparedness for practice.
How the charts and percentages are calculated
The values in the charts are calculated directly from the curriculum records. AI-generated text does not calculate these numbers. Each chart is based on a different type of evidence, so percentages from different charts should not be compared as though they use the same starting point.
- Learning outcomes
- Shows the share of classified learning outcomes identified as Knowledge, Skills or Attitudes.
- AFPC roles
- Shows the share of all curriculum links to AFPC professional roles.
- CCAPP topics
- Shows the share of all curriculum links to CCAPP topic categories. One documented topic can contribute to more than one category.
- Delivery
- Uses instructional hours when session-duration information is complete enough for comparison. Otherwise it shows the number of documented sessions.
- Assessment
- Uses assessment weight when comparable weighting information is complete enough. Otherwise it shows the number of documented assessments.
The year-by-year profiles are descriptive comparisons. A visible difference between years does not, by itself, mean that an educationally important change occurred.
How the written summaries are created
The written summaries are built in steps so that broad descriptions remain connected to the underlying curriculum records. Detailed session and assessment information is first organized into summaries for each stream and program year. Those summaries are then used to create the overall stream descriptions shown to reviewers.
AI-assisted writing is used to help produce concise reviewer-facing descriptions from these prepared evidence summaries. It does not calculate the charts or decide whether the curriculum is good, coherent, effective, or whether students have achieved the intended outcomes.
The written summaries are prepared before the report is displayed. Opening or browsing this report does not send a new request to an AI service.
How missing or incomplete information is shown
When the available records are incomplete, the report shows that limitation rather than making an assumption. Examples include missing session duration, incomplete assessment weighting, and older course or assessment records that do not contain the same descriptive detail as newer syllabus-derived records.
For relationships between streams, the same evidence rule is applied from either direction. If there is not enough information to describe a relationship for a particular year and cycle, both stream views show that limitation consistently.